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Abstract 
Multiple Sclerosis (MS) has long been considered as White matter (WM) 
disease. The last decade, the significance of cortical lesions (CL) and their 
contribution to MS pathology has been intensely investigated. They have been 
shown to play a major role in physical and cognitive impairment in MS 
patients. CL detection has proven to be challenging, mainly due to poor 
contrast between cortical lesion and surrounding normal grey matter (GM) 
tissue. Various magnetic resonance imaging (MRI) sequences have been used 
to improve cortical lesion detection in MS patients. In recent years, Double 
inversion recovery (DIR), Phase sensitive inversion recovery (PSIR) and 7 
Tesla T2* have been found to improve CL detection. Magnetization Transfer 
Imaging (MTI) has the advantage over conventional imaging as it reflects 
tissue myelin content. In this thesis, I present our studies using MTI at 7 Tesla 
to study cortical pathology in MS.  
1) For a pilot study aiming to validate the use of magnetization transfer 
ratio (MTR) to detect cortical lesions, We examined the sensitivity of 
MTR to detect cortical lesions in comparison with 3 T DIR, 7 T PSIR, 
and 7 T T2* in 18 MS patients and 9 healthy controls.  
2) A further 42 patients (11 clinically isolated syndrome (CIS), 11 
relapsing remitting MS (RRMS), 10 primary progressive MS (PPMS), 
and 10 secondary progressive MS (SPMS)) and 8 healthy controls were 
scanned at baseline, 23 of these patients had a follow up scan at 12 
months.   
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MTR at 7 Tesla has increased sensitivity to detect cortical lesions 
compared to 3T DIR, 7T PSIR and 7T T2*. CL myelin content as 
measured by the mean MTR lesional values were the lowest in SPMS 
patients in comparison with the rest of MS phenotypes. CL mean MTR 
values, more than volume was associated with the degree of physical 
and cognitive disability in MS patients.  
When MTR was studied in a longitudinal study, we have seen more 
changes in average MTR of cortical lesions in SPMS and CIS patients 
compared to RRMS and PPMS patients.  
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Chapter 1 
 Introduction 
1.1 Background: 
Multiple sclerosis (MS) is a chronic inflammatory condition that affects the 
central nervous system (CNS). It was first described in 1838. It is classified 
into subtypes depending on the pattern of presenting symptoms. MS shows 
different patterns of evolution and disability accumulation across different 
phenotypes. The main four disease subtypes are relapsing remitting (RRMS), 
primary progressive (PPMS), secondary progressive (SPMS) and progressive 
relapsing multiple sclerosis. Lublin et al in 2014 recommended 
1
 another 
classification, although it is not widely used. They suggested that RRMS 
diagnosis does not always reflect the level of disease activity, hence 
recommended annual assessment of disease activity by clinical and brain 
imaging. According to their recommendations SPMS patients required annual 
clinical monitoring without brain imaging to assess disease activity. The 
degree of disability in MS is widely assessed using Expanded Disability Status 
Score (EDSS).
2
 This scale was first recommended in 1983, and it assesses the 
degree of neurologic impairment using a combination of different scores 
reflecting function of different parts of the nervous system. The median age 
from the onset of the disease till reaching EDSS score of 4 and 6 is around 8 
and 30 years respectively.3 
1.2 Epidemiology: 
MS is the second most common cause of disability in young adults in the 
western world.
4
 Surveys have estimated the incidence of MS in the United 
Kingdom started since 1931, and show continuous increase in disease 
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frequency over time.  The numbers reported from different surveys across the 
United Kingdom vary depending on which classification they use. The rates of 
MS are higher in northern United Kingdom (> 180/10
5
) compared with the 
south (< 160/10
5
). It is generally believed that the northeast of Scotland has the 
highest frequency of MS in the UK. The incidence of MS in migrants in the 
UK varies depending on how old they were when they moved to the UK. 
Individuals tend to keep the same risk of MS as their place of origin if they 
moved to the UK after the age of 15 years old, but acquire the UK incidence of 
MS if they move to the UK before the age of 15. 
MS is normally more common in females than males. The reported figures 
vary but the ratio of females to males is usually 2-1.
4
 This ratio applies to the 
young age of onset. MS presenting in or after the fifth decade more commonly 
affects males and normally is of primary progressive type. 
1.3 Etiology: 
MS is caused by inflammation in the CNS. The triggers of the inflammatory 
process causing the disease have been widely investigated. Environmental, 
genetic and infectious causes are possible factors that have been suggested to 
influence the development of disease. A genetic cause was suggested with the 
increase concordance in monozygotic twins compared to dizygotic twins than 
general population. MS susceptibility is associated with the major 
histocompatibility complex (MHC) region, mainly the MHC class II DRB1 
gene.6 Vitamin D deficiency is another factor suggested to contribute MS risk,7 
with disease incidence/prevalence MS significantly decreasing with increasing 
levels of 25-hydroxyvitamin D in whites.8 Epstein-Barr virus (EBV) has been 
implicated in MS. A large study showed that all subjects who were EBV 
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seronegative at baseline, had seroconverted prior to MS onset, in comparison 
with only 35.7% of controls over the same period.9 Smoking has also been 
shown to be associated with susceptibility to developing MS.10 
1.4 Pathology: 
Demyelination means loss of the myelin sheath in MS brains, and it is mainly 
due to a process that targets the oligodendrocytes, the cells that make and 
maintain the myelin sheath. This is called sometimes primary demyelination to 
distinguish it from secondary degeneration or Wallerian degeneration in which 
demyelination is secondary to axonal loss.
11
  
MS is characterized by the presence of multifocal plaques. The first 
macroscopic demonstration of the lesions was by Carswell (1838) and 
Cruveilhier (1841).
12
 
 MS plaques evolve from acute stage in which activated mononuclear cells 
including lymphocytes, microglia and macrophages destroy myelin and 
oligodendrocytes. Within a few weeks, plaques contain a mixture of 
demyelinating axons and glial scar tissue. Depending on the degree of 
inflammation in lesions, attempts of remyelination start. If inflammation is 
arrested at early stage while gliosis in the plaques is not prominent, attempts of 
remyelination starts by remaining oligodendrocytes13  
Initially MS was considered to be a white matter (WM) disease but with 
advances in immunohistochemical stains, demyelinated plaques have been 
observed in the grey matter (GM) as well.  
Cortical lesions are difficult to visualise using conventional MR imaging. For 
pathological examination, immunohistochemical stains are necessary to 
identify cortical lesion (CL). The difference between pathology of WM and 
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GM lesions has been suggested to be due to the variation in the degree of 
inflammatory infiltration.
13
 
This variation in the degree of infiltration could be due to the relatively smaller 
lesions size, hence the tissue needs to be removed from the CL tissue in 
comparison with white matter lesions (WML), hence probably less 
inflammation is needed to induce demyelination in the GM.
13
 
 
Inflammation in MS is not restricted to demyelinated plaques, but extends to 
the regions surrounding the lesions, as well as WM and GM areas that are 
distant from established MS plaques.15   
MS is known as a neuroinflammatory disease; on the other hand axonal loss is 
frequently observed and correlated with permanent disability. The traditional 
view is that inflammation is the main cause of neuronal degeneration and 
axonal loss. 
1.5 Pathogenesis: 
Inflammation and further neurodegeneration is thought to be the main driving 
factor in MS pathology. The primary cause of this inflammation is still 
unknown. Disease heterogeneity amongst individual MS patients suggests 
various pathogenic mechanisms across patients, but observed to be similar 
within the same patient.
16
 These processes include  
1) Demyelination which is mainly immune-mediated  
2) Axonal loss which could be due to inflammation and glutamate 
excitotoxicity
17
 as observed in active MS lesions, or due to Wallerian 
degeneration in remote regions that are anatomically related to MS lesions 
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3) Primary oligodendrocyte dystrophy induced probably by toxin induced 
demyelination rather than autoimmunity
16
.  
It is likely that interaction between these processes determines the inter 
individual variation among MS phenotypes and presentations.   
 MS is considered an immune mediated disease, involving both the cellular and 
the humoral parts of the immune system. It is initiated by CD4  T cell auto 
activation in the peripheral immune system which triggered via bacterial or 
viral antigens or possibly due to molecular mimicry with other pathogenic 
proteins.18,19 The peripherally activated cells recognize autoantigens within the 
CNS parenchyma. CD4 T cells are then either polarized to Th1 with 
subsequent production of specific cytokines mainly interferon-gamma (IFN-Ƴ) 
or tumour necrosis factor-alpha (TNF-α), or polarised to Th2 with subsequent 
production of IL-13. It is recognised that Th1 CD4+ T cells are inflammatory 
while Th2 CD4+T cells are regulatory. Activated Th1 cells cause myelin 
disruption and the release of new potential CNS autoantigens. Moreover, the 
secreted proinflammatory cytokines, such as IFN-Ƴ and TNF-α recruit 
antimyelin antibody-forming B cells that further potentiates tissue injury.18 The 
interaction between the upregulating proinflammatory cytokines and the 
immune response down regulating cytokines decides the severity and extent of 
MS lesions.20  
IFN- Ƴ and TNF-α induce production of nitric oxide (NO), and osteopontin by 
macrophages, microglial cells and astrocytes. Nitric oxide synthase was found 
in demyelinating lesions.  NO in turn is involved in oligodendroglial cells 
destruction by microglia. Osteopontin induces more TH1 cytokines including 
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IFN- Ƴ and IL-12 and down-regulated TH2 cytokines such as IL-10.
21 TNF is 
also expressed in MS lesions and it was found that down-regulating the 
expression of TNF and up-regulating Th2 cytokines can decrease the size of 
new lesions in the WM.21 
In chronic MS, α-amino-3-hdroxy-5-methyl-4-isoxazoleppropionic acid 
(AMPA) mediates toxicity induced by glutamate secretion. AMPA is present 
on oligodendroglial cells and neurons. In MS, lymphocytes, microglia and 
macrophages release excessive amounts of glutamate, which in turn activates 
AMPA receptors. This causes calcium influx through ion channels, causing 
necrotic damage to oligodendrocytes and axons. Blocking AMPA receptors 
with AMPA-kainate antagonist has been shown to ameliorate relapses in 
EAE,17  it does not influence the immune response to myelin antigens but 
protects oligodendroglial cells and axons from immune mediated damage.21 
A pathology study in RRMS patients showed that the largest infiltration of T 
cells was observed in active MS lesions indicating active inflammation, 
followed by less marked infiltration in slowly expanding lesions. Relatively 
few T cells were found in inactive lesions and NAWM, while no T cells in the 
cortex. The majority of the infiltrating T-cells were CD8+ (i.e cytotoxic T 
cells).
22
 The number of B cells was 10 times lower than the T cells but B cells, 
HLA-D positive macrophages and microglia cells had the same pattern of 
distribution across tissue types.
22
 
It has been suggested that T-cells have beneficial as well as destructive effects. 
The variation in effect was put at least partially to genetic predisposition. After 
optic nerve injury in Experimental Autoimmune Encephalomyelitis (EAE), it 
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was observed that the number of surviving neurons in the optic nerve was 60% 
lower in the strains that are resistant to CNS autoimmune disease than in those 
susceptible mainly due to lacking mature T-cells (due to thymectomy at 
birth),
23
 which suggests that CNS injury initiates a protective response mainly 
T-cell dependent.
23
 
 1.6 Neuroinflammation versus neurodegeneration: 
MS is usually considered as inflammatory disease that affects the CNS. 
However, axonal loss is seen in the early stages of the disease particularly in 
acute WM MS lesions. The frequency of transected axons correlates with the 
degree of inflammation within MS lesions, with more axonal loss in active 
lesions, while axons more preserved within hypocellular lesions.
24
 The extent 
of axonal injury in MS patients spinal cords correlated with the degree of 
permanent disability.
25
  
Inflammation cannot be solely responsible for axonal loss. Degeneration of 
axons in the absence of inflammatory cells may be due to the degeneration of 
chronically demyelinated axons, due to the loss of myelin trophic support, 
which in turn leads to progressive swelling and cytoskeletal disorganisation of 
chronically demyelinated axons, especially in the chronic phase of the disease. 
In animal models, axonal injury is detected within inactive MS lesions to a less 
but still significant extent in comparison with active MS plaques.
26
 Moreover, 
a significant degree of axonal loss was observed on examining the NAWM of 
corpus callosum of post-mortem MS brains, which seem to be developing 
independently from MS lesions.
27
 The significance of disease modifying 
treatment in the early stages of the disease and its lack of effect in the 
progressive stages of the disease supports the view that axonal loss cannot be 
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solely due to associated tissue inflammation.
28
 The continuous chronic axonal 
loss in the cortex of progressive MS brains with no inflammatory cells 
infiltration
29
 is further  evidence supporting an independent neurodegenerative 
process that occurs either simultaneously with or in the absence of 
inflammatory drive. In the progressive stage of the disease, no correlation was 
detected between patients age or the disease duration and the extent of 
inflammatory infiltration.
22
 
Acute axonal injury was found to be more frequent in active MS lesions, to 
less extent in slowly expanding lesions, then in the inactive lesions, NAWM 
and the cortex.
22
 On comparing lesions of similar stages across patients of 
different disease phenotypes, there was no significant difference in the density 
of axonal density.
22
 The degree of axonal injury in progressive MS patient’s 
WM lesions correlated significantly with the degree of inflammation. 
However, this study did not include any patients with early or relapsing stage 
of the disease. A similar correlation was also detected in the NAWM tissue.
22
 
There is a big degree of inter patient variability in terms of the density of 
inflammatory infiltrates either in the lesions or in NAWM. In a pathology 
study Frischer et al divided their sample of progressive MS patients who died 
in the late progressive stage of the disease into two categories, patients with 
pathologically active progressive disease (with classical active or slowly 
expanding lesions) and patients with pathologically inactive disease (showed 
inactive plaques only). They found that patients who belonged to the latter 
category were significantly older, and had longer disease duration, while the 
degree of their disability at the time of death was similar.
22
 Interestingly, 
significantly higher amounts of meningeal plasma cell and B-cell densities 
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were observed in pathologically inactive patients in comparison with normal 
controls. Patients who died during the pathologically active progressive phase 
had more acute axonal injury than patients who died during the inactive phase 
of the disease. Patients who died in the pathologically inactive stage of the 
disease had similar density of acute axonal injury to age matched normal 
controls.
22
 Patients who died during the inactive stage of the disease had three 
additional pathological features, which are thick demyelinated axons within 
inactive plaques, synaptic pattern of SPY immunoreactivity within lesions, and 
axonal or neuronal injury.
22
  
It has been suggested that the ageing process may contribute its own 
pathological changes in the MS brain. A pathology study compared post-
mortem brains of progressive MS patients who had pathologically inactive 
disease with and without Alzheimer’s disease. Patients with associated 
Alzheimer’s disease pathology, showed more acute axonal injury in the cortex 
and in the WM compared to with those who had pathologically inactive 
disease in the absence of Alzheimer’s disease pathology. This suggests that in 
progressive MS, neurodegenerative changes may progress due to age related 
associated disease, even after cessation of MS related inflammation and axonal 
loss.
22
 
The above studies suggest that it is difficult to explain the pathogenesis of MS 
due to either pure inflammatory or neurodegenerative process. It is more likely 
to be explained by a combination of these two processes.  
1.7 Clinical Presentation: 
The hallmark of MS diagnosis is dissemination in time and space.
1
 The main 
MS phenotypes depend on their clinical course divided into RRMS, SPMS, 
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PPMS and progressive relapsing MS.30 Benign MS is another phenotype that 
describes very minimal disability and lesion load during the disease course. 
The disease course and severity are highly variable amongst individual 
patients.  
Around 85% of patients present with RRMS. Patients experience relapses at 
different frequencies and eventually enter the secondary progressive stage of 
the disease at variable rate. While PPMS constitutes around 15% of the 
patients, a percentage of those patients may later be revealed to have 
progressive relapsing MS when they start experiencing relapses. 
1.8 Role of Imaging in MS:  
Magnetic resonance imaging (MRI) has played a major role in the last 3 
decades as the main tool helping understand MS, and as a surrogate biomarker 
in managing the disease and assessing treatment response. Initially 
conventional imaging focused on WM plaques.31 The main sequences used are 
T1-weighted, T2-weighted and fluid attenuated inversion recovery (FLAIR).  
WM lesions appear hypointense on T1 images and hyperintense on T2 and 
FLAIR images. The diagnosis of MS is made based on dissemination of 
lesions in time and space. The presence of enhancing lesions, representing 
disease activity with break of the blood brain barrier (BBB), can be 
demonstrated using gadolinium chelates with T1 weighted acquisition. 
Diagnostic criteria based on white matter lesions (WML) on T2 weighted 
images have been proposed and revised over the years to facilitate diagnosis 
based on dissemination in time and space.32  
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(Figure 1.1)  Example for MTR maps  
 
The figure illustrates MTR maps for MS patients. The image is a result of 
reconstruction of Msat and Mnonsat  
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1.9 Diagnosis: 
The diagnosis of MS deploys the use of clinical and paraclinical assessments 
focusing mainly on demonstrating dissemination in time (DIT) and 
dissemination in space (DIS) and excluding any alternative diagnoses. 
Diagnostic criteria have been in development since 1965.33 Diagnostic criteria 
are mainly based on clinical relapses and WM lesions on MRI. The most 
recent criteria were revised in 201032 aiming to simplify diagnostic criteria 
while preserving sensitivity and specificity levels. 
Diagnosis of RRMS is usually suggested based on criteria as illustrated in 
(Table 1.1), while diagnosis of PPMS is mainly made with insidious onset of 
progressive neurological symptoms for at least 1 year plus 2 of 3 criteria: 
evidence of DIS (≥ 1 T2 lesions in periventricular, juxtacortical or 
infratentorial regions), evidence of DIS (≥ 2 T2 lesions in the cord), positive 
cerebrospinal fluid (CSF) for either oligoclonal bands or high IgG index or 
both. 
Those diagnostic criteria were based on studies on European and North 
American populations, hence their applicability on other ethnic origins and 
paediatric populations remains under debate. Among Asian populations, 
neuromyelitis optica (NMO) is more frequent than MS. Sometimes the MRI 
criteria in patients can overlap between NMO and MS. Some MRI findings 
which are considered atypical for MS patients according to McDonald criteria, 
such as long spinal MRI lesions and cord swelling, are seen frequently in 
Asian patients with MS. The term opticospinal MS is used to present a mix of 
MS and NMO.34  
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The McDonald criteria are mainly based on detecting non cortical brain lesions 
and spinal cord lesions on 1.5T scanners. In the last few years, with the 
increase in work involving CL detection using several sequences, it was 
reported that the presence of at least 1 CL, using double inversion recovery 
(DIR), in patients with clinically isolated syndrome (CIS) can predict the 
development of clinically definite MS (CDMS) in those patients.,35 On the 
other hand CL are still not part of the McDonald diagnostic criteria. 
In 85% of MS patients the onset is in the form of CIS. This is a presentation  
with an acute attack of neurological dysfunction including (but not limited to) 
optic neuritis, an isolated brain, brainstem or partial spinal cord involvement.
36
 
 The presence of MRI changes in CIS patients at time of presentation carries a 
higher risk of progression to clinically definite MS within 5 years.
37
  
Typical MS plaques have been detected in autopsy of individuals who were not 
symptomatic, and lesions were mainly located in the periventricular regions, 
hence probably the silent presentation.38 
 On comparing MRI characteristics in sporadic versus familial MS, it was 
shown that they only show difference in the T1 lesion volume with patients 
with familial MS having higher T1 lesion load.39 
Radiologically isolated syndrome (RIS) is an isolated MRI finding with no 
associated clinical presentation. Its actual incidence is difficult to accurately 
estimate as it is incidentally discovered by scanning patients due to other 
reasons.40  
A cross sectional study41 showed that WM lesions were detected in around 7% 
of first degree relatives of MS patients, with higher frequency in familial MS 
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relatives (around 10 %) than in sporadic MS relatives (around 4%). A 
longitudinal study was performed on 22 patients with RIS for a period of 
between 1 and 10 years.41 They found that 8 patients went on to develop MS 
within one year; six patients were followed for 5 years without developing MS, 
while 3 patients were followed for 10 years without developing MS. The rest 
of the study subjects were followed for variable periods between 1 and 3 years 
without developing MS.   
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(Table 1.1) Revised 2010 McDonald diagnostic criteria for MS  
Clinical Presentation 
Additional criteria for 
establishing MS diagnosis 
Clinical attacks Objective evidence 
 
 
None 
≥ 2 Attacks 
≥ 2 WM Lesions 
Or 
1 Lesion and history of 
prior attack 
≥ 2 Attacks 1 Lesion 
DIS demonstrated by: 
≥ 1 T2 lesion in at least 2 
regions (periventricular, 
juxtacortical, infratentorial 
or spinal cord) 
Or 
Await another attack 
affecting a different CNS 
site 
1 Attack ≥ 2 Lesions 
DIT demonstrated by: 
Presence of Gd enhancing 
and non-Gd enhancing 
lesions at the same time 
Or 
new T2 or Gd enhancing 
lesion on follow up scan in 
comparison with baseline 
scan 
1 Attack 1 Lesion 
DIS as well as DIT (as 
mentioned above) 
(DIS = dissemination in space, DIT= dissemination in time, WM= white matter, 
CNS= central nervous system) 
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1.10 Anatomy of the cerebral cortex: 
The volume of the adult human cerebral cortex varies between 197 and 331 
cm
3
 in females and between 242 and 358cm
3
 in males. Cortical volume of the 
right hemisphere is frequently larger than the left which is mainly due to the 
frontal lobe being usually slightly wider in the right than the left hemisphere. 
There are 2 main types of cortices;
42
  
1- Neocortex (Isocortex) which constitutes most of the cortex, is 
mainly found in the cerebral hemispheres, contains between 10 and 
14 billion neurons, and is formed mainly of 6 layers numbered with 
Roman numerals from superficial to deep. The depth of Isocortex 
varies depending on the cortical area but generally is between 1.5 
and 5.0 mm. Similarly cortical thickness vary, but mean neocortical 
thickness is 2.72± 0.24 mm in male and 2.61±0.21 mm in female 
brains.44 
2- The Archicortex (Allocortex) is mainly found in the limbic system 
cortex and contains on average 3 layers. The Allocortex can be 
further divided into paleocortex (olfactory bulb, piriform regions 
and part of the amygdala) and Archicortex (Hippocampus, cortical 
part of cingulate gyrus).   
The 6 layers constituting the cortical cytoarchitecture
45 are: 
 1) Molecular layer (Plexiform layer) (I) which is the outermost layer and 
contains dense network of tangentially oriented nerve fibers which are mainly 
derived from the apical dendrites of the pyramidal cells. This layer of the 
cortex is where large numbers of synapses between neurons take place.  
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2) External granular layer (II) which is a dense layer that is composed of small 
pyramidal and stellate cells. Dendrites of these cells terminate in the molecular 
layer, while the axons pass on to the WM.  
3) External pyramidal layer (III) contains pyramidal cells, with their dendrites 
passing into the molecular layer while the axons enter the WM.  
4) Internal granular layer (IV) contains mainly stellate cells. Fibers in this layer 
are horizontally arranged and known as the external band of Baillarger  
5) Ganglionic layer (Internal pyramidal layer) (V) which contains pyramidal 
cells. There are a large number of horizontally arranged fibers that form the 
inner band of Baillarger. In the motor cortex of the precentral gyrus, the 
pyramidal cells of this layer are very large and known as Betz cells and 
account for around 3% of the corticospinal tract projection fibers.  
6) Multiform layer (Layer of polymorphic cells) (VI) which is mainly 
composed of fusiform cells with many nerve fibers either entering or leaving 
the underlying WM.45 
Not all areas of the cortex typically composed of 6 layers. The agranular part 
of the cortex contains poorly developed granular layers 2 and 4, hence the 
pyramidal cells in layers 3 and 5 are densely packed, and those are present in 
the precentral gyrus, and give efferent fibers associated with motor function. 
The granular part of the cortex has well developed granular layers 2 and 4 and 
these cells receive thalamocortical fibers and found mainly in the postcentral 
gyrus. 
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In terms of functional organization, the cerebral cortex is organized into 
vertical units measuring about 300 to 600 µm wide.  
Brain tissue is composed of the neurons and the neuroglia.46 Neurons vary 
according to the number, length, and the mode of branching of their neurites 
into unipolar, bipolar and multipolar neurons. Neuroglia are smaller than 
neurons and 5-10 times more prevalent. The four main types of neuroglial cells 
are astrocytes, oligodendrocytes, microglia and ependymal cells. Astrocytes 
serve as “electrical insulators”, preventing axon terminals from influencing 
nearby neurons, as well as preventing spread of neurotransmitter substances 
released at synapses, they also serve as phagocytes for degenerating neurons, 
proliferate after the death of neurons to fill in the gaps (gliosis), secrete 
cytokines that regulate the immune cells entering the nervous system, and also 
play a significant role in the structure of the BBB. Oligodendrocytes are 
responsible for the formation of the myelin sheath. Microglia are found 
scattered throughout the CNS. They are normally inactive in the normal brain 
but in MS they become the immune effector cells and they migrate to the site 
of the lesion. At the inflammation site, they proliferate and become antigen 
presenting cells which together with the invading T lymphocytes react to the 
disease. They also work as phagocytic cells.   
 The cerebral cortex constitutes mainly of 3 main types of neurons arranged in 
layers. These cells are pyramidal cells, stellate neurons and fusiform neurons. 
In a smaller number two types of cells are also present which are horizontal 
cells of Cajal and cells of Martinotti. The apices of the pyramidal cells are 
oriented toward the pial surface of the cortex. An apical dendrite extends from 
the apex of each cell to the pia, while dendrites from the basal angles pass 
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laterally to synapse with surrounding axons. The axons terminate either in the 
deeper cortical layers or in the underlying WM. Stellate cells have short axons 
and usually terminate on a nearby neuron. The fusiform cells are located 
mainly in the deepest layers of the cortex and they have their long axis vertical 
to the surface. Their axons pass on to the underlying WM while their dendrites 
ascend toward the surface of the cortex. The horizontal cells of Cajal are small 
horizontally oriented cells located in the most superficial layers of the cortex, 
and their axons pass parallel to the surface of the cortex, making contact with 
the dendrites of the pyramidal cells. The cells of Martinotti are small cells 
present throughout all levels of the cortex. Their axons are directed toward the 
pial surface of the cortex and end usually in the most superficial layer of the 
cortex.44 
The nerve fibers of the cerebral cortex are arranged either radially or 
tangentially. The radial fibers run at right angles to the cerebral cortex and they 
are either leaving the cortex (e.g axons from pyramidal, stellate and fusiform 
cells) to the WM tracts, or afferent fibers terminating into the cortex. The 
tangential fibers run parallel to the cortical surface and mostly located in layers 
IV and V, where they are referred to as the inner and outer bands of Baillarger. 
They are mostly collateral and terminal branches of afferent fibers. The bands 
of Baillarger are well developed in the sensory areas due to the high 
concentration of the thalamocortical fibers endings, as well as in the visual 
cortex.44  
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1.11 Role of non-conventional imaging in MS: 
1.11.1 Diffusion weighted imaging: 
Diffusion – weighted imaging (DWI) is considered a quantitative technique 
that has advantage over the conventional MRI sequences in that it provides 
information for the microscopic changes in the normal appearing brain tissue. 
Initially spin echo T2-weighted sequence was used for acquisition, but such 
sequence was very sensitive to motion producing lots of artifacts. Hence this 
was substituted with echo-planar spin-echo T2-weighted sequence. Other 
techniques are also being used such as single-shot gradient and spin-echo or 
single-shot fast spin-echo techniques. Diffusion is defined as the microscopic 
random motion of molecules in fluid. In the brain tissue this random 
movement is influenced by the microstructural changes in abnormal brain 
tissue. This causes the diffusion coefficient in brain tissue to be lower than the 
diffusion coefficient in free water. Only the apparent diffusion coefficient can 
be measured, as the motion of the molecules cannot be differentiated if it is due 
to concentration gradient or any other cause such as pressure gradients or 
thermal gradients. There is no correction for increase in distance travelled due 
to tortuous routes, hence only apparent diffusion coefficient (ADC) can be 
calculated. Measuring the diffusion depends on the direction of the diffusion of 
molecules. Hence measuring diffusion can provide information about tissue 
integrity. The apparent diffusion in the brain is anisotropic. Usually ADC 
values of grey and WM are similar, so there is no contrast between the grey 
and WM on an ADC map, and the contrast between these two types of tissue is 
seen on the DW images due to the T2-weighted contrast.47 Diffusion tensor 
imaging (DTI) is one of the methods developed from DWI to provide more 
detailed description of water molecules motion and microstructural isotropic 
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and anisotropic tissues
48
. This particularly measures the magnitude, or mean 
diffusivity (MD) and the direction (fractional anisotropy (FA)) of motion of 
water molecules with FA values ranging from 0 (no directional dependence for 
diffusion) and 1 (diffusion along a certain direction). FA value usually increase 
with motion of molecules in a specific direction (anisotropy). Usually in GM, 
diffusion is isotropic whereas in WM it is anisotropic due to directionality of 
myelin fiber tracts.  
Diffusion studies have been used to investigate MS brains for decades. MS 
lesions have been shown to have higher ADC and reduced anisotropy in 
comparison with NAWM. Gad- enhancing lesions and T1 hypointense lesions 
particularly have the highest ADC values. The different lesions ADC values do 
not differentiate between different MS phenotypes.50  
Diffusivity was also found to be higher in lesions with lower mean 
magnetization transfer ratio (MTR) values.51 Diffusivity is higher in NAWM 
and normal appearing grey matter (NAGM) in comparison with controls.
52 
Areas with high diffusivity were correlated with lower MTR peak 
histograms.53 A reduction in FA was noted in NAWM regions with well-
formed tracts.54 Reduced diffusion anisotropy could result from either axonal 
damage or replacement of axonal fibers with glial cells.55 An increase in ADC 
in areas of NAWM preceded the development of lesions. There was 
simultaneous but milder increase in ADC in NAWM regions contralateral to 
the developed lesions suggesting structural damage to remote NAWM regions 
that are connected to lesions.56 Postmortem studies in MS brains suggested that 
FA and MD are affected mainly by myelin content and to a lesser extent by 
axonal count.57 As for cortical lesions, 9 patients and 9 healthy controls were 
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recruited in a study where DIR, PSIR and DTI were acquired.58 They found 
that mean FA values of cortical lesions were significantly higher in 
comparison with cortical GM in healthy controls.58 The increase in the FA 
values was suggested to be due to the increased activation of microglia with 
extended processes that ensheath neuronal cell bodies and neurites, and 
contribute to increased local organization of the cortical microstructure.58 
Although FA is commonly used in the literature, there are concerns that it 
might not be specific to demyelination. However, comparing diffusion parallel 
to the principal axis of diffusion to diffusion perpendicular to this axis has 
proven helpful to differentiate demyelination to axonal loss..59  
1.11.2 Magnetisation Transfer Imaging: 
Although conventional magnetic resonance imaging remains the gold standard 
for the diagnosis of demyelinating diseases, it lacks pathological specificity in 
detecting the changes in histopathological findings in MS, which range from 
oedema and inflammation to severe demyelination, axonal loss, gliosis and 
remyelination. 
Magnetization transfer (MT) scans can be interpreted in various ways. MTR 
values could be presented as normalised mean values for a region of interest or 
as histograms. Histograms of MTR values could be calculated for a whole 
brain (excluding the very low values as a measure of excluding the non-brain 
tissue such as skull and orbital tissue) or for a region of interest such as MS 
plaques or a selected region of normal appearing tissue. For each histogram the 
peak height (PH) and location (PL) could be presented, which represents the 
most common MTR values of the brain, and the MTR25, MTR50, MTR75, which 
are the MTR values corresponding to the 25th, 50th and 75th percentiles of the 
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histogram, and this indicates the MTR at which the integral of the histogram is 
25%, 50% and 75% of the total respectively. 
Using MT acquisitions in MS patients, brain tissue shows different features 
depending on its pathologic characteristics. Lesions with no MT, which usually 
appear hyperintense on T2W and hypointense on T1W sequences, represent 
almost complete tissue damage resulting in open fluid-filled spaces.  
Studies in animal models showed that MTR decreased by 5%-8% in 
oedematous tissue in comparison with the same region before the onset of any 
pathology, while MTR values in demyelinated regions was as low as 26%.60 
This was consistent with Kimura et al findings on correlating MTR and 
spectroscopy, where they showed that the moderate reduction in MTR values 
in MS plaques correlate with the reduced N- acetylaspartate (NAA)/creatine 
(Cr) ratio, which is mainly caused by myelin degradation, which suggesting 
mainly axonal loss in those plaques.61 NAA levels could also be influenced by 
metabolic dysfunction or changes in water content. Strong correlation was 
found between the tissue myelin content and MTR values in post mortem 
brains.62 
Magnetization transfer imaging (MTI) offers a good potential, through its semi 
quantitative analysis in distinguishing different pathologies that involves the 
WM and look similarly on conventional MR imaging.63 Hence MT imaging 
superiority over conventional MR sequences, which lack pathological 
specificity in distinguishing disease characteristics. 
MTR values for GM are generally higher than WM, with values of between 
23% (0.23)  and 24% (0.24) in the GM, and between 30% (0.3) and 33% (0.33) 
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in the WM.64 The variation in MTR values is also dependant on location. Gass 
et al found MTR values of around 30% (0.3) in the occipital lobe, 31.8%(0.31) 
in the frontal lobes and 33% (0.33) in the genu of corpus callosum.64 
The mean MTR values of WM MS lesions are lower than values in WM 
lesions in ischemic patients.64 Mean MTR values of MS plaques are higher in 
benign MS patients than in SPMS patients.64 MTR values of NAWM were 
found to be higher with increase distance from WM lesions.65 
On comparing the MTR values of MS lesions at various stages of the disease 
according to their appearances on T1 sequence, it was noted that MTR values 
were lower in hypointense lesions than for isointense lesions. The MTR values 
for MS lesions varied with the change in their intensity on conventional MR 
sequences.
66
 It was also reported that very low MTR values in MS lesions at 
initial enhancement was predictive of a persistent T1-weighted hypointensity 
and lower MTR values 6 months later.66 In post-mortem brains hypointense T1 
lesions showed lower MTR values and reduced myelin content in comparison 
with isointense lesions while no significant difference in axonal count and 
gliosis was noted.62 
Filippi et al noted that mean lesion MTR, MTR PH and PL were lower in 
SPMS patients than in other MS phenotypes. CIS, benign MS patients and 
controls had the same MTR parameters.67 
MTR values are known to be affected by several factors. Oedema and 
inflammation are known to cause mild reduction in MTR values, while 
demyelination and axonal loss cause a more severe reduction.68,69 MTR values 
below the mid-20% range is highly suggestive of demyelination.69 MTR values 
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were found to be higher in ischemic WM lesions (mean 34%) than in 
demyelinating MS plaques (mean 22.5%) and in oedema (mean 30.2%).69 
In a longitudinal study GM PH MTR was found to be lower on comparing 
SPMS patients with RRMS, RRMS with CIS and MS patients versus 
controls.70 On the other hand as quantitative MRI methods are not made for 
quantifying the extent of GM pathology at individual level, a very interesting 
study used individual GM MTR mapping to assess the degree of GM 
pathology in individual MS patients and its distribution. They noticed that 51% 
of their patients showed decrease in GM MTR in comparison to controls, and 
GM injury was very variable across patients from early stages of the disease.71  
MT imaging has several advantages over conventional MR sequences as it 
provides an opportunity to better understand MS pathology as it is more 
specific than the water dominated signals of conventional T-2 weighted MRI 
sequences.72 MT also provides better understanding of the invisible disease 
burden in the so called normal appearing brain tissue, as those regions which 
appear normal on conventional scans were found to have lesions on acquiring a 
high resolution sequences.65,73Derakhshan et al74 used two-dimensional 
parametric surface models of the cortex to examine the spatial extension of 
subpial reduction in MTR values in MS patients in the cortical GM. They 
found MTR was abnormal mainly in the cingulate cortex, insula and in the 
depth of the sulci which is consistent with the known pathological topographic 
subpial lesions distribution. Moreover the distribution of the subpial located 
abnormal MTR values was more prevalent in the SPMS patients than in the 
RRMS patients.74 CIS patients showed abnormally low GM MTR in at least 
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one brain region, most commonly in the temporal cortex, then frontal cortex 
and limbic cortex, while the parietal and occipital cortex were the least 
frequently involved.75 On examining the cerebral cortex of CIS patients who 
presented with optic neuritis, a significant reduction of GMMTR was noted 
bilaterally in the visual cortex. Interestingly patients who did not have any T2 
WM lesions did not show reduction in visual cortex MTR values in 
comparison with those who had T2 lesions.76 Clinical correlations at base line 
such as visual acuity and EDSS were significant with visual cortex MTR but 
not with T2 lesion load.76 
The major advantages of MT imaging and the MTR are that they are relatively 
easy to implement as MT is available from all major manufacturers. They also 
can be applied to both spin-echo and gradient echo sequences and are easy to 
post process. MT is a relatively high signal to noise ratio (SNR) technique and 
can be performed in clinically acceptable times.59 
Physics of Magnetization transfer imaging: 
MT was first discovered accidentally by Wolff and Balaban in 1989.77 They 
were trying to perform a spin transfer experiment by selective saturation of 
urea looking for small signal suppression in water. Instead, they found a 
significant loss of image intensity from tissue which was explained by 
exchange of magnetization.78 
MT is the nuclear magnetic resonance (NMR) phenomenon in which spinning 
of different materials causes exchange of their magnetization. The hydrogen 
nuclei (protons) of water are the main source of signal in conventional MRI as 
they have a high MR sensitivity, they are prevalent, and have sufficiently long 
relaxation times to allow easy detection. Hence image contrast is dependent on 
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the water content (proton density), characteristic spin-lattice (T1) and spin-spin 
(T2) relaxation times, and imaging sequence parameters. Proton MRI detects 
signal only from mobile protons which have T2 relaxation times greater than 
10 ms, so that spatial encoding gradients can be played out between excitation 
and acquisition before the signal has completely decayed. The T2 relaxation 
times of macromolecules are less than 1 ms and hence are too short to be 
detected directly in MRI, resulting in lack of visibility on MRI, hence they are 
MRI invisible. However, coupling between the maromolecular protons and the 
mobile (liquid) protons allow the spin state of the immobile protons to 
influence the spin state of the liquid protons through exchange processes.78 The 
macromolecular spins have a much broader absorption lineshape than the 
liquid spins, hence they are around 106 times more sensitive to an appropriately 
placed off-resonance irradiation.78 So it is possible to selectively saturate the 
macromolecular spins using an off-resonance radio frequency pulse.78 This 
selective saturation can be transferred to the liquid spins, with a variable rate of 
exchange depending on the nature of tissue, then the signal can be detected 
with MRI.78 (Figure 1.1) The effect of the off- resonance irradiation on this 
system is different for the two pools. For example for pool B, the protons in 
the macromolecules are strongly coupled to each other resulting in a 
homogeneously broadened absorption lineshape. In MT imaging, the intent is 
to manipulate the liquid pool indirectly by saturating the macromolecular pool. 
When an on-resonance excitation pulse is applied after an off-resonance pulse, 
the produced MR signal will be lower than without that prepulse. 
The exchange that transfers macromolecular saturation to the liquid pool,  
results in decreased longitudinal magnetization being available for imaging.78 
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Hence the greater the exchange rate, the higher the MTR. In tissues with no 
semi-solid component, such as CSF, the water magnetization is unaffected. So 
MT imaging provides an additional form of contrast that is a function of the 
relative semi-solid/water pool size and the strength of interaction between 
them.72 
Off-resonance irradiation in MRI can be applied in a continuous wave (CW) 
mode or in a pulsed mode. In MT imaging CW is the first used pulse mode as 
it provides the cleanest separation between the amounts of saturation in the two 
pools. However as a result of their long duration, they are considered time 
consuming and result in high-energy deposition. The radio frequency energy 
from an imaging sequence can cause heating of the tissues of the body. 
Exposure to RF energy should be limited. The specific absorption rate (SAR) 
is the limiting measure. The recommended SAR varies in different parts of the 
body. For the head it must be less than 3.2w/kg. So, any pulse sequence must 
not rise the temperature by more than 1 Cͦ. The pulsed MT technique, involves 
selective saturation of the immobile pool using either brief off-resonance RF 
pulses (at a frequency that is off-set from the free water resonance) or on-
resonance (near the free water resonance). The on-resonance pulsed saturation 
technique employs low flip angle saturation pulses to achieve selective 
saturation of the macromolecular pool. MTR maps are calculated via the 
equation  MTR = (Mnonsat - Msat) / Mnonsat × 100. Mnonsat provides the intensity of a 
voxels without applying the saturation pulse while Msat  provides the intensity 
of the same voxel after applying the saturation pulse. MS lesions appear 
hypointense on the MTR maps and they have lower MTR values than the 
surrounding normal appearing tissue.60 
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(Figure1.2) Layers of the cerebral cortex 
 
 
Diagram illustrates layers of the cerebral cortex (I to VI)   
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(Figure1.3) Variation in absorption lineshape causing macromolecular 
selective saturation 
 
This figure illustrated the macromolecular spins having broader absorption 
lineshape than the liquid protons, and can selectively be saturated using a 
specific off-resonance RF pulse.  
 
(Figure1.4) Model of MTR two pool exchange 
 
This figure illustrates a two pool model of magnetization transfer exchange. Pool 
A represents the liquid pool, while pool B represents the macromolecular pool. 
The shaded area in each pool represents saturated spins, while unshaded area is 
the spins in the longitudinal orientation. RA and RB represent the longitudinal 
relaxation rates. R is the magnetization transfer exchange rate between the two 
pools.78 The number of spins in each pool is represented by M0A and M0B. The 
number of macromolecular spins is much less than the liquid spins. 
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(Figure1.5) MTR formulation from MTsat and MTnonsat 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This figure illustrates the formation of MTR image from Msat and Mnonsat 
images  
 
 
 
 
MTR 
Mnonsat 
Msat 
MTR=(Mnonsat-Msat)/Mnonsat× 100 
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1.12 Cortical Grey Matter as focus of interest:  
Originally MS was thought to be a disease of the WM; however the GM 
involvement was noted over a hundred years ago in early pathological studies. 
In some MS patients, the pathological process starts in the cortex months and 
sometimes years before involving the WM.79 The advances in 
immunohistochemical staining techniques sensitive to myelin has advanced 
our understanding of the contribution of GM to the disease process.15 Recently 
the contribution of cortical injury to the diagnosis and prognosis of MS has 
become more widely appreciated.80 CL were found to be more prevalent in 
males and more associated with the presence of oligoclonal bands (IgGOBs) in 
the CSF, with patients who had IgGOBs having twice as many CL than those 
without IgGOBs .81 Interestingly the number of WML did not vary across 
patients with the presence or absence of IgGOBs in CSF.81  CIS patients with 
CL and intrathecal synthesis of Ig had higher risk of conversion to MS, 
moreover RRMS patients with CLs and intrathecal Ig synthesis showed more 
disease activity.82 
CL load was found to correlate with physical disability and cognitive 
impairment, and better explain them than WM lesion load.83,84 Cortical 
involvement and its correlation with cognition was demonstrated in early 
stages of the disease, as CIS patients with cognitive impairment showed 
increased cortical recruitment and connectivity patterns when compared with 
CIS cognitively preserved patients or healthy controls.85 Fillipi et al suggested 
that the presence of at least one intracortical lesion (IC) at the baseline DIR 
scans of CIS patients has a high accuracy for identifying patients at risk of 
developing clinically definite MS.86 MRI studies showed that CL and cortical 
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atrophy are present in early stages of the disease,81 and become more 
prominent during the progressive phase.83 The rate of CL accumulation was 
found to be similar in RRMS and SPMS forms of the disease.87 RRMS patients 
with epilepsy were found to have more severe and rapidly accumulating CL as 
well as cortical atrophy in comparison with RRMS patients without epilepsy.88 
The pathological changes in the cortex are reported from very early stages of 
the disease. Patients with higher CL load were found to have higher WM 
lesion load, and smaller brain parenchymal fraction in comparison with 
patients without cortical lesions.81 Longitudinal studies showed that CL 
volume at baseline correlated with baseline disability, and the rate of CL 
accumulation was higher in those patients who showed worsening disability 
than those who were clinically stable.87   
Buownell and Hughes reported in 1960 that 26% of MS lesions affect the 
GM.89 Cortical demyelination was found to be slightly more extensive in the 
frontal and temporal lobes (17% and 19% respectively) compared with the 
parietal and occipital lobes (12% and 8% respectively), while the insular cortex 
was found to be the mostly demyelinated with an average of 26%.90 
CL could vary in size between a few millimetres and 1 cm. The correlation 
between WM demyelination and cortical pathology are conflicting. Some 
studies15 suggest very small correlation between the WM inflammation and 
microglial activation with the degree of cortical demyelination, while others 
suggest that GM demyelination is an independent process from WM  
pathology.91 Studies in EAE showed that cortical inflammation is an early 
transient phenomenon in cortical demyelination.92 Diffuse meningeal 
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inflammation was strongly associated with cortical demyelination, whereas 
focal perivascular meningeal inflammation was less strongly associated with 
cortical lesions. Topographically moderate to marked meningeal inflammation 
was associated with subpial plaques, while focal perivascular meningeal 
inflammation was more associated with intracortical or leukocortical plaques.93 
(Figure 1.5) 
1.12.1 Role of imaging in cortical lesions: 
The above mentioned conventional imaging techniques are not optimal for 
cortical lesion detection, partially as GM lesions have longer relaxation times 
than normal WM which causes poor contrast between GM and lesions in the 
GM in comparison with WM lesions,94 but also because partial volume effect 
caused by the CSF surrounding the cortical GM plays a significant role as 
well.94 Another theory is that the high cellular density in the CL does not 
permit a sufficient expansion of the extracellular space to allow an increase in 
relaxation times in CL, as is seen in WML.94 Over the last few years, a few 
imaging sequences have been developed to improve CL detection. DIR is an 
MR sequence which involves suppression of the signals from both the WM 
and CSF, giving better delineation of the GM. This contrast is mainly due to 
the differences in T1 relaxation times between GM and CSF, as well as 
between GM and WM.95 Using 3D DIR showed an average increase of IC 
lesions detection by 152% per patient on comparison with 3D FLAIR,96 and 
was useful in differentiating MS from other similar presentations such as 
NMO.
97 On the other hand combined 3D DIR and FLAIR still failed to detect 
most of CL that were observed in histopathology.98 Moreover 3D DIR failed to 
detect subpial lesions (SP) and was difficult to differentiate between mixed 
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juxtacortical (MXL) or IC due to the difficulty in delineation of the cortex, and 
WM borders. It was also shown to have flow artifacts mainly in the occipital 
lobe.81 In 2011, recommendations were published to improve CL detection 
using DIR. On using the proposed recommendations, full agreement was 
reached by all teams only on 19 % of lesions.
99
 3D-FLAIR at 7 Tesla was 
found to detect more CL than 3D-DIR, mainly mixed lesions.
100
 On comparing 
7 Tesla 3D-MP-FLAIR and 3D DIR with the same sequences at 3T, it was 
found that 7T sequences showed higher number of lesions, with better 
classification, however 7T DIR images showed poorly attenuated peri-vascular 
spaces in the WM which can be mistaken for lesions.101 PSIR is a T1 sequence 
that showed superior GM-WM contrast with clear lesion delineation at shorter 
scan time in comparison with FLAIR.102 It provides higher signal intensity than 
conventional T1-weighted inversion recovery sequences by adding combined 
negative and positive longitudinal magnetization in the image. Not only the 
number of CL identified on PSIR was higher than 3D DIR but it was able to 
classify lesions more accurately.103 On comparing 3T DIR, 3T FLAIR and 7T 
MPRAGE, it was observed that each imaging sequence was sensitive to 
different lesions in the region of the cortex, on the other hand, high resolution 
scan (7T MPRAGE) had clearly improved the classification of CL and better 
classified artifacts.104 3D-FLAIR, 3D T1-weighted and 2D T2-weighted at 
7Tesla were found superior to the same sequences at 3 Tesla in CL detection 
and classification.105 
Currently available MRI sequences are not sensitive to depicting all CL 
subtypes especially SP. Hence any firm conclusions regarding the association 
between the degree of cognitive impairment or physical disability and the 
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extent of cortical demyelination are difficult to draw giving that most the 
disease burden is invisible.  
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(Figure 1.6) Cortical Lesions Classification 
 
The figure illustrated different types of cortical lesions: to the left mixed 
lesions with the lesion mainly in the cortex with partial extension into the 
white matter. In the middle intracortical lesions which are usually small lesions 
extending into the middle layers of the cortex. To the right the subpial lesions 
which usually extend to involve the whole cortex from the pia to the white 
matter junction without extending into the white matter106   
Mixed Lesion Intracortical Lesion Subpial Lesion 
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Chapter 2 
Detection of Focal Cortical Lesions Using 7T Magnetisation 
Transfer Imaging In Patients with Multiple Sclerosis 
2.1 Abstract 
 
Background: 
Cortical lesions account for a larger proportion of brain demyelination than 
WM lesions.  Recent studies reported improved cortical lesions detection using 
DIR, T2*, MPRAGE and PSIR.  
Hypothesis: 
Our hypothesis is that high resolution MTI at 7 T performed within reasonable 
scanning time is able to detect cortical lesions in MS patients in comparison 
with other currently used conventional MRI sequences.Methods: 
Eighteen patients with MS and nine healthy controls were scanned using 7T 
MTR maps, 7T MPRAGE, 7T T2* and 3T 3D DIR.  
Results:    
 We detected 365, 289 and 231 lesions with 7T MTR, 7T MPRAGE and 7T 
T2* respectively in the MS group. Few cortical abnormalities were detected in 
the controls. In 8 MS patients  who had 3T DIR on the same day, a total of 136 
lesions were detected as opposed to 171, 147 and 126  lesions with 7T MTR, 
7T MPRAGE and  7T T2* respectively . 
Conclusion: 
 We found that 7T MTR, in less than 10 mins scanning time, was very 
sensitive in detecting cortical lesions in comparison with the other sequences.  
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As MTR is more pathologically specific than other sequences in detecting 
tissue myelination, it raises the possibility that high resolution MTR will be 
able to demonstrate cortical remyelination in vivo. 
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2.2 Introduction 
2.2.1 Pathology of cortical lesions: 
A previous report suggested that inflammation of CL is less than that of white 
matter lesions,107 and lesions tended to arise in the deepest point of the sulci. In 
another study WM lesions contained 6 times more CD68-positive cells and 13 
times more CK3-positive lymphocytes than cortical lesions.108  Parts of the 
leukocortical lesions that appeared within the WM were no different to other 
white matter lesions. It was also observed that most of the cortical lesions arise 
within the territory of the principal vein V5, hence cortical lesions were 
classified into 7 subtypes depending on the cortical layer and venous territory 
they involve. The size of cortical lesions may vary depending on the size of the 
cortical vein involved, for example large type 7 lesions which might involve a 
whole gyrus are likely to reflect involvement of the central vein of the gyrus 
while smaller intracortical lesions (type 3 or 6), may arise as a result of 
involvement of small branch veins. 94    
A simpler classification has been proposed by Peterson et al. They classified 
cortical lesions identified in several postmortem studies depending on their  
location in the cortex.109,108 The first type is leukocortical lesions (type I), which 
extends from the cortex to the WM and usually accounts for about 34% of 
lesions. The second type is the intracortical type (type II) which is small 
confined to the cortical ribbon and forms around 16% of lesions. The third and 
fourth types are called subpial (type III &IV), they involve different layers of 
the cortex or sometimes the entire cortex without invading the subcortical WM 
tissue and they form around 50% of cortical lesions.  
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Although the previous classification is the most commonly used nowadays, it 
excludes some types of cortical lesions. Other research groups consider cortical 
lesions that are affecting all 6 cortical layers with only marginal involvement 
of the WM as subpial, rather than leukocortical lesions.110 The classification of 
cortical lesion that involves the entire thickness of the cortex as well as a 
considerable region of the sub adjacent white matter is even more challenging, 
as few possibilities are possible: it could be a subpial lesion that extends into 
the WM; a white matter lesion that extends into the cortex until it reaches the 
pia; or finally it could be merging of a subpial lesion with a leukocortical 
lesion.111    
Cortical lesions can be classified according their stage of inflammation and the 
density and distribution of MHC class II positive cells into active, chronic 
active, and chronic inactive lesions.108 Active lesions have a distinct border of 
MHC class II positive cells and also high density at the cores, while chronic 
active lesions had MHC class II positive cells at the borders not in their cores. 
Chronic inactive cortical lesions had no clear borders but their cores had 
similar positive cells density similar to this of normal appearing cortex. 
Inflammation level was similar in all types of cortical lesions. Compared to 
active WM lesions, active cortical lesions contained 4 times fewer CD68-
positive cells at their borders and in their cores, while chronic active cortical 
lesions had 10 and 13 times fewer CD3-positive cells at their border and core 
respectively compared to chronic active white matter lesions. 
On comparing different types of cortical lesions, it was found that intracortical 
lesions were the least inflammatory and lacked the lymphocytic and 
macrophagocytic inflammatory infiltrates and complement deposition, while 
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leukocortical lesions were more inflammatory than subpial and intracortical 
lesions.107 
There is a growing interest in type III subpial lesions. It has been noticed that 
the depth of the demyelinated area is constant, and a subpial lesion can extend 
over multiple gyri. It is believed that demyelination or oligodendrocyte death 
in subpial lesions may be associated with elements that spread from the surface 
of the brain, hence the mechanisms of demyelination in subpial lesions may be 
different from those in intracortical and mixed lesions.108 
Popescu et al reported the presence of a type of inflammatory subpial cortical 
lesion associated with MRI gadolinium contrast enhancement that preceded the 
white matter lesions dissemination which suggests that inflammation – induced 
cortical blood-brain barrier damage and demyelination may be an early 
pathogenic event in MS. 110 
2.2.2 Contribution of MRI to cortical lesion detection: 
MRI plays a major role in cortical lesion detection in MS patients. GM lesions 
are difficult to detect on conventional MRI scans, mostly due to the relatively 
low myelin content of the cortex, causing a smaller increase in T2 relaxation 
times in cortical lesions compared to that observed with WM lesions.98 This 
has hindered the in vivo assessment of the effect cortical demyelination has on 
the physical and neuropsychological status of MS patients. 94 New MRI 
techniques have emerged over the last few years that have improved cortical 
lesion detection. 
Different types of cortical lesions behave differently in terms of their 
histopathological characteristics. This heterogeneity means that they have 
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different sensitivity to MR imaging, hence the different rates of cortical lesions 
detection by different MR sequences depending on their type as well as their 
stage. 
DIR is one of the more recently developed, yet commonly used sequences to 
help with improved identification of cortical lesions. This technique combines 
two inversion pulses that suppress the signals of both CSF and WM, providing 
better cortical delineation and cortical lesion prominence.
112
 Three dimensional 
(3D) MRI improves spatial resolution by allowing small voxel acquisition 
while maintaining a good SNR.113 A postmortem study compared the 
sensitivity of 3D DIR to detect cortical lesions in comparison with 3D FLAIR. 
They found the rate of cortical lesion detection using 3D DIR was 1.6 folds 
higher than 3D FLIAR and this increased to 2 folds with retrospective scoring. 
3D DIR had a particular higher sensitivity to intracortical lesions with 3D DIR 
having specificity of 90% to detect cortical lesions.114  
Because of the prominent increase in the SNR, high –magnetic fields ( higher 
than 1.5 Tesla ) offer several advantages in terms of higher sensitivity to 
cortical lesions detection as well as better classification. An in vivo study has 
been performed to examine the sensitivity of 3D DIR, T2- weighted and 
FLAIR sequences at both 1.5 T and 3T field strengths. This showed that the 
sensitivity to cortical lesion detection was definitely improved by the high field 
strength.115 The total number of lesions detected was higher at 3T compared 
with 1.5 T across all pulse sequences. More infratentorial, periventricular and 
juxtacortical WM lesions were detected using T2-weighted and FLAIR 
sequences at 3T in comparison with 1.5T.115 However, one of the main draw 
backs for DIR at 1.5 or 3T is the presence of artefacts due to vessel and CSF 
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pulsation which was more observed than any other sequences such as T2-
weighted and FLAIR.115  
3T PSIR is another emerging sequence that has shown improved cortical lesion 
detection. In a direct comparison between 3T DIR and 3T PSIR in terms of 
their ability in detecting cortical lesions, it was shown that 3T PSIR was able 
to detect a significantly higher number of cortical grey matter lesions.103 7T 
FLASH T2* is another sequence that improves cortical lesion detection. In a 
recent study that directly compared the sensitivity of 3D 3T DIR and 7T 
FLASH T2* in detecting cortical lesions, it was shown that 7T FLASH –T2* 
detectd more cortical (especially subpial) lesions than 3T DIR. 116  
MT MR imaging is a tool that has been used to assess demyelination and 
remyelination in MS. Mougin and colleagues have previously reported the use 
of ultra-high field MTR, which benefits from improved signal to noise ratio, 
allowing better spatial resolution compared to lower field MTR.117  
In this study we examine the use of ultra-high field (7T) MTR for the detection 
of cortical lesions in MS and validate it with other sequences reported 
previously at ultra-high field. We tried to strike a balance between high quality 
scans and reasonable scanning times. Therefore, we employed sequences that 
cover the whole brain in less than 10 minutes each. In addition, a subset of 
patients was also scanned on the same day with 3 Tesla 3D DIR; to compare 
our findings with the most common clinically used method for cortical MS 
lesion detection. 
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2.3 MATERIALS AND METHODS 
Subjects 
 Eighteen patients with MS were recruited from the neurology outpatient clinic 
at Nottingham University Hospitals NHS Trust. These include 12 women and 
6 men (16 relapsing remitting, 1 secondary progressive, 1 primary progressive 
(median Expanded Disability Status Scale (EDSS) score 3.0 (range 0-7.5); 
mean age 48 years (range 32-65 years); mean disease duration 7.25 years 
(range 2-19 years). Nine healthy controls subjects (6 men, 3 women); of mean 
age, 36.5 years (range 24-50 years) were also scanned.  All subjects gave 
informed consent prior to examination and the study had received prior ethical 
approval from the local research ethics committee.  
Data Acquisition 
The 7T images were acquired using a 7T Achieva scanner (Philips Medical 
Systems), equipped with whole body gradient coils, head only quadrature 
transmit radiofrequency (RF) coil and a NOVA 32 channel receive coil 
equipped with SENSE reconstruction. The 3T images were acquired on a 3T 
Achieva scanner (Philips Medical Systems) equipped with a whole body 
gradient coil, a 32 channel SENSE receive coil and a whole-body transmit coil. 
All the patients and healthy volunteers were scanned on the 7T scanner. Eight 
patients were also scanned on the 3T scanner. 
Sequences 
(1) High resolution MPRAGE images were acquired with a tailored inversion 
pulse to reduce effects of B1 inhomogeneities. 99 Acquisition parameters are 
TI=1070ms, FA=8˚, TE/TR=7/15ms for a total of 280 slices at a resolution 
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of 0.5x0.5x0.5mm3 isotropic, for a total FOV of 205×215×140mm. The 
sequence was optimized to provide the maximum contrast between the 
different tissue types, as usually produced for subsequent segmentation 
procedure. 
 (2) The MTR maps were obtained with a magnetisation transfer turbo field 
echo (MT-TFE) acquisition, giving two images (MTsat and MTnosat): the MT 
sat was acquired by applying 20 off-resonance pulses (sinc pulses with 
bandwidth of 300 Hz and off-resonance by 1.0 kHz (-3.4ppm), 20 ms between 
each pulse) before each TFE readout train, chosen to maximize the GM/WM 
contrast in the MTR maps. The sequence used a turbo-field-echo readout 
(TR/TE=12/6.4ms, flip angle=8˚, 0.5×0.5×1 mm3 , FOV 205×175×80mm, 
centre-out sampling, TFE factor=450, shot to shot interval (SSi) of 10s, 
acquisition time=8min 50s). Images were then coregistered and high resolution 
MTR maps were calculated from (MTnoSat-MT Sat)/MT noSat on a pixel by pixel 
basis.  
(3) T2*-images were also acquired with a 3D FLASH-T2*w spoiled Gradient 
Echo sequence with the following parameters: TR/TE=150/20ms, flip 
angle=14˚, FOV of 216×216×85mm, with a resolution of 0.5×0.5×0.5mm3 and 
acquisition time of 9min. The contrast in the T2* images was optimized to 
provide good WM/GM contrast with a sufficient TR for 3D imaging. It was 
also checked that the optimal sequences gave similar contrast to the sequences 
presented in the literature. 118 
(4) 3T DIR images were acquired on a 3T Philips Achieva system in eight of 
the 18 patients using a standard 3D Turbo Spin Echo sequence. Parameters for 
the DIR were TI1= 2600ms, TI2=625ms, Flip angle=90°, Refocusing 
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angle=180°, TE/TR=250/5500ms, FOV of 250x250x195mm
3
 with a resolution 
of 1x1x0.65mm
3
 acquired sagittally, Number of Average=2 for a total 
acquisition time of 6.30min.  
Image analysis 
Cortical lesions were detected manually in patients and healthy controls by 2 
independent observers. To avoid any bias by the presence of WM lesions in the 
MS group, and to ensure robust blinding in the detection of cortical lesions, the 
WM was masked. The cortical grey matter ribbon (cGMR) mask was produced 
from the MPRAGE sequence. The bias in the MPRAGE image was first 
removed using spm (http://www.fil.ion.ucl.ac.uk/spm/) before segmenting the 
GM ribbon volume via freesurfer. (Figure 2.1) 
(http://surfer.nmr.mgh.harvard.edu). As the segmentation produced by 
freesurfer is not optimized for high-resolution MPRAGE scans acquired at 7T, 
extra care was taken to produce the grey matter ribbon mask (cGMR). 119 The 
mask of the cGMR was first dilated by one pixel to compensate for any loss of 
GM volume due to classification and registration errors. The masked images 
were then manually checked for accuracy of classification and manually edited 
if necessary by an experienced independent observer. The mask was then 
projected on each of the volumes (MPRAGE, MTR, DIR and T2*w) which 
were previously registered to the MPRAGE scan using FLIRT FSL 
(http://www.fmrib.ox.ac.uk/fsl/), using mutual information for the cost 
function for the inter-modal registration. All the subsequent ribbon modalities 
were randomised, before a segmentation consensus was reached between three 
independent reviewers on four subjects. The DIR scans were segmented 
according to the recent recommendations proposed by the MAGNIMS group. 
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Lesions had to be hyperintense compared with the surrounding GM and 
occupy more than three pixels. 118 Similar consensus was reached for the other 
modalities: cortical lesions had to be hypointense on MTR and MPRAGE, 
hyperintense on T2* and DIR scans, had to be visible on a minimum of two 
consecutive slices and to have a diameter of at least three pixels. Manual 
cortical lesion detection was performed by consensus to all the slices in all the 
scans using imageJ. Retrospective analysis of all the original unmasked scans 
was then performed to identify cortical lesions undetected by the blinded 
assessment.  Classification of the type of cortical lesions was performed 
retrospectively for all lesions on the original images. Lesions were classified 
according to their location as intracortical (IC, located within the cerebral 
cortex), Leukocortical, also known as mixed
120
 ( present mainly in the cortex 
with some (∼25%) extending into the WM ), and subpial (extending from pial 
surface through the entire width of the cortex without involving subcortical 
WM ) lesions by consensus between all modalities. Examples of cortical 
lesions in different sequences (2.4 and 2.5), and artifacts on MTR sequences 
are illustrated in figure 2.2 and figure 2.3 respectively. 
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Registration of all 
images on MPRAGE 
using FSL 
Segmentation of 
cortical ribbon via 
free surfer 
Ribbon mask applied 
to all modalities 
(Figure 2.1) Scans 
analysis and cortical 
ribbon segmentation 
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(Figure 2.2) Cortical ribbon of MS patient with mixed cortical lesion 
appearing as hypointense in the MTR images (left and middle) and 
hyperintense in the MTsat (Right) 
 
 
 
 
 
 
 
 
 
 
 
 
(Figure 2.3) An artefact in the MT images in the form of a vein appearing as 
hypointense in the MTR images (left and middle )and hypointense in the MT 
sat (Right) as well 
 
 
 
 
 
 
 
 
 
 
  
MTR MTR MTsat 
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(Figure 2.4) Mixed cortical lesion in different MR sequences 
 
 
 
 
 
 
(Figure 2.5) Intracortical lesions in different MRI sequences 
Figure illustrates intracortical lesion (small lesion within the cortex, not 
extending to pial surface or the WM/GM junction) in different MRI sequences  
7T MPRAGE 7T MTR 7T MTR 7T T2* 
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(Figure 2.6) Subpial lesion in different MRI sequences 
 
 
Figure illustrates subpial lesion detected on 7T MTR (middle grey scale and 
coloured versions), but is not detected on 7T MPRAGE (left) or on 7T FLASH 
T2* (right)  
7T MPRAGE 7T MTR 7T MTR 7T T2* 
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2.4 Statistics 
Statistical analysis was performed using GraphPad Prism software by non-
parametric ANOVA (Friedman test) with post hoc Dunn's multiple-
comparisons. As the analysis was done twice (comparing lesion counts for 7T 
MTR, 7T MPRAGE, and 7T FLASH T2* from all patients and then comparing 
7T MTR, 7T MPRAGE, 7T FLASH T2* and 3T DIR, for a subset of patients), 
p-values (for non-parametric ANOVA) and adjusted p-values (for multiple 
comparisons) of less than 0.025 were considered to indicate a significant 
difference. For multiple comparisons analysis, firstly I compared mean lesion 
counts from 7T MTR versus mean lesion counts from 7T MPRAGE and 7T 
FLASH T2* for all patients. Then I compared mean lesion counts from 3T 
DIR versus mean lesion counts from 7T MPRAGE, 7T MTR and 7T FLASH 
T2* for a subset of patients who had 3T DIR acquired on the same day. 
Bootstrap method was used to construct 95% confidence intervals for the 
proportion of number of lesions seen on two sequences. 
The correlation between the numbers of lesions detected using different 
sequences was assessed using the Spearman correlation coefficient rho. 
Intraobserver reproducibility was assessed for MTR cortical lesion detection 
on 200 slices using agreement for positive rating measure, while interobserver 
reproducibility was assessed using kappa coefficient test. 
2.5 Results 
Imaging at both field strengths (7T and 3T) was well tolerated in all our 
subjects. None of the subjects reported any discomfort within either of the 
scanners, beyond the occasional vertigo few of the subjects had as they were 
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entering or leaving the 7T scanner. Examples of MS lesions in different 
modalities are shown in figures 2.4 and 2.5 
In order to assess scan reproducibility, four patients (2 CIS and 2 RRMS) were 
scanned twice on the same day, using the same protocol described before. In 
the first MTR scans, four mixed leukocortical lesions, three intracortical 
lesions; six subpial GM lesions were detected. The same scans acquired an 
hour later demonstrated the same lesions. 
Intraobserver reproducibility for MTR sequence segmentation was estimated 
by agreement for positive rating as 0.91, while interobserver reproducibility 
was estimated by kappa coefficient as 0.8. 
On prospective analysis, 335 cortical GM lesions in total were detected with 
7T MTR in the patient group while 14 GM abnormalities were detected in the 
MTR scans of the control group in our blinded assessment. Full data on the 
prospective review of lesions can be found in table 2.1. 
Statistical analysis of retrospective scoring of 7T MTR, MPRAGE and 7T 
FLASH T2* indicated statistically significant differences between lesion 
counts (p<0.0001). The mean number of lesions detected with 7T MTR was 
significantly higher (1.26-fold) than the mean number of lesions detected by 
7T MPRAGE (adjusted p=0.001) and higher (1.6-fold) than the mean number 
of lesions detected by 7T FLASH T2* (adjusted p<0.0001). (Table 2.2) 
 Using retrospective review of all the sequences for each patient 365 GM 
abnormalities were detected using MTR scans in all subjects and seven in 
healthy controls. The lesions detected on MTR, when visualised along the 
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MPRAGE scans that provided better WM-GM contrast, were classified into 
201 leukocortical lesions, 39 intracortical lesions and 125 subpial lesions.  
When we compared lesions in different sequences, a significant overlap was 
found confirming that the lesions detected represent genuine cortical 
abnormalities.  Fifty-nine per cent of MTR lesions were also (95% confidence 
interval 35% to 80%) visible on 7T MPRAGE, and 52% (95% confidence 
interval 32% to 70%) on 7T T2*. Sixty nine percent (95% confidence interval 
56% to 79%) of lesions were visible on 7T MPRAGE and 7T T2*. 
 In those patients who have had 3T DIR acquired on the same day (n=8), 133 
DIR lesions out of 136 were also detected in MTR, but DIR did not detect 38 
lesions seen on 7T MTR.  Similarly 89.7% of DIR lesions were seen on 7T 
MPRAGE (122 out of 136) and 84.6% (115 out of 136) seen on 7T T2*. 
(Table 2.3) 
The total number of lesions detected in each patient with 7T MTR significantly 
correlated with the lesions detected on 7T MPRAGE (rho=0.84, p<0.001) and 
on 7T FLASH T2*(rho= 0.73, p<0.001). Only weak correlation was observed 
between the total number of lesions detected on 7T FLASH T2* and 7T 
MPRAGE (rho= 0.45, p=0.049). 
In those patients who also had high resolution 3T 3D DIR scan, the number of 
lesions on DIR was significantly correlated with the number of lesions on 
MTR (rho= 0.75, p<0.001), the number of 7T MPRAGE lesions (rho = 0.82, 
p<0.001) and the number of 7T FLASH T2* lesions (rho = 0.76, p<0.001). 
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Leukocortical lesions constituted the highest percentage of cortical lesions 
detected by all modalities. (Table 2.4)  
In this small cohort of mainly RRMS patients, we did not find any significant 
correlation between the lesion load on any of the sequences and EDSS or the 
disease duration of the subjects in the patients group using Spearman 
correlation coefficient rho. 
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(Table 2.1) 
Prospective Grey Matter Lesion Detection comparison between sequences   
 
 
7T MTR 7T MPRAGE 7T FLASH T2* 
Total lesion 
number in 18 
patients. 
 
335 234 51 
Mean no. of 
lesions per 
patient.(range) 
18.6 
(1-49) 
13 
(1-43) 
2.8 
(1-10) 
 
Mean lesion 
volume. In 
patients  
1412 mm3 538 mm3 162 mm3 
 
 
 
 
(Table 2.2) 
Retrospective Grey Matter Lesion Detection in Different sequences.   
 7T MTR 7T MPRAGE 7T FLASH T2* 
Total lesion 
number in 18 
patients. 
365 289 231 
Mean no. of 
lesions per 
patient.(range) 
20.28 
(1-49) 
16.06 
(1-43) 
12.83 
(1-10) 
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(Table 2.3) 
Retrospective Lesion Detection in the Subgroup of Patients who had an 
Additional 3T DIR Imaging on the same day. (n=8) 
  
7T MTR 
 
 
7T MPRAGE 
 
7T FLASHA T2* 
 
3T 3D DIR 
Total lesion 
number. 
171 147 126 136 
(range) (4-49) (2-43) (1-10) (0-29) 
 
 
Mean no. of 
lesions per 
patient. 
21.38 18.38 15.75 17 
 
 
 
(Table 2.4) 
Location of Cortical Lesions in Different Sequences 
 
Sequences 
examined 
 
Intracortical Lesion 
 
 
Mixed 
Leukocortical 
 
Subpial 
7T MTR 
(n = 365) 
 
10.41 % 55.06 % 34.53 % 
7T MPRAGE 
(n = 289) 
 
7.28 % 63.66 % 29.06 % 
7T T2* 
(n = 231) 
 
4.76 % 68.39 % 26.85 % 
3T DIR 
(n = 136) 
17.65 % 82.35 % 0 
Location of lesions detected in each of the four sequences. Note that the DIR 
sequence was used in a subset of patients, as described in the methods section. 
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(Figure 2.7) 
Correlation between lesion numbers on different sequences 
 
 
The figure illustrates significant correlation between the numbers of cortical 
lesions detected on different sequences. The highest correlation was between 
7T MTR and 7T MPRAGE (rho = 0.84), while correlation between 7T MTR 
and 7T T2* was slightly weaker (rho = 0.73), and similar to correlation 
between 7T MTR and 3T 3D DIR (rho = 0.75) 
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2.6 Discussion 
Ultra-high field MTR has proven very sensitive in detecting GM lesions in MS 
patients. The aim was to test a semiquantitative “myelin” sequence that would 
be sensitive enough to depicting cortical lesions within reasonable acquisition 
time and full brain coverage. In this study, 7T MTR demonstrated a good 
ability to detect cortical lesions of different types. 
The ability to detect GM lesions with MTR opens exciting avenues in MS 
research, as it provides a semi quantitative measure of the myelination status of 
those lesions. Accumulating evidence suggest that remyelination is important 
in MS and a number of remyelinating treatments are in the pipeline. In 
longitudinal studies, high resolution MTR is a promising method to assess 
remyelination in vivo at least in the research setting.   
In this “less than 10 minutes per sequence” study 7T MTR appears to improve 
GM lesion detection compared to other 7T sequences (MPRAGE and T2*) and 
3T DIR. We believe that the MTR abnormalities detected correspond to 
cortical lesions, as only a few cortical MTR abnormalities were detected in 
healthy controls, and the MTR lesions overlap significantly with lesions 
detected with other sequences. Furthermore, MRI pathological studies showed 
that MTR lesions correspond to GM demyelination. 120, 
As with all sequences in our blinded assessment, we detected few GM signal 
abnormalities in the healthy controls. This is a very common finding in the 
WM,
122
  and with the increasing resolution of GM imaging might become 
more frequent also in the GM. This is not surprising considering the high 
resolution of our imaging. 
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Ultra-high field MRI increases the signal to noise ratio and hence has the 
potential to enhance the detection of GM lesions. Mainero et al 118 found 
increased sensitivity of 7T T2* MRI in detecting cortical lesions, with more 
than 50% of the detected lesions of subpial type III or IV. 
116
  I did not aim to 
compare the sensitivity of MTR with T2* used previously at 7T.  The 7T 
FLASH T2* we used had lower in-plane resolution but provided larger 
coverage of the brain in significantly shorter acquisition time. In addition, the 
sequence that was used in this study is 3D, thereby reducing partial volume 
effects and the risk of tissue misclassification. 116 
DIR despite being the most commonly used sequence for GM lesion detection 
has been criticised for being prone to artifacts. In a recent consensus paper for 
the detection of cortical lesions using DIR, there was agreement by all five 
teams involved on only 19.4% of the lesions. Mixed WM/GM lesions were 
visualised with more consistency. 99 In this study reassuringly, our use of DIR, 
detected lesions that correlated strongly with the total number of GM lesions 
seen at 7T high-resolution imaging. The better performance of DIR than 
previously reported, 116 might be due to the higher resolution 3T scans, whole 
brain coverage and 3D acquisition. Still with 3T DIR, we could not detect any 
subpial lesions with confidence. 
There are of course many other sequences, which we have not been able to 
study in our cohort. We had not optimised and not performed 7T FLAIR  at the 
time of this study, although a recent publication100 suggests that 3D-FLAIR at 
7T is sensitive to depict GM lesions compared to DIR,T1 and T2.  It is 
possible that the moderate but not perfect overlap between sequences in the 
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cortical lesions may reflect the different sensitivity of sequences to different 
pathologies as it has been found in the WM lesions.
100,123
 This is a promising 
avenue to follow in a larger study focusing mainly on GM lesions.  
Prospective blinded analysis of all the scans did not detect as many lesions as 
the retrospective analysis of all the sequences simultaneously. Review of all 
scans particularly helped identify lesions missed initially on T2* and 
MPRAGE. Some of the lesions still, could not be detected on any modality 
other than MTR, even with careful retrospective examination.  
Previous studies using MT MR measured the MTR globally in the brain or 
regionally through histogram analysis. This proved extremely informative in 
providing a global reflection of GM pathology but has not separated focal from 
diffuse GM damage. 71,123 As MTR better reflects tissue myelin content than 
other commonly used MRI sequences, it could also allow in vivo detection of 
lesion remyelination. 124  
MTR maps are prone to artifacts, especially at high field strengths. For 
example, typical dropout of signal near the sinuses and in the temporal lobes is 
common due to B0 and B1 inhomogeneites. The protocol described in this 
paper has been optimized to reduce these effects to a minimum,125 but a 
dropout in the contrast to noise ratio (CNR) was visible in some of the maps.  
As two different images necessary to compute the MTR maps are acquired 
separately, movement artefacts can contaminate the images. Despite 
registration of those images, intra-scan movement could degrade the quality of 
the final MTR maps. It is worth noting that unlike MTR in white matter lesions, 
MTR in cortical lesions has not been validated in post mortem studies so far. 
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Using MTR alone, we were able to classify most of the cortical lesions. As 
MTR has a lower WM-GM contrast compared to MPRAGE, we found that 
combining those sequences improved significantly the GM lesion subtype 
classification.  
As MTR at 7T was shown to detect cortical lesions bettern than other currently 
research applicable imaging sequences, we wanted to employ it to examine the 
correlation between the degree of damage in cortical lesions reflected by their 
mean MTR values and the degree of physical disability. 
In the next chapter we examined a larger group of patients of different MS 
phenotypes aiming to assess the variation in the degree of damage in cortical 
lesions among the groups. I also aim to examine the correlation between 
patients’ degree of physical disability and the degree of damage in their 
cortical lesions.  
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 Chapter 3 
Cortical lesions in secondary progressive MS are more 
destructive compared to other MS phenotypes 
3.1 Abstract  
Introduction: 
The presence and significance of focal GM lesions is undisputed, but it is 
unclear if GM lesions exhibit the same pathological heterogeneity as is found 
in the WM. Cortical lesions are more prevalent in progressive than in relapsing 
multiple sclerosis. MTI is useful in depicting WM and GM lesions. MTR 
values in the brain have been shown to reflect tissue myelin content. 
Hypothesis: 
We hypothesise that: 
1- There is a difference in the level of myelin loss in focal GM lesions as 
determined by MTR among different MS phenotypes. 
2- There is a correlation between the degree of focal cortical lesion 
demyelination and the degree of physical disability in patients with 
MS. 
Methods: 
Forty two patients with demyelination were examined along with eight healthy 
controls, using MTI at 7Tesla.  Cortical lesions were segmented and their 
individual mean MTR values were calculated. Clinically I estimated their 
clinical disability using EDSS. 
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Results: 
Focal cortical lesions in patients with SPMS had lower mean MTR values 
compared to PPMS, RRMS or CIS.  Larger cortical lesions had lower MTR.  
Mixed lesion volumes and mean MTR values correlated with the level of 
physical disability, while the other lesion types did not play an important role.  
Conclusion: 
These findings suggest that different MS phenotypes exhibit differences in 
their CL characteristics. Similarly different types of cortical lesions might be 
correlated to a different degree to the level of clinical symptoms.  
Leukocortical/mixed lesions are the main lesion type associated with physical 
disability in MS patients.  
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3.2 Introduction: 
3.2.1 MS Pathology in Different MS Phenotypes 
White matter lesion pathology in different MS phenotypes: 
MS phenotypes usually present with different courses of a similar spectrum of 
symptoms. The pathology seems to vary between these phenotypes as 
described in previous reports.126 The pathology of RRMS consists mainly of 
lesions disseminated in time and space. Lesions are normally in different 
stages of chronicity. WM and cortical lesions vary in stages from 1) acute 
plaques with active inflammatory infiltration and macrophages loaded with 
myelin degeneration products to 2) plaques that are only active at their margins 
and finally 3) chronic inactive demyelinated lesions. Lassman et al. 127 
described four main types of lesions, of which the first 3 types are mainly 
present in RRMS patients, while the fourth type is only seen in PPMS patients. 
The classification of these lesion types was mainly based on the presence of 
inflammation and active demyelination. Lesions types were as follows:  
(1) Plaques with inflammation and macrophages containing early myelin 
debris.  
(2) Plaques with inflammation in the absence of early myelin degradation 
products in the macrophages. 
(3) Plaques with early myelin degradation products in the absence of 
perivascular infiltrate.   
(4) Plaques without inflammatory infiltrates and without myelin degradation 
products. 
The main question for MS pathogenesis is whether the presence of several 
plaques types indicates that, MS might be caused by several different 
immunological pathways, probably acting at different times, causing 
demyelination in individual patients. The other theory is that probably the 
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mechanisms of demyelination may vary between patients, due to the variation 
in immunological mechanisms involved. This could explain the clinical and 
genetic heterogeneity of the disease.127 
SPMS patients are most likely to have chronic inactive or occasionally active 
plaques showing demyelination and /or degeneration of multiple individual 
fibers. Degenerative changes in SPMS were shown to involve normal 
appearing tissue and were not restricted to lesions. Normal appearing tissue 
involvement is usually independent of current inflammatory demyelination 
activity. This might explain why disease modifying treatment and 
immunosuppressive drugs do not have an effect on SPMS patients’ disability. 
This has led to suggestions that SPMS is not caused by continuous immune 
processes, but by demyelination affecting axonal transport and ultimately 
axonal loss and what is called “dying back process”. This process affects long 
axons first such as the pyramidal tracts which may explain the significant 
impact on EDSS.128 
The distribution of lesions varies between different types of MS. PPMS lesions 
have predilection for the spinal cord, whereas SPMS patients are more likely to 
have brain involvement compared to other disease phenotypes. In a report by 
Revesz et al.129 they found that in the PPMS patients, 54% of the lesions were 
found in the cerebral hemispheres, 14% in the brainstem and 32% in the cord, 
while the distribution in the SPMS was 75% in the hemispheres, 17% in the 
brainstem and 8% in the cord. There were areas of prominent perivascular 
cuffs and increased cellular density in lesions of the SPMS compared to PPMS 
patients. Also the chronic hypocellular lesions had a hypercellular edge more 
often in the SPMS than in the PPMS group. 
 
 
82 
 
Cortical lesion pathology in different MS phenotypes: 
It has been difficult to detect cortical lesions in the past due to the lack of 
sensitivity of classical myelin histochemical staining methods (luxol fast blue) 
that have always been used in the past. Over the last few years, the appearance 
of immunohistochemical markers improved the detection of cortical 
demyelination. 
Cortical demyelination is classified into type I (leukocortical) lesions which 
extend between the cortex and white matter and they account for around 34% 
of cortical lesions, type II (intracortical) lesions which are small confined to 
the cortical ribbon and often have a vessel in their centre and account for 
around 17% of cortical lesions, and types III and IV which account for the 
remaining 50% and extend from the pial surface into the cortex without 
invading the subcortical WM.108 Leukocortical lesions, also called mixed 
lesions (MXL) are the most common type of lesions in early  MS, constituting 
around 50% of cortical lesions detected while subpial and intracortical lesions 
constitute around 34% and 16% consequetively.93 
Cortical involvement varies in different stages of the disease. Leukocortical 
and intracortical lesions are generally found in all disease subtypes, including 
acute MS, RRMS, PPMS and SPMS.130 However, these lesions constitute only 
a small percentage of the total cortical lesion load generally; they are the 
dominant subtype in patients with RRMS. Subpial lesions are mainly found in 
patients with PPMS or SPMS. In chronic patients the subpial lesions could 
extend to involve multiple adjacent gyri and penetrate into the cortex in 
variable depth.130 In an immunohistochemical study by Lucchinetti et al.93 that 
included tissue from 138 patients  with early MS, cortical demyelination was 
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found in 38% of the patients. All three types of cortical lesions were observed 
with leukocortical lesions being the commonest type of lesions detected. Sixty 
six percent of lesions had foamy macrophages, indicating ongoing 
demyelination in all types of cortical lesions. Perivascular CD3+ T cells 
inflammation were observed in 77% of patients. Leukocortical lesions were 
highly inflammatory. Most of the intracortical and subpial plaques contained 
perivascular CD3+ and CD8+ Tcell infiltrates. Patients with cortical 
demyelination especially subpial lesions were more likely to have diffuse 
meningeal inflammation than patients without cortical demyelination. 
Oligodendrocyte density was reduced in a subset of lesions, as compared with 
adjacent, nondemyelinted cortex. 
Similarities were reported in the CL volume and their topographical 
distribution between RRMS and PPMS patients.131 Patients with benign MS 
did not show cortical lesions accumulation over a one year period in 
comparison with RRMS patients.132 
In a large autopsy study, including patients of different disease phenotype, 
clinical and pathologic characteristics with varying extents of cortical 
demyelination and different types of CLs were examined. One of the main 
findings was the paucity of CLs generally and inflammatory changes 
particularly in PPMS patients. They found around 50% of all patients of all 
phenotypes harboured extensive subpial demyelination, however there was no 
difference in the age at death, or disease duration between those who had or 
did not have CLs. They found that some of the CL had a rim of active 
microglia hence called RAM-CL versus non-RAM-CL. In the RAM-CL group, 
a significantly higher proportion of the cerebral cortex was demyelinated 
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compared with that in the non-RAM-CL group. They also found a lower mean 
age of death, and shorter disease duration in the RAM-CL group than in the 
non-RAM-CL group, but no difference of the age of death was found between 
the non-RAM-CL group and the non-CL group. In this study most of the 
PPMS patients autopsy included (16 PPMS patients) did not have CLs. 
Furthermore, the presence of chronic active WMLs was associated with a 
higher load of RAM-CLs in the RAM-CL group. Most importantly they found 
that leukocortical lesions were more prominently present in the RAM-CL 
group and to a smaller extent in the non-RAM-CL group. The exact pathogenic 
role activated microglia play in CLs is still under defined, on the other hand 
the strong correlation with chronic active WMLs may suggest more 
pronounced activity of the innate immune system in disease progression in a 
subset of patients with MS. Based on the pattern of their neuropathological 
data, they suggested that CLs with RAM may similarly contribute to MS 
disease progression and disease severity.133  
Intracortical lesions were reported to be prevalent in 36.2% of patients with 
CIS, while SPMS patients had higher numbers of IC lesions than those with 
RRMS or CIS patients.81 In histopathology, biopsies of early diagnosed MS  
patients showed that 38% of patients showed cortical demyelination while 14 
% of the patients who did not show evidence of cortical demyelination showed 
cortical inflammation.93 
It was also reported that the functional loss produced by the lesions of MS 
depends on the phase of pathological evolution; the different phases look alike 
on conventional unenhanced MRI. Regardless lesion count and volume must 
also have a relevant role.134 
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The extent of cortical demyelination was found to be significantly higher in 
patients with a disease duration of more than 10 years.90 
The pathology of cortical lesions has been examined using focal cortical EAE 
model, by injecting pro-inflammatory mediators in adult female Lewis` rats 
that were immunized with myelin oligodendrocyte glycoprotein (MOG). This 
generated highly reproducible demyelinated lesions in the neocortex with very 
high histological similarities to cortical lesions in MS. This focal cortical EAE 
model led to typical intracortical and subpial demyelination, inflammatory cell 
infiltration, complement deposition, acute axonal damage and neuronal cell 
death. They also found that the extensive cortical inflammation had largely 
resolved within 2 weeks and demyelination was compensated rapidly by 
remyelination. It is believed that the transient and rapidly reversible nature of 
cortical inflammation and demyelination in early MS may prevent the 
development of larger demyelinated lesions, hence making their clinical or 
radiographic detection more challenging in MS patients.110 
The pathology of cortical demyelination in early MS differs substantially from 
that which happens at the chronic stages of the disease. Although the variation 
in cortical lesion characteristics among different MS phenotypes has been 
previously explored, the variation in their myelination status has not yet been 
widely investigated. This will help improve our understanding to the different 
pathology in different MS disease phenotypes. 
3.3 Patients and methods: 
Forty two patients with MS (11 CIS, 11 RRMS, 10 PPMS, and 10 SPMS), 
were recruited from the multiple sclerosis outpatient clinics, at Nottingham 
University Hospitals: 18 were male and 24 female.  Eight healthy volunteers 
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(two male and six female) without neurological disease were also recruited. 
Patients and volunteers were between 18 and 65 years of age, with no other 
reported neurological disease. The MS patients had to be free from recent 
clinically overt disease activity (in the form of a relapse) for at least three 
months prior to scanning. The study was approved by the local ethics 
committee and all subjects gave written informed consent. The MS patients 
underwent a neurological examination and their EDSS score was determined. 
Data acquisition: 
MRI scans were acquired using a 7T Achieva Philips scanner, with a 32 
channel receive coil. PSIR data was acquired from each patient using a 3D 
interleaved PSIR sequence,
135,136  
with imaging parameters: TI1=780ms (first 
TFE read out), TI2=2380ms (second TFE readout), shot to shot interval (SSi) 
=5000ms, flip angle (FA)=8°, TE/TR=6/13ms, 0.6mm
3
 isotropic resolution, 
field of view 200x180x120 mm
3
, acquisition time 12 minutes. These 
parameters were chosen to ensure PSIR images with good grey-matter/white-
matter contrast in a reasonable scanning time. MTR data was acquired with a 
MT-TFE sequence as described by Mougin et al.
125
 and consisted of a 
presaturation at a specific offset frequency, followed by a 3D Turbo Field-
Echo (TFE) readout consisting of gradient echoes sampling k-space radially in 
a centre-out fashion. The presaturation consisted of 20 off-resonance pulses 
(B1avg of 1.02 μT, BW=250 Hz, T=50 ms) applied at offset frequencies of 
Δω= 3.3 ppm, chosen from the results of Mougin et al,
125
 to give high 
sensitivity to NOE with reasonable insensitivity to variations in RF amplitude 
and B0 inhomogeneity, and setting B1peak 25% higher than optimum to 
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compensate for overestimation of nominal B1 compared to actual B1. The 
pulse train was followed by a 3D TFE readout with resolution of 0.6x0.6x0.6 
mm
3
, TR/TE=13/6 ms, SSi= 12 s, a = 8°, TFE factor= 500, 
FOV=192x180x120 mm
3
; the acquisition time was 13 min. 
Data analysis: 
MTR maps were registered to the PSIR images using FSL FLIRT 
(http://www.fmrib.ox.ac.uk/fsl/). Mutual information was used as the cost 
function to handle this inter-modal registration task.  The relative effect of B1 
field inhomogeneity on MTR values was corrected using the method described 
by Ropele et al,
137
 which models the relationship between the B1 error and the 
MTR error as linear (a reasonable assumption, both in theory and in practice). 
Two independent observers (RAF and CMA) manually segmented all cortical 
lesions in the anonymised scans of both patients and healthy controls using the 
MIPAV medical images processing, analysis and visualization software 
package (http://mipav.cit.nih.gov/). The segmentation criteria were as follow: 
lesions had to be hypointense compared with the surrounding GM and occupy 
more than three pixels; they also had to be visible on a minimum of two 
consecutive slices.
99
 Lesions were classified according to their location as 
intracortical, as illustrated in figure 3.1, leukocortical, also known as mixed, 
and subpial lesions, as illustrated as in figure 3.2, by consensus between both 
modalities. Finally, the mean MTR values for each lesion were computed. 
WML were also segmented and their MTR values were computed similarly to 
cortical lesions. 
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(Figure 3.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Example of intracortical 
lesion in MTR images in two 
consecutive slices in an MS 
patient brain 
Example of subpial lesion 
in MTR images in two 
consecutive slices in an 
MS patient brain 
(Figure 3.2) 
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(Figure 3.3) 
Example of mixed lesion in MTR images in MS brain 
 
The figure illustrates a mixed lesion in MTR images (grey scale on the left and 
coloured on the right) with the lesion mainly in the grey matter but extending 
to involve the white matter as well.  
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(Figure 3.4) 
Correlation between total grey matter count and subpial lesion 
 
The figure illustrates the strong positive correlation between subpial lesion 
count and total grey matter lesion count. (rho = 0.83, p <0.05) 
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3.4 Statistics: 
Intraobserver reproducibility was assessed using agreement for positive and 
negative rating measures, as well as variation coefficients while interobserver 
reproducibility was assessed using kappa coefficient. Spearman’s correlation 
coefficients between the variables, indicated as rho, were used to investigate 
correlations between the CL and WML count, volumes, and their MTR values 
with the level of patient’s physical disability as measured by EDSS scores. We 
also tested the correlations between different CL and WML parameters. 
As mean GML MTR values and NAGM MTR are normally distributed, one 
way ANOVA was used to assess significant variations across MS phenotypes. 
An ordered logit regression was used to identify the association between MRI 
measurements as independent variable with EDSS as the dependant variable. 
This method takes into account the ordinal, rather than continuous nature, of 
the EDSS score. EDSS was estimated as a function of cortical, WML volume, 
mean lesion MTR value, disease duration, age and gender, as independent 
variables.  
As individual focal lesions MTR values in all subjects are normally distributed, 
linear  regression was used to assess the association between individual lesion 
MTR (dependent variable) and their volume controlling for disease duration, 
age and gender.  
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3.5 Results: 
Descriptive statistics: 
Clinical Data: 
Patients’ demographics are shown in table 3.1. Intra-observer reproducibility 
for cortical lesion detection: agreement for positive rating and negative rating 
as 0.91 and 0.09 respectively, while kappa coefficient was 0.8, (95%CI 0.46-
1.07). Inter-observer reproducibility was estimated by kappa coefficient as 0.8 
(95% CI 0.6-1.02), while variation coefficient was 3.5%.  
Cortical lesions (CL): (Table 3.2) 
Descriptive statistics for all MS subtypes are shown in table 3.2. The total 
number of cortical lesions (of all types) was the highest in the SPMS group in 
comparison with other MS subtypes.  Total CL count was 6 times higher in 
SPMS than in CIS patients. Mixed lesions (MXL) were higher in SPMS 
compared to CIS, RRMS and PPMS by 18 times, 6 times and 4 times 
respectively. Patients with SPMS showed higher median total CL volume in 
comparison with the other MS disease subtypes. This was mainly due to the 
higher MXL volume in SPMS compared to the other groups. SPMS patients 
had the highest subpial lesion load. Focal CL mean MTR values were different 
between disease subtypes. SPMS patients had the lowest focal CL mean MTR 
values, while CIS patients had the highest values. (Table 3.2) 
MRI metrics correlations: 
GML count and volume correlated with WML count and volume (rho = 0.5, 
rho =0.6 with p = 0.00 and 0.00 respectively). GML count and volume 
correlated the highest with SP lesion count and volume (rho = 0.83 and rho = 
0.71 with p = 0.00 and 0.00 respectively). In terms of WML count and volume, 
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they had the strongest correlation with MXL count and volume (p = 0.62 and 
0.71 with p = 0.00 and 0.00 respectively). Individual correlations are 
demonstrated in table 3.5).  
Correlations between Disability and different clinical parameters and MRI metrics: 
A significant positive correlation was detected between EDSS and patient age 
(rho = 0.55, p = 0.01). Similarly, a positive correlation was seen between 
EDSS and disease duration (rho = 0.59, p < 0.05), while no significant 
correlation was detected between EDSS and gender (rho = - 0.21, p = 0.15).  A 
significant correlation was found between the total CL volume and disease 
duration (rho = 0.4, p = 0.01). Subject age correlated with CL volumes (rho = 
0.3, p = 0.04) and their mean MTR values (rho = - 0.36, p = 0.02). EDSS 
correlated with total CL volume (rho = 0.6, p = 0.01). The strongest correlation 
was found between MXL volume and EDSS (rho = 0.5, p = 0.01), while a 
smaller correlation was detected between EDSS and intracortical (IC) lesion 
volume (rho = 0.34, p = 0.02). There was no significant correlation between 
subpial lesion volume and EDSS (rho = 0.23, p = 0.13).  
There was a significant correlation between EDSS and total CL count (rho = 
0.53, p = 0.00) with highest correlation with MXL subtype (rho = 0.6, p = 
0.00), a lower correlation with subpial lesion count (rho = 0.36, p =0.01), 
while the correlation with IC lesion count was insignificant (rho= 0.2, p = 
0.1).A significant positive correlation was found between EDSS and WML 
volume (rho = 0.5, p < 0.05).  
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There was no significant correlation between age and WML volumes or WML 
mean MTR values. I did not find any correlation between gender and CL 
volumes, CL mean MTR values, WML volumes or WML mean MTR values.  
Regression analyses of disability and clinical parameters to MRI measurements: 
In this regression analysis, disease duration was a significant predictor (p = 
0.01) of disability as measured by EDSS. MXL volumes and MXL mean MTR 
values were significant parameters correlated with disability with p values of 
0.03 and 0.02 respectively. MXL mean MTR values appeared to associate with 
the degree of disability more than MXL volumes. EDSS was not associated 
with either WML volume or their MTR values. (Table 3.6) 
Focal CL MTR values in SPMS patients was the lowest in comparison with 
CIS, RRMS and PPMS (p = 0.00, 0.01 and 0.02 respectively). There was no 
significant effect of chronicity of the disease on the NAGM MTR values. 
Individual CL and WML volume influenced lesion MTR values, with larger 
volume lesions having lower mean MTR values (p = 0.045), after controlling 
for age, gender and disease duration. There was a trend for the disease duration 
influencing the individual CL mean MTR values (p = 0.09), while the patients’ 
age and gender were not significant. (Table 3.6) 
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(Table 3.1) Patient’s demographics: 
 
CIS =Clinically Isolated Syndrome, RRMS = Relapsing Remitting Multiple 
Sclerosis, PPMS = Primary Progressive Multiple Sclerosis, SPMS = Secondary 
Progressive Multiple Sclerosis, IQR = Interquartile ratio* Mean and standard 
deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CIS RRMS PPMS SPMS Controls 
Female, 
n (%) 
6(54%) 8(72%) 4(40%) 
 
6(60%) 6(75%) 
Mean age * 
 
38 ± 14 43 ± 7 50 ± 8 51 ± 6 36.7 ± 10 
Mean 
disease 
duration * 
 
0.9 ± 0.5 5 ± 3 6.9 ± 3 12 ± 6 NA 
 
Median 
EDSS 
(IQR) 
1 (1-1) 
 
 
1.5 (1-2) 
 
6 (4-6) 
 
 
6 (6-6.5) 
 
 
NA 
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(Table 3.2) Median count and volume of different cortical lesions subtypes 
in MS patients and controls 
CIS = Clinically Isolated Syndrome, RRMS = Relapsing Remitting MS, PPMS = Primary 
Progressive MS, SPMS = Secondary Progressive MS, CL = Cortical Lesion, MXL = Mixed 
Lesion, IC = Intracortical Lesion, IQR= Interquartile Ratio 
 
 
 
 
 
 
 
CIS RRMS PPMS SPMS Control 
Median CL 
count (IQR) 
8 
(5 – 9) 
 
15 
(13 – 35) 
19 
(10 – 38) 
49 
(22 – 83) 
0 
Median CL 
volume in 
mL (IQR) 
215 
(0.168 – 0.367) 
504 
(0.274 – 
0.837) 
413 
(0.153– 0.1232) 
1,797 
(0.767– 0.2182) 
0 
Median 
MXL count 
(IQR) 
1  
(0-3) 
3  
(1-6) 
4 
 (2-11) 
18 
 (6-60) 
0 
Median 
MXL 
volume in 
mL (IQR) 
44  
(0- 0.088) 
66  
(0-0.03) 
638  
(0.033- 0.723) 
 
1659 
 (0.405- 1.733) 
0 
Median IC 
lesion count 
(IQR) 
3 
(1-5) 
6 
(2-11) 
3 
(1-10) 
9 
(4-14) 
0 
IC lesion 
volume in 
mL(IQR) 
50 
(0.025 – 0.075) 
50 
(0.025 – 0.158) 
51 
(0.007 – 0.177) 
95 
(0.062 – 0.174) 
0 
Median 
subpial 
lesion count 
(IQR) 
3 
(2-4) 
10 
(5-14) 
10 
(1-18) 
16 
(7-20) 
0 
Median 
subpial 
lesion 
volume in 
mL(IQR) 
122 
(0.016 – 0.3) 
244 
(0.097 – 0.483) 
148 
(0.057- 0.459) 
368 
(0.09 – 0.533) 
0 
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Table 3.3: Mean MTR values of different cortical lesions subtypes in MS 
patients and controls 
 
 CIS RRMS PPMS SPMS Controls 
CL mean 
MTR (std) 
0.31 
(0.04) 
0.29 
(0.05) 
0.27 
(0.03) 
0.21 
(0.05) 
0 
MXL mean 
MTR (std) 
0.17 
(0.16) 
0.28 
(0.06) 
0.27 
(0.05) 
0.17 
(0.1) 
NA 
IC lesion 
mean MTR 
(std) 
0.28 
(0.1) 
0.28 
(0.05) 
0.27 
(0.04) 
0.22 
(0.05) 
NA 
Subpial 
lesion 
mean MTR 
(std) 
0.28 
(0.1) 
0.26 
(0.1) 
0.24 
(0.09) 
0.22 
(0.05) 
NA 
NAGM 
mean MTR 
(std) 
0.38 
(0.04) 
0.35 
(0.06) 
0.36 
(0.06) 
0.31 
(0.05) 
0.35 
(0.1) 
CL = Cortical Lesion, MXL = Mixed Lesion, IC = Intracortical Lesion, 
NAGM = Normal Appearing Grey Matter 
 
(Table 3.4) White matter lesions median count, median volume and mean 
MTR values for patients of different MS phenotypes and controls 
 CIS RRMS PPMS SPMS Controls 
Median 
WML 
count 
(IQR) 
11 (7 -13) 
 
26 (12 – 34) 
 
23 (17 – 47) 
 
40 (26 – 65) 
 
0 
 
Median 
WML 
volume in 
mL (IQR) 
 
1,161 
(0.526–6.649) 
 
3,010 
(0.838 – 5.648) 
7,764 
(2.102 – 29.816) 
18,416 
(5.013 – 34.226) 
0 
WML 
mean 
MTR          
(sd) 
0.35 
(0.06) 
0.34 
(0.09) 
0.33 
(0.06) 
0.23 
(0.07) 
NA 
WML = White Matter Lesion 
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(Table 3.5) Correlations between different lesions types count and volumes 
 
 WML 
count 
WML 
volume 
GML 
count 
GML 
volume 
MXL 
count 
MXL 
volume 
IC 
count 
IC 
volume 
SP 
count 
SP 
volume 
WML 
count 
- - - - - - - - - - 
WML 
volume 
0.58 
(0.00) 
- - - - - - - - - 
GML 
count 
0.53 
(0.00) 
0.49 
(0.001) 
- - - - - - - - 
GML 
volume 
0.58 
(0.00) 
0.59 
(0.00) 
0.79 
(0.00) 
- - - - - - - 
MXL 
count 
0.62 
(0.00) 
0.81 
(0.00) 
0.62 
(0.00) 
0.65 
(0.00) 
- - - - - - 
MXL 
volume 
0.53 
(0.00) 
0.71 
(0.00) 
0.51 
(0.00) 
0.67 
(0.00) 
0.91 
(0.00) 
- - - - - 
IC 
count 
0.29 
(0.05) 
0.11 
(0.45) 
0.74 
(0.00) 
0.43 
(0.00) 
0.19 
(0.21) 
0.12 
(0.42) 
- - - - 
IC 
volume 
0.25 
(0.09) 
0.16 
(0.29) 
0.59 
(0.00) 
0.44 
(0.00) 
0.20 
(0.18) 
0.155 
(0.31) 
0.81 
(0.00) 
- - - 
SP 
count 
0.38 
(0.01) 
0.27 
(0.07) 
0.83 
(0.00) 
0.66 
(0.00) 
0.29 
(0.05) 
0.21 
(0.15) 
0.63 
(0.00) 
0.48 
(0.00) 
- - 
SP 
volume 
0.3 
(0.04) 
0.26 
(0.08) 
0.49 
(0.00) 
0.71 
(0.00) 
0.1 
(0.51) 
0.11 
(0.45) 
0.26 
(0.08) 
0.24 
(0.10) 
0.71 
(0.00) 
- 
Spearman’s correlations presented with rho and (p value) 
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(Table 3.6) Regression analysis of the association between focal cortical 
lesions MTR values as a dependant variable and lesion volume, disease 
duration, gender and age as independent variables 
 Coefficient P 
value 
95% conf. Interval 
  Lesion 
Volume 
- 5.82 0.045 - 0.0000115      - 1.26 
Disease 
Duration 
               -   0.0022198 0.89    - 0.0047936      0.0003541 
Gender               -   0.0070501 0.763    - 0.0541456      0.0400454 
Age 0.000643 0.63    - 0.0020354      0.0033214 
Regression illustrates that individual cortical lesions correlate significantly 
with the degree of damage in those lesions. With bigger lesions show more 
damage reflected in their mean MTR values. Disease duration, gender, and age 
don’t show as significant association. 
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3.6 Discussion: 
In this study, individual CL in SPMS patients had lower mean MTR values 
than those in CIS and RRMS patients, suggesting a higher degree of tissue 
destruction and demyelination. In agreement with previous studies I also found 
that patients with progressive MS had higher CL load than those with non- 
progressive phenotypes.
138
  
In agreement with previous reports, I found that SPMS patients had the highest 
CL count and volume, especially Mixed lesions (MXS).
84
 Subpial lesion 
volume was larger in the progressive forms of the disease, although the 
difference was to a smaller extent. This could be due to the shorter disease 
duration for our SPMS patients, as previous pathology studies suggested that 
subpial lesions tend to accumulate in later stages of the disease.
139
  
Early MS patients may have more extensive capacity to repair; while in the 
later stages of the disease there may be a reduction in the effectiveness of 
remyelination.
140
 Alternatively, irrespective of remyelination, more chronic 
lesions in the progressive stage could simply show the result of continuing 
progressive demyelination. Only longitudinal studies will be able to determine 
the contribution of demyelination and remyelination processes to the final 
degree of tissue damage in CL. 
The individual lesion damage appears to have clinical significance. In this 
study, MTR of CL was independently associated with the degree of disability 
in MS patients, a finding that we could not replicate when we examined the 
MTR value of WM lesions. This is additional evidence in support of the 
contribution of CL to the degree of disability over WML. However, despite the 
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significant association between CL mean MTR values and physical disability, 
we cannot assume causality as other factor could contribute as significantly. 
For example, we did not take into account various elements, such as NAWM 
volume or topographical distribution of cortical lesions, which could be 
relevant. 
In a previous longitudinal study
138
, it was found that development of new DIR 
CL was associated with deterioration of EDSS. Nielsen et al
141
 found that 
using 7T T2* scanning, mixed and subpial CL correlated with disability. In our 
study, using regression analysis and taking into account disease duration and 
other clinical parameters, I found that among all CL subtypes; only the volume 
and MTR values of mixed lesions were significantly associated with disability. 
It is possible that the proximity of mixed lesions to the cortex, hence the cell 
soma of long projecting axons, such as the corticospinal neurons, might play a 
more important role compared to more distant WM lesions.
142
   
In several previous studies
53, 143
, whole GM MTR was found to be lower in 
progressive than in early MS patients. I did not find a difference between 
NAGM MTR among the groups, nor compared to healthy controls. We cannot 
exclude low grade tissue damage in the NAGM but our findings are in 
agreement with previous pathology reports
144
 suggesting that demyelination is 
most pronounced in CL surrounded by normal appearing cortical tissue. Our 
results suggest that the low cortical GM MTR found in other studies may have 
been caused by undetected focal CL
145
  rather than diffuse GM disease.
103
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In this study, the duration of the disease seems to be correlated to the degree of 
destruction within lesion tissue. On the other hand, the tissue destruction 
observed with time might not be linear.  Agosta et al. ,who studied the whole 
GM rather than just focal lesions, found that after 12 months, the reduction in 
GM MTR was higher in the progressive than in the early stages of the 
disease.
146 
As reported previously, I found that cortical lesions are more 
common in late disease, possibly reflecting accumulation of cortical lesions 
with increasing disease duration.
147
 I, like others,
138
 found increasing WM 
lesion load with longer disease duration. 
Directly comparing the mean MTR values for all lesion subtypes in this cohort,  
subpial lesions had the lowest MTR values compared to IC and mixed lesions. 
This is not surprising in view of the lower myelin content in the outermost 
layers of the cortex. Great care has been taken during manual segmentation of 
subpial lesions, which was done on the MTR sequence. An element of 
compromise of the mean MTR values due to involvement of CSF voxels 
cannot be completely excluded. 
Although this study focused mainly on GM pathology, my findings related to 
the WM lesions were similar to those reported previously in the literature. The  
mean MTR values in SPMS patients were lower than PPMS, RRMS and 
CIS.
148
    
It is difficult to explain the variation of lesion load as well as the difference of 
the degree of demyelination between different MS groups solely by the 
different disease duration or other demographic imbalances.149 Bramow et al 
found that WM plaque types, as well as the plaque density, were similar 
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between PPMS and SPMS patients, although there was a difference between 
lesions in both groups in the degree of demyelination and remyelination. 149 
Hence the variation in the lesions mean MTR values in our study might reflect 
different response to the usual mechanism of demyelination pronounced in the 
variation in the degrees of demyelination and remyelination rather than 
different mechanisms of the plaques formation in different types of the disease. 
In this chapter we showed there is variation in the degree of damage in cortical 
lesions and its association with the degree of physical disability. As the 
contribution of normal appearing tissue damage in the degree of disability is 
well established, we wanted to explore the effect of cortical lesions on 
surrounding normal appearing tissue in the same patient cohort. 
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Chapter 4 
Correlation of Normal Appearing Grey Matter and Normal 
Appearing White Matter to Cortical Lesions in MS: Cross 
Sectional Study 
4.1 Abstract 
 
Background  
Pathological and MRI studies have shown that WM lesions cause axonal loss 
in the NAWM but the role that focal GM demyelination plays in determining 
NAWM or NAGM pathology has not yet been systemically explored yet, 
mainly due to the difficulties in detecting cortical demyelination using 
conventional MR imaging. MTR at ultra-high field benefits from increased 
signal to noise ratio, which makes it possible to study small variations across 
both WM and GM. 
Hypothesis 
We hypothesize that focal GM/WM lesions influence nearby NAWM/NAGM 
in patients with MS. We will test this hypothesis using ultra high resolution 
MT imaging. 
Methods 
42 MS patients (18 males/24 females; age= 46±10 years; EDSS= 3.5±2.4; 
disease duration= 6.3±5.7 years) and 10 age-matched controls were scanned on 
a Philips 7T platform. For each participant, high-resolution, 0.63 mm3, PSIR 
and MTR images were acquired, on which GM and WM lesions were 
manually segmented by 2 trained operators. Tissue maps were estimated using 
SPM8 and mean MTR ratios for NAWM and NAGM MTR were calculated as 
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a function of the distance to the nearest GM or WM lesion. The ratios were 
obtained by normalising each MTR values for the average MTR value in the 
corresponding normal appearing tissue. When considering NAWM, we 
computed a fibre tract-weighted mean rather than an arithmetic mean using the 
JHU tractography atlas, to model the influence of fibres. In order to distinguish 
between natural spatial variations in MTR and those induced by the presence 
of lesions, the above analysis was repeated, substituting control scans for the 
patient ones. 
Results 
In agreement with the literature, NAWM MTR was significantly reduced in the 
vicinity of WM lesions compared to controls, up to 10mm away from the 
closest lesions. There was also an effect of cortical lesions on both NAGM and 
NAWM but at shorter range (up to 3mm). 
Discussion  
The observed distance effect between GML, WML and NAWM suggests that 
WM lesions are important in the pathogenesis of NAWM damage and play a 
more significant role than GM lesions. This is probably due to the arborisation 
of cortical neurons in comparison with the much simpler pathways of WM 
tracts. It is also possible that GM lesions cause neuronal dysfunction rather 
than tissue loss.  
Conclusion: 
GM lesions appear to cause much less prominent long distance tissue damage 
in the NAWM and NAGM compared to WM lesions as detected with MTR.  
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4.2 Introduction: 
4.2.1 Pathology on Normal Appearing Grey Matter in Multiple sclerosis 
Early quantitative studies showed that there were lower MTR values in the 
cortical GM in different MS phenotypes in comparison with controls.
53
 With 
the emergence of higher resolution MRI enabling the detection of very small 
lesions, as well as the development of more sophisticated quantitative MR 
techniques, studying of NAWM and NAGM has become even more promising. 
Understanding the abnormalities in the NAWM and NAGM is very important 
to help us understand the clinical progression in MS patients that is not fully 
explained by macroscopically visible pathology.
150
 
In a study on a 102 patients of all MS subtypes, GM lesions were segmented 
using a diffusion anisotropy thresholding based technique. They observed a 
higher mean diffusivity in SPMS than other MS patients and controls; however 
no difference was noticed between both RRMS or PPMS patients and 
controls.
151
 The difference in the GM diffusivity could be partially due to the 
small cortical lesions that went undetected with conventional MR scanners. 
Another study showed a reduction of the average MTR as well as increase in 
the diffusivity in the NAGM in MS patients compared to controls after using 
manual as well as thresholding techniques to get rid of the lesions, 
Significantly these changes correlated with the T2 lesion load which suggests a 
role that lesions might play in inducing pathology in NAGM structure.
53
 
On using MTR maps, it was noticed that the majority of patients show 
significant regional GM MTR decrease, although the extent of the regional 
GM injury in these regions did not exceed 25% of the volume of this region.
71
 
In a longitudinal study which followed PPMS patients over 1 year, it was noted 
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that cortical GM mean MTR value decreased more than rate of reduction in 
NAWM , it was suggested that this could be due to the development of new 
cortical lesions which went undetected with conventional imaging.
152
 
The variation of GM MTR across groups could be due to cortical lesions going 
undetected which is supported by the lower GM mean MTR values on 
comparing the RRMS with the PPMS and the SPMS patient groups.
151
 Another 
theory  is that WM lesions cause retrograde degeneration of the GM neurons 
which could be explained by the detected correlation between WM T2 lesion 
volume and MTR of the GM.
151
 
4.2.2 Pathology of Normal Appearing White matter in Multiple Sclerosis 
Focal cortical and WM demyelination has long been the main feature of MS 
pathology. Physical and cognitive disability cannot be fully explained by the 
focal cortical and WM demyelination. Hence interest has grown over the last 
few years in exploring the extent of normal appearing tissue involvement in 
patients with MS. 
Studies focusing on the NAWM in MS started as early as 1978 in a combined 
histological, biochemical and histochemical study, which showed widespread 
changes in the NAWM, mainly astrogliosis, microglial activation, vascular 
hyalinisation, blood brain barrier breakdown, reduced myelin density, axonal 
loss and remyelination.153,154 Similar findings were found in WM tissue of 
patients with mild and mainly spinal varies of MS.155 NAWM is the term used 
to describe parts of the WM in MS that appear normal on some MRI sequences 
but have been found to be abnormal153 using different imaging methods.156,65 
Unlike MS plaques, NAWM tissue is normally myelinated, however it shows 
some axonal changes.24 Diffuse NAWM involvement can start early in the 
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disease course. Widespread gliosis and astrocytic proliferation in the WM 
away from the WM lesions has been described.157 Recently pathology studies 
described changes in NAWM, in the form of diffuse inflammatory reaction 
that consisted of perivascular cuffs of mononuclear cells and a diffuse 
infiltration of the tissue by T-lymphocytes and microglia activation. This 
widespread injury was more pronounced in patients with progressive forms of 
the disease than those with relapsing MS. Moreover MRS studies showed that 
reversible and irreversible neuronal injury in NAWM shows different patterns 
in RRMS from PPMS.158  
Reduction of axonal density and volume by around 34% and 66%, 
respectively, was found in the corpus callosum of MS patients, and the 
reduction in axonal density correlated with regional white matter lesion load in 
the brains of individual patients.159  
The evidence of the contribution of WM lesions to NAWM damage is 
conflicting. A correlation was established between the extent of NAWM injury 
and cortical demyelination, while only a weak correlation was detected 
between WM lesion load and NAWM injury. Further analysis of individual 
cases in that study further supported the view that diffuse WM injury and 
cortical lesions develop independent from WM lesions.15 On the other hand, 
MTR values were significantly lower in the NAWM surrounding a WM lesion 
and increased gradually with increasing distance from the lesion.160 The 
pathological component in NAWM with subtle MTR changes vary depending 
on their proximity to WM lesions.161 Axonal pathology and microglial 
activation seem to be responsible for the slight changes in NAWM MTR 
values in NAWM tissue that is close to WM lesions, while microglial 
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activation alone was noticed in NAWM regions far from the WM lesions. 
NAWM changes are apparent in all MS phenotypes even in patients at first 
presentation with CIS.162 
Contribution of MRI in Assessing Normal Appearing Tissue Damage in MS 
GM MTR not NAWM MTR in normal controls was found to decrease with 
increase in age.145 Studies investigated the early involvement of normal 
appearing tissue in patients with MS using MTI and DTI giving their tissue 
quantitative values.163 They found that involvement of the WM starts earlier 
than the GM. Compared to healthy volunteers, patients with early MS (mean 
disease duration of 2 years) had significantly higher MD and FA peak height 
and lower average FA of the NAWM. On the other hand, there was neither 
MTR nor diffusion differences in the GM between the groups.  
Proton magnetic resonance spectroscopy (H-MRS) is a non-conventional MR 
technique that has the potential to assess the microstructural damage in the 
normal appearing tissue in MS brains in vivo. In RRMS patients, NAA, Glx 
and Cho were all reduced in CGM in comparison with healthy controls, whilst 
the changes in the NAWM were more limited than for CGM, moreover Ins 
was significantly elevated and modestly related to T2 lesion loads.
164
 T2 
relaxation time was used to compare normal grey matter (NGM) tissue to 
NAGM tissue and similarly normal white matter (NWM) tissue to NAWM 
tissue. They found that NAGM did not show any significant difference form 
NGM, while average myelin content was around 15% less in NAWM than in 
NWM.165 Another study showed that NAWM mean MTR and PL was lower on 
comparing MS patients versus controls, RRMS and SPMS versus CIS but not 
RRMS versus SPMS, while GM PH MTR was significantly lower on 
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comparing MS patients versus controls, SPMS and RRMS versus CIS and 
SPMS versus RRMS.70 Similar observation was noted using DTI, with GM 
pathology more prominent in in SPMS and PPMS than in those with other 
forms of the disease.151 In another study, each of the RRMS and SPMS patient 
groups had a significantly smaller MTR histogram mean values in NAGM and 
NAWM than in controls.166 NAA was also found to be reduced and Cr 
increased in NAWM in RRMS and PPMS patients suggesting that axonal 
dysfunction extends beyond focal lesions.158 
MTI was used to examine MS patients in a longitudinal study and showed that 
NAWM MTR values correlated highly with the length of time since the 
patient’s initial clinical presentation. Moreover NAWM MTR values showed 
gradual steady decline over 12 months period.167 
NAWMMTR and GMMTR at baseline in early MS patients are lower than 
those in controls. Moreover progressive decline of cortical GMMTR was noted 
in early MS patients when followed up over a year. Similar decline was 
observed in the NAWMMTR in comparison with controls.168 The rate of 
change in GMMTR was significantly greater than the rate of change in 
NAWM.168 No correlations were found between the rate of change and EDSS, 
cognitive decline, or T2 lesion load in the patient group.168 More interestingly, 
on assuming the gradient of change in controls was zero and in patients was 
linear at all times, NAWM MTR abnormality began 2.9 years before clinical 
onset, while NAGM MTR changes began 0.4 years after clinical onset.168 
A study on 12 RRMS patients using 1.5 T scanner compared diffusion tensor 
MR and MT imaging to assess the variation in pathological entity of different 
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regions in NAWM amongst patients and between patients and controls.
169
 
Interestingly, the FA values and mean MTR values were significantly different 
between WM plaques, perilesional NAWM, and remote NAWM regions, with 
the values being the lowest in the WM plaques, followed by perilesional 
NAWM regions, while remote NAWM regions had the highest values.
169
  On 
the other hand, the correlation between FA and mean MTR values of 
individual lesions was poor.
169
   
T1 and T2 relaxation times were found to be longer in NAWM tissue in MS 
patients compared to controls.170 The difference in the relaxation times from 
values in the healthy controls was ascribed partially to the abundance of 
invisible lesions in the WM.171 T1 relaxation time of cortical GM was 
significantly longer in patients than in controls which was ascribed to the 
possibility of partial volume effect induced by the global cortical atrophy in 
MS patients.172 
Correlation of Normal Appearing Tissue Damage with Clinical Parameters 
in MS Patients  
Conventional MR imaging has been found to be invaluable in examining the 
extent of the disease and its evolution via examining the extent of macroscopic 
WM abnormalities. On the other hand, microstructural changes in the NAWM 
reflected by low MTR values were found to correlate highly with the level of 
physical disability and cognitive impairment in MS patients.173,174,175 NAWM 
MTR was shown to correlate highly with the disease duration,167 and was 
found to prospectively predict the worsening of clinical disability in individual 
MS patients.175 
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A cross sectional study on 31 RRMS patients showed a significant negative 
correlation between EDSS and N-Acetyl Aspartate/creatine (NAA/Cr ratio) 
levels in NAWM in these patients, however there was no significant 
correlation with disability measured by MSFC.  
NAWM as well as GM demyelination have been found to correlate to the 
clinical outcome, with GM having more influence than NAWM.70  
In PPMS patients a correlation was found between GMMTR, but not 
NAWMMTR and EDSS.145 On the other hand, in a longitudinal study on 
PPMS patients it was noted that low baseline NAWM MTR values predicted 
EDSS and MSFC deterioration in patients 1 year later.152 
The PSIR sequence 102,176,103 was introduced to provide T1-weighted (T1w) 
images of the brain with increased contrast to noise ratio (CNR) compared to 
other anatomical sequences such as MPRAGE, in a fashion similar to the 
MP2RAGE modality.135,177 In a typical PSIR acquisition, two images are 
collected during a single inversion recovery and the phase images are used to 
restore the sign of the inversion recovery signal in the magnitude images, 
thereby doubling the dynamic range in the reconstructed image. In turn, this 
increase in range can be exploited by increasing image resolution, reducing 
scanning time or, crucially, increasing image contrast. PSIR has been shown to 
improve classification of cortical lesions.176  A recent large study indicated that 
combining PSIR and DIR at 3T increased the rate of detection of cortical GM 
lesions.103 
MTR at 7T benefits from increased signal to noise ratio and increased 
sensitivity to MT due to the increase in longitudinal relaxation times with field 
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strength. Overall this provides a two-fold increase in the CNR between GM 
and WM in MT images at 7T compared to 3T.178 This gain in sensitivity has 
allowed acquiring high spatial resolution MT data to study variations in MT 
across the cortex.117 Although ultra-high field MRI is more prone to the effects 
of RF and static field inhomogeneities we have overcome these effects with the 
use of Ropele et al. approach mainly by field mapping and post-
processing.137,117 Indeed MTR has been shown to be sensitive in detecting focal 
and diffuse abnormalities in the GM.179 
The aim from this analysis is to explore the relationship between focal 
GM/WM lesions and NAWM/NAGM in patients with MS, using ultra high 
resolution MT imaging.  
Previous work outlining the effect of different types of lesions on normal 
appearing tissue is illustrated in Table 4.1 
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(Table 4.1) Literature illustrating the effect of different types of lesions on 
various normal appearing tissues 
Lesions type 
effect 
Publications Nature of the 
study 
Effect 
WM lesions to 
NAWM 
NAWM to GM 
"Regional axonal 
loss in the corpus 
callosum 
correlates with 
cerebral white 
matter lesion 
volume and 
distribution in 
multiple 
sclerosis." Brain 
123.9 (2000): 1845-
1849. 
Pathology Total number of 
axons crossing the 
corpus callosum 
(CC) was reduced 
in MS brains in 
comparison with 
controls. WML 
load in the 
anterior, middle 
and posterior 
cerebral WM 
volumes correlated 
with both axonal 
density and total 
number of axons 
crossing the CC in 
the corresponding 
region. This 
correlation 
remained strong 
on testing the data 
on data from 
individual patients. 
“A longitudinal 
study of MR 
diffusion changes 
in normal 
appearing 
white matter of 
patients with early 
multiple sclerosis”  
Magn Reson 
Imaging. 2002 
Jun;20(5):383-8 
MRI acquired in 
19 CIS patients 
(16 converted to 
MS during the 
study period)at 
baseline and 12 
months later 
No significant 
difference in trace 
of apparent 
diffusion 
coefficient 
(TADC) was 
found between 
NAWM in CIS 
patients and 
controls at 
baseline but 
significant 
difference was 
noticed at the end 
of 12 months 
period. WML load 
in T2 correlated 
with NAWM 
TADC at the end 
of the study. 
 
 
 
115 
 
 
Lesions type 
effect 
Publication Nature of the 
study 
Effect 
WM lesions to 
NAWM 
NAWM to 
GM 
“Meningeal T cells 
associate with 
diffuse axonal loss 
in multiple sclerosis 
spinal cords” Ann 
Neurol. 2010 
Oct;68(4):465-76. 
doi: 
10.1002/ana.22054 
Pathology on 
13 SPMS, 
5PPMS 
CD3- T, not B cells, 
were observed in 
similar density in 
the NAWM and 
NAGM of the 
spinal cords of MS 
patients’ not in 
controls. Axonal 
density is around 
24% less in the 
NAWM of MS 
patients in 
comparison of 
controls.70 
“Absolute 
quantification of 
brain metabolites  
by proton magnetic 
resonance 
spectroscopy in 
normal appearing 
white matter of 
multiple sclerosis 
patients”  Brain 
(1999), 122, 513–521 
1.5 T MRI. 27 
RRMS, 13 
SPMS, 12 
healthy controls 
A significant 
decrease in the N-
acetyl-aspartate 
concentration in 
NAWM in MS 
patients than control 
and in SPMS than 
in RRMS. The 
decrease in N-
acetyl-aspartate 
correlated with WM 
lesion load and 
EDSS. 
“Assessment of 
normal-appearing 
white and gray 
matter in patients 
with primary 
progressive 
multiple sclerosis A 
Diffusion-Tensor 
Magnetic 
Resonance Imaging 
Study” Arch Neurol. 
2002 Sep;59(9):1406-
12 
MRI DTI 1.5T. Average diffusivity 
higher in SPMS 
than in PPMS in 
WM lesions, 
NAWM and 
NAGM. 
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Lesions type effect Publication  Nature of the 
study 
Effect 
WM lesions to 
NAWM 
NAWM to GM 
“Axonal injury in 
the cerebral 
normal-appearing 
white matter of 
patients with 
multiple sclerosis 
is related to 
concurrent 
demyelination in 
lesions but not to 
concurrent 
demyelination in 
normal-appearing 
white matter” 
NeuroImage 29 
(2006) 637 – 642 
MRI 
spectroscopy 
The fractional 
size of the 
restricted pool in 
NAWM (F-
NAWM) was 
significantly 
smaller in 
patients than 
controls but not 
different between 
RRMS and 
SPMS. Mean F 
within Tw lesions 
was lower than in 
NAWM 
“Water diffusion 
is elevated in 
widespread 
regions of 
normal-appearing 
white matter in 
multiple sclerosis 
and correlates 
with diffusion in 
focal 
lesions Mult Scler 
April 2001 vol. 7 
no. 2 83-89 
1.5 T PD, EPI 
diffusion 
imaging. 
Water diffusion is 
elevated in 
NAWM and 
correlated with 
diffusion in WM 
lesions. No 
significant 
difference 
between MS 
subtypes but was 
higher than 
controls. WML 
had the highest 
ADC. WML 
ADC correlated 
with NAWM 
ADC values, with 
correlation higher 
in PPMS and 
benign MS than 
in RRMS and 
SPMS. 
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Lesions type effect Publication Nature of the 
study 
Effect 
WM lesions to 
NAWM 
NAWM to GM 
“Axonal loss in 
normal-appearing 
white matter in a 
patient with acute 
MS” NEUROLOGY 
2001;57:1248–
1252 
Pathology Spinal cord 
ventral column in 
MS patients 
showed a 22% 
axonal loss 
despite the 
absence of MS 
lesions in the 
spinal cord post-
mortem, with 
normal axonal 
numbers in the 
posterior column.  
This could be 
explained by the 
remote effect of 
the lesion at the 
cervicomedullary 
junction. 
“The impact of 
isolated lesions 
on white-matter 
fiber tracts in 
multiple sclerosis 
patients” 
NeuroImage:  8 
(2015) 110–116 
MRI, DTI Directly at the 
lesion site, FA 
values decreased 
in the ipsilesional 
fibers in the 21 
patients with 
lesions affecting 
the ICP compared 
to the 
Corresponding 
site in HC and 
contralesional 
NAWM. A 
decrease in FA 
was also 
observed in the 
contralesional 
NAWM relative 
to HC 
 
 
 
118 
 
 
 
Lesions type 
effect 
Publication Nature of the 
study 
Effect 
WM lesions to 
NAWM 
NAWM to GM 
“Brain metabolite 
changes in cortical 
grey and 
normal-appearing 
white matter in 
clinically early 
relapsing remitting 
multiple sclerosis” 
Brain. 2002 
Oct;125(Pt 10):2342-
52 
MRI, 
27 RRMS 
patients, 29 
Controls 
Reduced NAA, 
Cho and Glx in 
CGM in MS pts 
in comparison 
with controls and 
this was 
unrelated to WM 
lesion load. 
Metabolite 
changes in 
NAWM more 
limited than for 
CGM with Ins 
significantly 
elevated and 
modestly related 
to T2 lesion load. 
“Cortical 
demyelination and 
diffuse white 
matter 
injury in multiple 
sclerosis” Brain 
(2005), 128, 2705–
2712 
Pathology 
52 MS patients, 
30 controls 
Diffuse WM 
injury in part 
correlates with 
cortical 
demyelination 
but not with focal 
WMLs. Diffuse 
axonal injury in 
NAWM more 
pronounced in 
PPMS and SPMS 
than in early MS. 
“Unravelling the 
relationship 
Between Regional 
Gray Matter 
Atrophy and 
Pathology in 
Connected 
White Matter 
Tracts in Long-
Standing MS” Hum 
Brain Mapp. 2015 
;36(5):1796-807 
Conventional and 
DTI on 3T was 
performed in 208 
pts. And 60 
controls. 
Cortical atrophy 
prominent in 
frontal and 
temporal regions. 
Tractography 
using robabilistic 
atlas based on 
healthy controls. 
Pathology in 
connected WM 
tracts y explained 
82% of cortical 
GM atrophy in 
RRMS. 
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Lesions 
type effect 
Publication Nature of 
the study 
Distance 
measured 
Effect 
WM 
lesions to 
NAWM 
NAWM 
to GM 
“Normal-appearing 
white matter changes 
vary with distance to 
lesions in multiple 
sclerosis” 
AJNR Am J 
Neuroradiol. 2006 
Oct;27(9):2005-11. 
MRI (MTR) 
63 RRMS  
 
1×1×2 
(4 layers) 
MTR 
histograms of 
distant 
NAWM in 
controls 
similar to 
patients.   2 
Layers near 
the lesions 
had low 
MTR 
“Multiple sclerosis 
normal-appearing 
white matter: 
pathology-imaging 
correlations” Ann 
Neurol. 2011 
Nov;70(5):764-73 
Pathology 
and 1.5 
Tesla 
postmortem 
MTR, DTI 
in 4 SPMS 
brains. 
NAWM 
close (1-
4mm), 
NAWM far 
(≥5mm) 
Abnormal 
looking 
voxels 
0.2mm 
distance from 
lesion low 
MTR. Sa-
WM close 
and far 
similar mean 
MTR. All sa-
WM Far as 
well as many 
sa-WM Close 
ROIs were 
located in 
close 
proximity to 
the cortex. 
“Evaluation of 
Normal Appearing 
White Matter in 
Multiple Sclerosis 
Comparison of 
Diffusion Magnetic 
Resonance, 
Magnetization 
Transfer Imaging 
and Multivoxel 
Magnetic Resonance 
Spectroscopy 
Findings with 
Expanded Disability 
Status Scale” Clin 
Neuroradiol. 2011 
Nov;21(4):207-15 
 
MTR, DTI. 
30 pts, 30 
controls 
 
WML, 
perilesions, 
NAWM 
(1cm from 
lesions) 
MTR lowest 
in lesions 
than 
perilesional 
then NAWM 
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Lesions type effect Publication Nature of the 
study 
Effect 
WM lesions to 
NAGM 
“Magnetisation 
transfer ratio and 
mean diffusivity 
of normal 
appearing white 
and grey matter 
from patients 
with multiple 
sclerosis”. J Neurol 
Neurosurg Psychiatry 
2001;70:311-317  
 
MRI, MTR Correlation 
between T2 
lesion load and 
NAGM MTR 
histogram 
GM lesions to 
NAWM 
“Cortical lesion 
load correlates 
with diffuse 
injury of multiple 
sclerosis normal 
appearing white 
matter” Mult Scler. 
2014 Feb; 20(2):227-
33. 
MTR at MRI 7T Cortical lesion 
volumes and 
counts all had 
significant 
correlation with 
NAWM mean 
MTR. The 
strongest 
correlation was 
with cortical 
lesion volumes 
obtained using 
MTR images. 
WML volume 
had no significant 
correlation with 
NAWM mean 
MTR. 
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4.3 Patients and Methods: 
Forty-two patients with MS (18 males, 24 females) between 18 and 65 years of 
age were recruited from the Multiple Sclerosis outpatient clinics, at 
Nottingham University Hospitals. The patients included 11 with CIS, 11 
RRMS, 10 PPMS, 10 SPMS. This is the same cohort of patients that was 
recruited for the study in chapter 3. None of the subjects had any other 
comorbidities (such as diabetes, uncontrolled hypertension, major depression, 
or epilepsy) apart from MS. Patients included did not have a relapse within 3 
months from the scanning. All patients underwent a neurological examination 
and were scored on the Expanded Disability Status Scale. Ten healthy controls 
(4 males and 6 females) were also recruited. 
Acquisitions: 
We acquired on all subjects PSIR and MTR as per protocol described in 
Chapter 3. 
Image Analysis: 
All MR images were inspected for artifacts that could affect image analysis, 
such as movement noise, susceptibility or Gibbs effects. 
Inhomogeneity correction and co-registration: 
The relative effect of B1 field inhomogeneity on MTR values was corrected 
using Ropele et al approach,137 which models the relationship between the B1 
error and the MTR error as linear, a reasonable assumption both in theory and 
in practice. The PSIR images were inherently corrected for inhomogeneities. 
For each participant (patient and control), the PSIR image was linearly 
registered onto the MTR image using SPM8's “Coregister” approach.180 The 
default parameters were used and normalised mutual information was selected 
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as the objective function since the registration task was multimodal. Tissue 
maps were estimated using SPM8 and the mean MTR ratios for NAWM and 
NAGM were calculated as a function of the distance to the nearest GM or WM 
lesion. The ratios were obtained by normalising each MTR values by the 
average MTR value in the corresponding normal appearing tissue. When 
considering NAWM, a fibre tract-weighted mean rather than an arithmetic 
mean was computed using the JHU tractography atlas, to model the influence 
of fibres. In order to distinguish between natural spatial variations in MTR and 
those induced by the presence of lesions, the above analysis was repeated by 
substituting control scans for the patient ones. To remove the influence of WM 
lesion on WM MTR, all WM tissue closer than 5 voxels (5mm) from the 
nearest WM lesion was excluded. Then the same analysis was repeated 
examining the effect of WML on mean NAWM MTR values as a function of a 
distance to the nearest WM lesion. 
Statistical Analysis: 
Since the NAWM mean MTR values and NAGM mean MTR values for all 
disease subtypes are not normally distributed, I used Kruskall Wallis to 
compare values across groups. Pair wise comparison was performed and 
correction for multiple comparisons was applied. Pearson’s coefficient was 
used to examine the relationship of NAWM mean MTR values and NAGM 
mean MTR values with the WML volume and CL volume. For each patient, 
we estimated the parameters for a robust linear regression of the average 
NAWM MTR value on the distance to the nearest GM lesion using iteratively 
reweighted least squares. Similarly we examined the effect of WM lesions on 
mean NAWM MTR values as a function of distance to the nearest lesion. 
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Spearman’s rank correlation analysis was used to explore the relationship of 
clinical parameters (mainly EDSS and disease duration) with NAWM mean 
MTR values and NAGM mean MTR values. 
4.4 Results: 
The mean NAGM MTR and mean NAWM MTR values for patients of all 
disease phenotypes are displayed in table 4.2.  
Mean NAGM MTR and mean NAWM MTR values were lower with the 
chronicity of the disease. Mean MTR values were also lower in NAGM than in 
NAWM. The variation in mean MTR values of NAGM and NAWM across 
groups did not reach statistical significance after correcting for multiple 
comparisons. 
NAWM mean MTR values and NAGM mean MTR values correlated 
significantly with WML volume (rho = -0.54, p = 0.001 and rho = -0.39, p = 
<0.05 respectively), not with cortical lesions volume (rho = - 0.23, p = 0.17 
and rho = - 0.15, p = 0.34 respectively). 
A one sample Wilcoxon signed rank for the association between cortical 
lesions and mean NAWM MTR values, showed that the regression slopes were 
not significant. NAWM MTR was significantly reduced in the vicinity of WM 
lesions with respect to controls, up to 10mm away from the closest lesions. We 
also found an effect of cortical lesions on both NAGM and NAWM but at 
shorter range (up to 3mm). Figure 4.1&4.2 
A significant correlation was demonstrated of disease duration with NAWM 
mean MTR values and NAGM mean MTR values with rho = -0.64. p = 0.00 
and rho = - 0.36, p = 0.25 respectively. A negative correlation was noted 
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between NAWM mean MTR values and age (rho = -0.41, p = 0.01) while no 
correlation was detected between NAGM mean MTR values and age. No 
correlation was detected between NAWM mean MTR values, NAGM mean 
MTR values and gender. EDSS correlated significantly with both NAWM 
mean MTR values and NAGM mean MTR values, although the correlation 
with the former was higher (rho= - 0.57, p= 0.00 and rho = - 0.33, p = 0.03 
respectively).  
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(Table 4.2) Mean NAGM and NAWM MTR values in different MS 
phenotypes and healthy controls 
 CIS RRMS PPMS SPMS Control 
NAGM 
MTR mean 
(std) 
0.318 
(0.05) 
0.297  
(0.036) 
0.310  
(0.064) 
0.250  
(0.044) 
0.322 
 (0.056) 
NAWM 
MTR mean 
(std) 
0.449  
(0.018) 
0.438  
(0.034) 
0.406  
(0.027) 
0.372  
(0.063) 
0.481  
(0.056) 
NAGM = Normal Appearing Grey Matter, NAWM = Normal Appearing 
White Matter 
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(Figure 4.1) Mean MTR values as a function of distance from cortical 
lesions 
 
 
Figure illustrating mean MTR values of NAWM tissue as a function of the 
distance to the nearest GM lesion. Arithmetic mean values are presented in the 
upper panel, while the lower panel shows fibre tract weighted means. Each line 
represents a patient, with the red line representing the mean for all patients. 
Both figures show that mean MTR values are the lowest in NAWM tissue just 
outside the GM lesions. The meat MTR values increase with the distance from 
the lesion. The effect of GM lesion on NAWM tissue extends to 3mm from the GM 
lesion before reaching a plateau. 
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(Figure 4.2) Mean MTR values as a function of distance from white 
matter lesions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure illustrating mean MTR values of NAWM tissue as a function of a 
distance to the nearest WM lesion. In the upper panel arithmetic mean values 
are shown, while the bottom panel shows fibre tract weighted means. Each line 
represents a patient and the red line represents the mean for all patients. Both 
figures show that mean MTR values are the lowest in NAWM tissue just 
outside the WM lesions. Mean MTR values increase with the distance from the 
lesion. The effect of WM lesion on NAWM tissue extends to 10 mm from the 
WM lesion before reaching a plateau. 
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(Figure 4.3) Correlation between disease duration and NAWM mean 
MTR values 
 
The figure illustrates the significant negative correlation between disease 
duration and NAWM mean MTR values in MS patients. (rho = - 0.64, P< 
0.05)  
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4.5 Discussion:  
Cortical demyelination and diffuse WM injury are more prominent in patients 
with progressive forms of the disease than in RRMS or CIS patients. On the 
other hand, the pathogenesis of the diffuse injury in the NAWM is 
controversial. The observed distance effect between NAWM and WM lesions 
suggests white matter lesions are important in the pathogenesis of NAWM 
damage. Two possible pathogenic mechanisms have been proposed for the 
diffuse axonal loss in the NAWM. The first mechanism is due to diffuse 
axonopathy which independent from the focal demyelinating changes, and this 
could simply apply to PPMS patients who have diffusely spread NAWM 
changes despite very small lesion load. On the other hand axonal loss in 
NAWM could be secondary to retrograde wallerian degeneration of the axons 
transecting demyelinated lesions. Supporting the second theory is the work by 
Evangelou et al, who reported that the WML load correlated with the axonal 
density and the number of axons crossing the corpus callosum in the 
corresponding region, and this correlation held strong on applying on 
individual patients.159 The low MTR values of the NAWM regions close to the 
WM lesions or the cortical demyelinated lesions suggests that either WM or 
cortical lesions may contribute to these changes.161 
CD3+ T cells (CD4+ &CD8+ with predominance of CD8+ T cells), not B 
cells, were observed in the NAWM and NAGM of the spinal cords of MS 
patients’ not in controls.181 The density was similar in NAWM and NAGM. 
Axonal density was around 24% less in the NAWM of MS patients compared 
to controls.181 Interestingly, the extent of diffuse axonal loss in NAWM 
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correlated with the density of MHC II
+
 microglia in the NAWM as well as 
with CD3
+
 T cells in meninges..181 Post mortem studies showed reduction in 
axonal density in NAWM in SPMS brains by around 34%.27 
Axonal injury in early stages of the disease can cause significant axonal loss in 
NAWM distal to the lesion while sometimes sparing myelin in these areas.157 
The spinal cord ventral column in MS patients showed a 22%axonal loss 
despite the absence of MS lesions in the spinal cord post-mortem, with normal 
axonal numbers in the posterior column.157  This could be explained by the 
remote effect of a lesion at the cervicomedullary junction.157 
An interesting longitudinal MRI study followed 5 cases over a year. They 
found that T2-hyperintense lesions develop along the ipsilateral corticospinal 
tract following an initial lesion developing proximally in the corona radiata.182 
They suggested that axonal injury can occur distally as a result of a proximal 
acute MS lesion, which in turn can cause subsequent T2-hyperintense lesions 
that are temporally and spatially dissociated from inflammatory activity.182 In 
this study, they measured Wallerian degeneration by the presence of T2-
hyperintense abnormality developing along the course of the corticospinal tract 
inferior and contiguous to an initial acute T2-hyperintense lesion.  
The density of T cells, B cells, and CD68+ macrophages is higher in the spinal 
cord meninges of MS patients in comparison with controls.181 The density of 
lymphocytes in the meninges was strikingly higher than in the NAWM and 
NAGM.181  
Significant reduction in MTR was found in NAWM regions up to 3 months 
prior to the appearance of gadolinium enhancing lesion, which could explained 
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by the susceptibility of these regions of NAWM to the development of new 
lesions, or possibly that new lesions form in NAWM before the disruption of 
the BBB as indicated by the gadolinium enhanced lesions.183 This view is 
supported by observing the NAWM uptake of PK11195, a positron emission 
tomography radioligand which is a marker of activated microglia.
184
 Another 
possibility is the presence of a degree of leakage in the BBB with trafficking of 
pathogenic T cells into the CNS.185  It is also possible that the pathology in the 
NAWM plays a significant role in influencing the pathological response to a 
lesion within different areas of the brain.170 This is supported by the reduced 
frequency of T1 hypo-intense regions in certain areas of the brain. The degree 
of axonal loss in the corpus callosum was found to correlate with the lesion 
load of the corresponding projection areas which suggested mutual local and 
collateral effects on the changes in NAWM.27 De Stefano et al found normal 
NAA/Cr ratio in normal appearing tissue in the hemisphere contralateral to the 
lesion in the acute phase. However, the ratio was reduced in the same region 1 
month later. They suggested that the abnormalities in NAWM could be due to 
long tract injury with remote effect on connected brain regions. Of note, in all 
patients there was a lesion detected near the corpus callosum s.186 Only modest 
correlation was detected between normal appearing tissue MTR histograms 
and T2 lesion load suggesting a more widespread pathology rather than mainly 
the influence of the lesions.187 
In a previous report NAWM mean MTR value was found to vary depending on 
the distance to WM lesions, with the regions close to the WM lesions showing 
more axonal swelling than areas further away.161 They found that NAWM 
regions with reduced mean MTR values were often located close to cortical 
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lesions as well.161 It was suggested that cortical lesions might contribute 
indirectly to the degree of damage in the NAWM that is reflected in their mean 
MTR values.161 In this study the proximity to WM lesions, rather than to 
cortical lesions influenced the mean MTR values in the NAWM. On taking 
into account the fiber tracts going between GM and WM, the NAWM regions 
located in the vicinity of the fiber tracts course were more prone to have lower 
mean MTR values than those located in the surrounding areas.   
There are several factors that could influence mean MTR values in the 
NAWM, such as the location in relation to the ventricular CSF interface. Mean 
MTR values were found to be lower in the NAWM regions close to the 
ventricles in MS patients.188 
D Pelletier et al found that changes in NAWM expressed in the form of 
reductions of mean NAA:Cr were found in PPMS patients with high and low 
lesion load in comparison with controls. More importantly, there was no 
significant difference between the high and low lesion load groups in the mean 
level of NAA:CR.189 This in turn supports the view that widespread NAWM 
damage happens independently of focal tissue demyelination, resulting in 
diffuse NAWM injury in PPMS patient despite the small load of focal tissue 
demyelination.  
Previous studies showed that T2 lesion load had negative correlation with 
cortical GM mean MTR values in RRMS and SPMS patients.166   
The variation in the degree of damage of NAGM as indicated by their MTR 
values unlike other studies was not statistically significant, which could be 
either due to segmenting the cortical lesions out, which probably went 
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undetected on using previous conventional scans, and hence contributed to the 
previously reported high degree of damage in progressive forms of the disease. 
Another possibility is the small number of subjects in each of our patients 
groups making comparison between values in each group difficult. On the 
other hand on comparing the CIS and RRMS patients as one group against the 
PPMS and SPMS in one group, we still could not find a significant difference 
between the two groups in the NAGM mean MTR values. 
One of the advantages of this work is the ability to study both GM lesions and 
the NAWM using a semiquantitative imaging methods that has been correlated 
previously with tissue integrity, and more specifically with myelin  both in the 
grey and WM. In this study WML segmentation was done using a 7T T1 based 
sequence which was shown previously to be more sensitive than clinical 
FLAIR. In this way we have possibly detected most of the small white matter 
lesions that have been considered a possible cause of contamination when 
NAWM was examined in previous studies.  
 
We showed previously that the variation in the degree of damage in cortical 
lesions as reflected by their mean MTR values has a significant role in the 
degree of physical disability. However, cognitive decline is considered one of 
the most disabling MS symptoms as disease progresses; therefore, in the next 
chapter I will explore the contribution of the degree of damage in cortical 
lesions as indicated by mean MTR values to patients’ cognitive performance. 
  
 
 
134 
 
Chapter 5 
The contribution of different cortical lesions’ parameters 
and neocortical volume to physical and cognitive 
performance in MS patients 
 
5.1 Abstract 
Background 
Cognitive impairment has long been described in association with MS. The 
role GM plays in MS generally and cognitive impairment specifically has 
come under more scrutiny during recent years. Recently, it was reported that 
cognitive impairment correlates better with cortical lesion load than with 
cortical atrophy.  
Hypothesis: 
We hypothesise that the degree of damage in cortical lesions as well as in 
NAGM as reflected by their mean MTR values plays an important role in 
cognitive decline in MS patients. We aim to examine the contribution of 
cortical lesion volume and their MTR values, as well as cortical volume and 
NAGM MTR values to the degree of cognitive impairment using a simple 
practical cognitive test, the Brief International Cognitive Assessment for 
Multiple Sclerosis (BICAMS).  
Methods: 
42 MS patients were included (11 CIS, 11 RRMS, 10 PPMS and 10 SPMS).  
Patient demographics were as described in chapter (3). BICAMS was used to 
assess cognitive performance in subjects. 7T PSIR and 7T MT images were 
acquired on all patients. The images were then coregistered, then cortical and 
white matter lesions were segmented out manually. Neocortical grey matter 
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was segmented using SPM8. Cortical grey matter fraction (GMFc) was 
computed for all subjects. 
 
Results: 
GML volume and mean MTR values are presented in chapter (3). Single digit 
modality test (SDMT) was associated with cortical lesion mean MTR values 
(with the lower SDMT scores associating with lower cortical lesions mean 
MTR values), and not with volume. SDMT was also associated with WM 
lesion volume and mean MTR values with mean MTR values having a 
stronger association. Brief visuospatial memory test-revised (BVMT) was 
associated with cortical lesion volume, mean MTR values and WM lesion 
volume. GMFc was only associated with BVMT. 
Discussion:  
The significant association between different cognitive scores with cortical 
lesions, and WML mean MTR values could reflect the disruption in the 
cortical-subcortical tract connections. The observed contribution of lesions’ 
mean MTR values over their volume is an emphasis of the previously 
described impact of the degree of damage of demyelination and axonal loss in 
MS plaques over simple lesion load.  
Conclusion:  
I found that the cognitive performance in MS patients correlates not only with 
lesion volume but more importantly with the degree of damage in these lesions 
indicated by the mean MTR values. Cortical and WM lesions contributed more 
to the degree of cognitive impairment than neocortical volume in MS patients. 
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5.2 Introduction: 
5.2.1 Cognitive Impairment in Multiple Sclerosis: 
Cognitive impairment has long been described in association with multiple 
sclerosis. The frequency of cognitive dysfunction is relatively high in MS 
patients, occurring in more than four in 10 patients.190  It is frequently 
overlooked, as  intact language skills, especially early in the disease process, 
could mask some deficits in concentration, memory and reasoning.191 It has 
been reported that information processing speed192 rather than working memory 
is the primary deficit underlying poor cognitive performance in patients.193  It 
has also been suggested that memory impairment in MS patients could be a 
result of inadequate initial learning and not a function of impaired retrieval.194  
However, there was a relative sparing of verbal learning amongst MS 
groups.195 
Although MS is more prevalent in women than men, reports of variation of the 
risk of cognitive impairment according to gender in MS patients are rather 
conflicting. Savettieri et al reported that cognitive impairment is more frequent 
among men than women. In men, an older age, longer disease duration, a 
higher EDSS score, a lower education level, and the APOE ε4 allele are 
significant risk factors for developing severe cognitive impairment. Among 
women, no association was found between any level of cognitive deterioration 
and the other variables.196,197 On the other hand meta-analysis198 by Prakash and 
colleagues showed that studies which recruit mainly females show more 
cognitive impairment than those recruiting males.  
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Cognitive impairment affects patients’ functional status. It could be predictive 
of functional status in MS.199 It can affect patients at any stage of disease, 
including CIS patients, but is more marked in patients with progressive forms.  
Studies of the relationship between cognitive impairment and Quality of Life 
(QoL) have been contradictory. In some studies, cognitively impaired MS 
patients showed lower quality of life scores than cognitively preserved 
patients.200 Even in early stages of the disease, it was found that patients with 
mild cognitive impairment and slowed processing speed tend to have reduced 
health related quality of life (HQOL). This was ascribed to the fact that slowed 
information processing may impact an individual’s ability to complete tasks 
and to cope in demanding work and social situations.201 
Various batteries of cognitive tests have been used to test cognitive impairment 
in MS patients. The most commonly used is the Rao Brief Repeatable Battery 
(BRB), which includes tests of verbal memory acquisition and delayed recall 
using selective reminding test (SRT), spatial memory acquisition, delayed 
recall, speed and accuracy in visual search and scanning with the Symbol Digit 
Modalities Test (SDMT), sustained attention, concentration and processing 
speed using Paced Auditory Serial Addition Task (PASAT), and verbal 
fluency on semantic stimulus using the Word List Generation Task (WLG).  
Several studies have examined the differences in cognitive impairment of 
RRMS, PPMS and SPMS. One such study included 108 RRMS, 71 SPMS, 55 
PPMS patients and 67 healthy controls. SPMS patients performed worse than 
PPMS patients on SRT and WLG. RRMS patients performed generally better 
than SPMS patients except on WLG. RRMS patients performed better than 
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PPMS patients on the PASAT.202 It was noticed that SRT and WLG 
distinguished RRMS and SPMS patients from PPMS patients. The authors 
hypothesized that CNS inflammation in different MS phenotypes might 
selectively affect some working memory operations more than others.   
In a separate longitudinal study over 2 years 25 PPMS, 30 SPMS and 33 
controls were examined.  Foong and colleagues found that cognitive 
performance of both patient groups remained largely stable during the study 
period.202 Although their patient sample was very small, which require cautious 
interpretation of their results. 
5.2.2 Cognitive impairment and MRI metrics in MS patients: 
The role GM plays in MS generally and cognitive impairment specifically has 
come under more scrutiny over the last decade, especially after it was reported 
that GM atrophy predicts physical and cognitive disabilities better than WM 
damage.203 Trying to correlate the degree of cognitive impairment with the 
severity and site of lesions on MRI has proven difficult and showed conflicting 
results. This is usually due to the difficulty in assessing the contribution of 
focal pathology in the presence of widespread brain abnormalities. Foong et al 
204 reported that the contribution of frontal lobe pathology to cognitive 
impairment is difficult to delineate, and according to their results, is less 
significant than previously reported. In their study they showed moderate 
correlations between MRI frontal lesion load and some of the 
neuropsychological scores, such as verbal fluency, and working memory. But 
when controlled for the total WML load, all previous correlations were lost. 
On the other hand, they found some similarities in the pattern of performance 
on the neuropsychological tests between their MS patients and those with 
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frontal lobe excisions (mainly due to brain tumour or arteriovenous 
malformation), but patients with frontal lobe excisions had more impairment in 
the planning tasks.
205
    
Swirsky-Sacchetti et al reported that the combination of several MRI measures 
which are total lesion load, ventricular-brain ratio and the size of the corpus 
callosum are predictive of cognitive impairment in patients with MS. They 
used a total lesion load of > 30 cm
2
 as an arbitrary cut off point for the best 
sensitivity and specificity for overall cognitive impairment in their sample. 
This supports the notion that the left frontal lobe is significantly involved with 
word fluency and abstract, nonverbal problem solving,  the right parieto-
occipital region involvement is more prominent in measures of sustained 
attention and visual scanning (Symbol Digit Modalities) and the left parieto-
occipital region is most predictive of verbal learning repeated over several 
trials, while memory for complex figures is predicted by right parietal lobe 
involvement.206 
Patients with RRMS who showed cognitive impairment on the BRB also had a 
lower neocortical volume (NCV) than those who were cognitively unimpaired. 
The degree of atrophy in these patients significantly correlated with their 
cognitive scores.83 Another study found that corrected GM volume (corrected 
for tissue segmentation misclassification) was the only MRI variable that best 
predicted the short and long-term auditory/verbal memory performance, as 
assessed by California Verbal Learning Test - second edition (CVLT-II), total 
learning and delayed recall. On the other hand, corrected WM volume was the 
best predictor for mental processing speed and working memory as assessed by 
the  subject’s performance on SDMT and BVMT-R delayed recall, which is 
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consistent with the notion that manipulation of new information requires 
communication between different parts of the brain through WM tracts.207 GM 
and WM volume were more related to patients neuropsychological 
performance in comparison with lesion burden.207 
In a longitudinal study208  that followed patients with  early MS for 2years, 
significant cognitive impairment was demonstrated, starting early on in the 
disease course and steadily progressing. Furthermore, those patients who 
demonstrated cognitive deterioration by the end of the study also showed a 
more conspicuous decrease of brain parenchymal volumes than an increase of 
T2 and T2 lesion loads, although there was a significant increase in the T1 and 
T2 lesions load detected. It was also shown that the cognitive impairment was 
independently predicted over 2 years only by the mean absolute change of 
brain parenchymal volumes. This supports the view that the rapid development 
of brain atrophy determines substantial cognitive decline in MS patients. 
Some studies have looked at the effect of cortical lesions on cognitive 
function. Histopathology studies 130 showed the distribution of subpial cortical 
demyelination in MS patients to involve areas known to be engaged in 
information processing, and this may play a role in cognitive impairment in 
some MS patients. It is not surprising that a number of studies examined the 
effect of cortical lesions on cognitive functions. Nelson et al 120 compared the 
correlation between cortical lesion location, number and type with the different 
degrees of cognitive impairment. They used DIR and PSIR at 3T for lesion 
detection and classification. The authors found that the presence of 
intracortical lesions has less impact on cognitive functions than mixed and 
 
 
141 
 
juxtacortical lesions. This finding was explained by either the bigger size of 
mixed lesions over the intracortical lesions, or the inability of current MRI 
techniques to capture all the intracortical lesions due to their relatively small 
size.  There was a significant increase in the total IC lesions count in the 
patients with mild and moderate cognitive impairment, however a stronger 
association was found with the mixed cortical lesion type. There was a very 
strong association between CL load and information processing speed (using 
Wechsler Adult Intelligence Scale III) in particular. In another study using 3D 
FLAIR and 3D T1-weighted IR-SPGR in 26 MS patients, information 
processing speed and working memory (SDMT), visuospatial memory 
(BVMT-R) scores as well as verbal learning and memory (CVLT-II) scores 
were correlated with cortical lesion count and volume.209 Cortical lesions on 
DIR in RRMS patients were found to increase significantly  in patients over a 
period of 3 years and were associated with worsening performance on 
neuropsychological measures at follow up whilst WM lesion load did not 
change significantly,210 which suggests that GM lesions play a more important 
role in cognitive functions. In agreement with these results, a longitudinal 
study on early RRMS patients over 2.5 years, found that neocortical volume 
changes were significantly more pronounced in MS patients who had a 
deterioration in their cognitive performance (using Rao Brief Repeatable 
Battery) than in those with stable or even improving cognitive performance, 
while the changes in T2 WM lesion load was not signifcant.211 
On comparing the results of 1.5T scans with 3T scans in terms of the cortical 
lesion load, different MR parameters and their correlation with variable 
neuropsychological tests, they found that the higher magnetic field improved 
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the sensitivity of the scans to depict WM and GM lesions in the whole brain. 
Significant association was found between the lesion load on 3T scans and 
cognitive tests scores specially SDMT, CVLT DR, CVLT TL, BVMT DR and 
PASAT2, while on the 1.5T scans, only SDMT and CVLT DR were 
significantly associated with lesion load.212  
Previously mentioned studies used conventional MR imaging. These imaging 
sequences do not have any pathological specificity. An early study by van 
Buchen and colleagues suggested both that structural macroscopic atrophy and 
microscopic structural damage in the form of MTR values have 
complementary role in influencing the neuropsychological functioning in MS 
patients. They found that neuropsychological tests correlated with MTI 
measures of brain volume. Also variation of the MTI values between severely 
impaired, moderately impaired, and cognitively normal patients was 
observed.213 Comi et al further explored the correlation between MTR values 
and cognitive impairment, demonstrating that the average MTR, peak height 
and location of overall brain and frontal lobe histograms were significantly 
lower for cognitively impaired than for  cognitively intact patients.214 In a more 
detailed analysis, Filippi et al found a significant correlation between cognitive 
scores and average WML mean MTR as well as normal appearing brain tissue 
peak height and location MTR histograms. They found that average lesion 
MTR was significantly lower in the patient group with more cognitive 
impairment than those with mild cognitive impairment. This indicated that 
patients with severe cognitive impairment not only have higher lesion load but 
most of these lesions seem to have more severe tissue damage.215  
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Significant correlations have also been observed between lower PASAT scores 
and lower mean MTR values in the right inferior parietal cortex and right 
inferior occipital gyrus. Regions that showed reduced mean MTR values 
without significant atrophy represent reversible changes without any 
irreversible neuro-axonal loss, but these areas were considered most vulnerable 
for atrophy in the future.216  
5.2.3 Physical disability progression and cortical atrophy 
Longitudinal studies showed that GMF at baseline correlates with EDSS in 
RRMS and SPMS patients with higher degree of GM atrophy in patients who 
experience EDSS progression over the period of the study, nevertheless a 
similar pattern was not observed for the change in WMF.203 Neocortical 
volumes were found to correlate significantly with EDSS scores in MS patients 
but this correlation was much stronger in PPMS patients than in RRMS 
patients.217 EDSS score and age at disease onset were found to be a significant 
predictors of GM atrophy (1- point increase in the EDSS score corresponded to 
a 0.54 % decrease of GMF), similarly GMF was found to significantly predict 
the level of patient disability.218 Patients with EDSS score of < 3.5 also showed 
the lowest GM atrophy compared with those with higher EDSS score.218 In a 
longitudinal study, the change in EDSS at follow-up correlated significantly 
with the cortical thickness of precentral gyrus and superior frontal gyrus.219 
Regional cortical thinning in primary motor and visual cortex was found to 
correlate significantly with pyramidal and visual FSS scores consecutively, not 
EDSS scores in MS patients.220 This is consistent with the view of the role  that 
retrograde axonal degeneration plays in cortical atrophy.220 Similarly another 
study showed average loss of 0.08 mm in cortical thickness per unit increase in 
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EDSS, with the most significant correlations found in bilateral middle and 
superior frontal gyri as well as the anterior pole of the left inferior temporal 
gyrus.221 However this was not a reproducible finding in other longitudinal 
studies.222 
In a study that acquired MTR and FSPGR at 1.5 Tesla on PPMS patients 
within 5 years from symptoms onset, a significant correlation was found 
between EDSS scores and reduced MTR values in the pre-central and the post-
central gyri.216 
5.2.4 Pathology of Cortical Atrophy in Multiple Sclerosis in Different 
Disease Phenotypes 
Interest in brain atrophy generally and neocortical atrophy specifically has 
been growing over the last few years, hoping to improve our understanding of 
the pathophysiology of MS.223 
It is still not known if cortical atrophy is due to the decrease in the size or the 
number of neuronal cell bodies in MS brains. In healthy individuals, age-
related atrophy is more evident in the GM than in the WM, with average tissue 
loss around – 0.3% per year and -0.2 % per year respectively. Similarly, 
significant differences are seen in both GM and WM fraction between males 
and females, which points the importance of taking both age and gender into 
consideration when comparing degree of atrophy between different MS 
phenotypes.224  
Brain atrophy starts at early stage in the disease course.224 Neocortical volume 
is significantly lower in MS patients than controls,217 and is more pronounced 
in progressive MS patients rather than RR patients, and in CIS patients who 
convert to RRMS compared to those who remain CIS.224 Sensitivity (78.0%)  
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of dissemination in space  of lesions in predicting the conversion to MS was 
lower in comparison to GM atrophy (89.8%) mainly in the cerebellum and 
motor cortex, while the specificity was 58.7%, and 52.2% for DIS, and grey 
matter atrophy respectively.219 
However, not all studies show GM atrophy as the prominent feature. Some 
studies found that atrophy in the context of MS seems to affect the WM to a 
higher degree than the GM, hence the view that tissue loss early in the MS 
course does not simply reflect a simple acceleration of the age related 
atrophy.224,225  On the other hand another study showed that the rate of GM loss 
over a period of two years was found to exceed the 95% limit of the change 
observed in the normal control subjects, while there was no significant change 
in the white matter fraction (WMF) in patients with low Gd enhancing lesions 
load observed over the same period.226 It was suggested that atrophy may occur 
secondary to inflammation, possibly due to Wallerian degeneration from 
transected neurons which pass through acute lesions. Significantly, this study 
was conducted on early RRMS patients with short disease duration (2 years 
from symptom onset). 
 During the 19
th
 and early 20
th
 century, there was a common assumption that 
demyelination was the main pathologic substrate in MS pathology, resulting in 
loss of tissue volume, and contributing to the brain atrophy observed in MS 
brains. However, axonal loss has also been recognised to be a major 
component of lesions, especially in progressive disease, and thus may also play 
a key role in brain volume loss. Pathology studies have found no significant 
correlation between the mean cortical thickness and the mean degree of 
cortical demyelination observed in MS patients.227 Several studies have 
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correlated brain volumes with other neuronal markers indicating that atrophy 
mainly reflects axonal loss.228 
Topographical distribution of cortical atrophy: 
According to pathology studies, cortical atrophy usually involves the motor, 
somatosensory, superior and middle frontal gyri, superior and middle temporal 
gyri of MS patients’ brains. On the other hand the difference has mostly been 
shown to be significant in the motor cortex.227 Using Tract based spatial 
statistics and Optimized voxel-based morphometry, GM atrophy in PPMS 
patients was found to be mainly pronounced in bilateral sensory motor cortex 
followed by the insula then the right superior temporal gyrus.229 In another 
study which included PPMS patients within 5 years of symptom onset, MTI as 
well as 3D-FSPGR were acquired. SPM2 was used to compare the regions 
with lower MTR values and smaller volumes in the cortex in comparison with 
controls. It was reported that the neocortical volume was mostly reduced in the 
right pre-central gyrus, as well as right middle frontal gyrus, left post-central 
gyrus and left insula.216 Using voxel based morphometry on 1.5T 3D MPRAGE 
images, cortical atrophy in RRMS patients mostly involved the precentral 
cortex, while postcentral gyrus involvement was more pronounced in SPMS 
patients.230 Compared to RRMS and PPMS patients, SPMS patients had 
widespread neocortical volume loss in the occipital lobes bilaterally as well as 
in the anterior lobe of the cerebellum.230 In RRMS patients, significant 
neocortical GM loss was predominantly noticed in the left dorso-lateral frontal 
lobe and bilateral anterior cingulate gyrus with a preferential involvement of 
the left hemisphere.231 
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Pathophysiology of atrophy: 
The mechanisms underlying neocortical pathology in MS are not fully 
understood, nevertheless, it seems to be not driven by one single mechanism 
but a combination of several methods. Chard et al224  assessed cortical 
thickness in a large sample of patients using 1.5T scanners in a multicentre 
study. Measuring cortical thickness is usually a more accurate approach than 
other techniques such as voxel based morphometry as it follows the curvature 
of the ribbon rather than using the surface blurring technique. A high 
correlation was detected between white matter lesion load on T2w and grey 
matter fraction (GMF) and not WMF, and more than 50% of the GMF 
reduction can be explained by the variations in T2 white matter lesion load. 
Total WM lesion load particularly correlated with cortical thinning in bilateral 
cingulate gyrus and bilateral posterior insular cortex.221 GM atrophy could be 
explained partially by focal lesion genesis, but probably another more 
widespread process is involved. On the other hand, the anisotropic voxels and 
the lower spatial resolution in the images used in this study could influence the 
sensitivity to cortical thickness measurements. Some studies reported a 
significant reduction in neocortical volume in MS patients even with minimal 
WM lesion load,217 and no correlation was found between white matter 
enhancing lesions, which was found to represent active inflammation,232 and 
GMF.226 Nevertheless, high Gd-enhancing lesion volume at  baseline was 
associated with more WMF not GMF loss over the subsequent 2 years, which 
might indicate that the loss of WM tissue occur as a delayed effect following 
inflammation.226 Wallerian degeneration (defined by the presence of newly 
developed T2 WM lesions in follow up MRI scans along the course of 
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corticospinal tract distal to initial acute T2 hyper intense lesion) was found in 
the corticospinal tracts that was temporally and spatially distant from focal 
demyelinating lesions.182 This could explain white matter plaques causing 
retrograde injury to different areas of the cortex depending on the axons 
involved, hence the focal cortical thinning of the cortex that was detected by 
some studies.233 Nevertheless, it was also reported that axonal atrophy can 
happen in  the absence of inflammation or demyelination.234 As cortical lesions 
are associated with demyelination and axonal damage, they in turn may 
contribute to tissue loss in the cortex.94 Pathology studies showed that the mean 
neuronal density and mean neuronal cell size, as well as glial density is usually 
reduced in cortical lesions than in the surrounding normal-appearing MS 
neocortex.227 The only significant difference between normal appearing 
neocortex and control brains was the shape of the neurons as they were more 
circular in the MS brains.227 
Some studies suggest that the mechanisms contributing to GM atrophy change 
over the course of disease. So in the early stage of the disease, pathological 
changes in the WM might be the main culprit whilst latter in the disease course 
widespread GM involvement is the more responsible for the cortical atrophy.203 
This could explain the lack of correlation detected between WMF and GMF at 
baseline or follow-up scans in RRMS patients, while in SPMS patients GMF 
and WMF were moderately correlated at baseline and 4 years later.203 Another 
theory is that the mechanism of cortical atrophy vary among different MS 
phenotypes since the disease onset, so neocortical atrophy in PPMS is more 
due to neurodegeneration and progressive axonal loss rather than due to WM 
lesion accumulation while in RRMS the reduction in neocortical volume is 
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explained to some extent with the WM lesion load from very early on in the 
disease course, and this could partly contribute to the clinicopathologic 
difference between these two disease types.217,218 In PPMS and SPMS patients, 
regional GM atrophy in a given lobe correlated to the T2 lesion load within the 
same lobe.230 
How early cortical atrophy starts in the disease course is still controversial. 
Some studies report no difference in neocortical volume between CIS patients 
and controls,230 while others document cortical volume loss in CIS patients in 
early stage of the disease course, and evolves faster in the grey than in the 
white matter tissue.235 One study involved 53 RRMS patients with short disease 
duration (between 1-5 years), following the patients for 2 years with 1.5T T1-
w and T2 sequences. They analysed the whole brain volume, and reported the 
mean rate of brain atrophy to be 1.33% a year, indicating that brain atrophy 
could be one of the primary pathological events in early disease development 
and progression.208 Chard and colleagues in a longitudinal study examined the 
difference of cortical atrophy in early MS patients and controls. Although there 
was no difference between the GM volume between early MS patients (mean 
disease duration 1.9 years) and controls at baseline, there was a significant 
difference in the rates of change between MS and healthy controls.236 To 
investigate if there was a difference in the rate of cortical atrophy in patients 
depending on how long they had the disease, Zivadinov et al performed a 
longitudinal study including 181 RRMS patients. They classified the patients 
into two groups, one with short disease duration (less than 2 years) and the 
other group is with longer disease duration (longer than 2 years). Patients 
received a 2 monthly scans for 2 years. They found that patients with longer 
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disease duration at baseline had a smaller cortical volume; on the other hand 
there was no significant difference in the rate of cortical atrophy between the 
two groups.237 Two hundred and sixty seven patients were scanned at baseline 
and 24 months later showed a mean reduction of GMF of 0.38 % in 
comparison with 0.21% in healthy controls, with higher GMF at baseline 
correlated with higher GMF variation over the period of the 24 months.238 It 
also suggested that the decrease in GMF reduces over time.238 
On comparing the neocortical volume between different groups of MS patients 
with similar disease duration (7 years), there was no significant difference 
between RRMS and PPMS patients in their normalized cortical volumes. On 
the other hand they were both lower than normal controls. There was no 
correlation between the neocortical volumes and the WML load, suggesting 
that a proportion of neocortical pathology could be due to WM involvement, 
however the extent of the changes suggests that an independent 
neurodegenerative process may also be active.217 An alternative explanation 
would be a temporal delay between the process leading to T2 lesion formation 
and the subsequent GM atrophy.226 Similarly, on comparing the neocortical 
volumes between SPMS and RRMS patients, they found that neocortical 
volume in SPMS patients was less than in RRMS patients.218,239 
Cortical thickness is another way of estimating cortical atrophy in MS patients, 
and it is normally defined as the average of the distance between the GM-CSF 
boundary and the GM-WM boundary. Unfortunately, measuring cortical 
thickness has proved to be technically challenging mainly due to the complex 
folding patterns of the cortex. Mean cortical thickness negatively correlates 
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with age, with an average loss of 0.1 mm in cortical thickness per decade. 
Bilateral primary motor, somatosensory and visual areas are mostly 
involved.221  A 25% reduction in cortical thickness of primary motor and visual 
areas was reported in MS patients in comparison with healthy controls.220 The 
primary motor cortex is significantly thinner in CIS patients with pyramidal 
onset while no such correlation was found in PPMS or SPMS patients.220 
Cortical thickness was examined by Chen et al in a longitudinal cohort of 
RRMS and SPMS patients over a period of 1 year.147 A correlation between 
cortical grey matter thickness and brain volume was observed. There was no 
difference in baseline cortical thickness between the patient’s group who 
progressed and those who have not, however, the patients who showed 
progressive disability over the period of a year showed more progressive loss 
of cortical thickness involving especially the parietal and precentral areas than 
the stable group.147  
Whether the abnormalities in the NAWM correlate with the diffuse cortical 
grey matter damage was investigated in PPMS patients using DTI.229 They 
found a negative correlation between the FA in the corticospinal tract and the 
GM atrophy in the adjacent sensory-motor cortex. Also the reduction in the FA 
of the tracts adjacent to the left insula correlated with GM atrophy of the 
insula.229 On the other hand, they found that some abnormal WM tracts did not 
show any corresponding GM atrophy, and similarly some areas of GM atrophy 
were not adjacent to any regions of reduced NAWM FA.229 This suggests that 
the abnormalities in the GM, at least in some part, could develop 
independently from the abnormalities in the NAWM.  
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Overall, we think the mechanisms of atrophy are still poorly understood and in 
need for further exploration. As per previous studies the correlation between 
the degree of atrophy and either the WML or the GML load is only moderate, 
which suggests that further mechanisms need to be explored. As per 
pathological studies, diffuse pathological changes affect the NAWM which 
constitutes a significant proportion the brain by volume; hence the role the 
NAWM plays in the pathogenesis of cortical atrophy is worth exploring using 
quantitative imaging. Lower normal appearing brain tissue (NABT) MTR was 
associated with a greater rate of BPF change over a period of 4 years. On the 
other hand this effect was more pronounced in the RRMS than in the SPMS 
patients.203 
The accuracy of volume measurements is mainly influenced by the image 
resolution in three dimensions and the tissue contrast. So it is always 
preferable to have a higher scan resolution which can be achieved using higher 
field strength, 3D acquisitions and small voxel sizes with high white matter, 
grey matter, CSF, and lesions tissue contrast.240 MT imaging can be very 
sensitive to tissue damage in the early stages before any apparent brain volume 
loss. Reduced MTR values were reported in all regions where cortical atrophy 
was observed.216 On the other hand, reduced MTR was also observed in the left 
pre-central and superior frontal gyri without significant atrophy.216  
To what extent the degree of damage in cortical and white matter lesions 
contribute to cognitive impairment in comparison with cortical atrophy have 
not yet been fully investigated in patient samples that are representative of the 
total MS population. Small lesions that are not normally detected by 
conventional MRI may play a crucial role on the degree of cognitive 
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impairment in MS patients.241 Structural high resolution imaging has proven to 
be effective for predicting cognitive impairment. On the other hand there have 
been no studies so far using high resolution MRI, exploring the contribution of 
the degree of damage in focal cortical lesions, using magnetisation transfer 
imaging, on cognitive impairment in MS patients of different disease 
phenotypes.  
5.3 Hypothesis: 
1- We hypothesise that cortical atrophy, cortical lesion subtype and white 
matter lesion load contribute to the degree of cognitive impairment to 
variable degrees in MS patients of different disease phenotypes. 
2- We also hypothesise that there is an association between the degree of 
damage in focal cortical and white matter lesions, as indicated by their 
mean MTR values, and cognitive impairment in MS patients. 
5.4 Methods: 
We used the same cohort of patients as in chapter 3. 
Neuropsychological evaluation: 
A neuropsychological evaluation was implemented to all patients by 
the same assessor on the same day of the scan prior to acquisition. We 
used BICAMS, which is a simple neuropsychological (NP) assessment 
that consists of three sub-tests from the Minimal Assessment of 
Cognitive Function in Multiple Sclerosis (MACFIMS) battery. The 
BICAMS test consists of three tests SDMT, CVLT-II (first five trials), 
and BVMT-R (first three recall trials).  
MRI acquisition:  
As per chapter (3) MRI acquisition protocol 
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Analysis: 
The relative effect of B1 field inhomogeneity on MTR values was corrected 
using Ropele et al’s approach.137 PSIR and MTR images were linearly 
coregistered for each subject using SPM8 “Coregister” tool.180 Default 
parameters were used, and normalised mutual information selected as the 
objective function since the registration task was multimodal. Cortical and 
WM lesions were segmented out using MIPAV medical images analysis 
software. Cortical lesion segmentation criteria are the same as delineated in 
chapter 3. Tissue maps were created using SPM8 and the mean MTR ratios for 
NAWM or NAGM were created. MTR values were normalised by average 
MTR values in the corresponding normally appearing tissue. As the presence 
of lesions can potentially affect the ability of automated tissue classification 
methods to correctly handle normally appearing tissues, Chard et al.’s242 
approach has been used to inpaint the PSIR images. Inpainted PSIR images 
were then classified using SPM8’s “New Segment” approach. GMFc was 
calculated as GM/ (GM+WM+CSF). 
Statistics: 
One way ANOVA was used to compare GMFc across different MS 
phenotypes. Pearson correlation coefficient was used to assess the association 
between different MRI parameters, mainly GML volume, mean MTR values, 
WML volume, mean MTR values with GMFc. 
Multiple linear regressions were used to examine the association between 
different MRI metrics and cognitive performance. Each cognitive score such as 
SDMT, CVL and BVMT was indicated as dependent variable while CL 
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volume, their mean MTR values, WML volumes, their mean MTR values were 
considered as independent variables controlling for age. Ordinal logistic 
regression was used to assess the correlation between physical disability 
measured by EDSS and GMFc. 
5.5 Results: 
Descriptive statistics for the cortical and white matter lesions are described in 
chapter 3. Descriptive statistics for cognitive scores as well as GMFc are 
presented for all subjects by their MS phenotype in table 5.1.  
GMFc was the smallest in the SPMS patients in comparison with other disease 
phenotypes. There was no significant difference in GMFc between the groups 
using one way ANOVA (p =0.45).  
MRI metric correlations: 
 GMFc consistently showed stronger correlation with tissues mean MTR 
values than with simply lesion load. GMFc was significantly correlated with 
mean cortical lesion MTR (rho= 0.5, p = 0.002) and white matter lesion MTR 
(rho= 0.4, p= 0.02). Significant correlation was detected between GMFc and 
NAWM MTR values (rho= 0.4, p= 0.005) not with NAGM MTR values (rho= 
0.2, p= 0.3). No significant correlation was detected between GMFc and CL 
volume (rho= -0.3, p= 0.07) or WML volume (r= -0.3, p= 0.1). No significant 
correlations were detected between cortical lesions volume and GMFc even on 
taking into account the cortical lesion subtypes. 
Regression analyses of MRI metrics to cognitive performance and EDSS: 
On taking into account individual lesions’ mean MTR values, we used a 
multivariate regression with SDMT (as previously explained is consistently 
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found to be the most sensitive test for cognitive performance in MS patients) 
as a dependant variable and mean cortical lesion volume, their mean MTR 
values as independent variables controlling for age, we found a significant 
association between SDMT performance mean cortical lesion MTR values not 
CL volume (p= 0.00, p = 0.9 respectively). A significant association was 
demonstrated between SDMT as a dependant variable and WML volume and 
mean MTR values controlling for age (p=0.03, p = 0.00 respectively), with 
mean lesion MTR values having stronger effect than WML volume. There was 
no significant association between CVLL and either cortical or WML volumes 
or their mean MTR values. BVMT was significantly associated with CL 
volume, mean MTR values and WM lesion volume controlling for age 
(p=0.001, p = 0.001, p = 0.005 respectively), while WM lesion mean MTR 
values was not a significant predictor. Mean cortical lesion MTR values had 
the strongest effect on BVMT in comparison with the other variables.  
The GMFc in SPMS was the lowest in comparison with the rest of the MS 
phenotypes. GMFc showed significant association with BVMT (p = 0.04) not 
with SDMT or CVLT controlling for age. NAWM MTR as well as NAGM 
MTR showed significant association with SDMT (p= 0.002 and 0.047 
respectively), not with any of the other cognitive scores.  
We used a linear model to describe the association between SDMT with the 
degree of damage in cortical lesions and NAGM. We modelled the NAGM 
MTR and the CL mean MTR values as independent variables and SDMT as 
the dependant variable, the NAGM MTR lost significance while cortical lesion 
mean MTR values remained the significant parameter associated with 
cognitive performance (p= 0.95 and 0.016 respectively). Similarly, on 
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modelling NAWM MTR and white matter lesion mean MTR values as 
independent variables while SDMT as dependant variable, the NAWM MTR 
not white matter lesions mean MTR values significantly associated with 
SDMT scores (p= 0.014 and 0.676 respectively). No significant association 
was seen between EDSS and GMFc. 
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(Table 5.1) Descriptive statistics for cognitive performance and cortical 
volume in MS patients 
 MS phenotypes 
CIS RRMS PPMS SPMS 
Mean (std) Mean (std) Mean (std) Mean (std) 
SDMT 56.56 (8) 50.86 (8) 41.63 (7) 35.13 (9.9) 
CVLTTL 54.89 (6.5) 57.13 (9) 54.89 (11.4) 48.5 (13) 
BVMTR 29.44 (4.9) 30.38 (2) 25.89 (6) 22 (6) 
GMFc 0.489 (0.009) 0.490 (0.009) 0.482 (0.014) 0.479 (0.008) 
Table illustrating the means and standard deviation for cognitive tests such as 
SDMT, CVLTTL, BVMTR and GMFc 
Std = standard deviation 
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(Figure 5.1) correlation between grey matter fraction and cortical lesion 
mean MTR values 
 
The figure illustrates significant high positive correlation between cortical 
lesions mean MTR values and cortical grey matter fraction indicating the 
important contribution of the degree of damage in cortical lesions to nearby 
tissue volume. 
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(Figure 5.2) correlation between SDMT and cortical lesion mean MTR 
values 
 
 
 
 
 
 
The figure illustrates the significant positive correlation between SDMT 
(single digit modality test) and cortical lesion mean MTR values in MS 
patients, suggestive of the important role the degree of damage in cortical 
lesions play in cognitive performance in MS patients.  
 
 
 
 
 
  
 
 
161 
 
5.6 Discussion: 
There are a number of neuropsychological tests used to assess cognitive 
decline described in the literature. We aimed to use a neuropsychological 
battery test that was sensitive enough to detect cognitive decline, and at the 
same time not time consuming, and so could be implemented in clinical 
settings. The diagnostic accuracy of the BICAMS in comparison with other 
conventional NP batteries (MACFIMS) was assessed in a large group of MS 
patients by Dusankova et al.243 They showed that despite the simplified 
application of the three included tests in the NP battery, it did not diminish its 
overall sensitivity or specificity. They found that SDMT and BVMT-R are the 
two most sensitive tests of the battery showing the largest differences between 
MS patients and controls. I similarly found in this study that SDMT and 
BVMT-R show the most prominent differences between different MS 
phenotypes. Like others I found that SDMT was the most sensitive measure for 
cognitive decline in MS patients.244 
Cognitive decline in MS patients has been correlated with both macro 
structural and microstructural changes in MS brains. In this study, I assessed 
cognitive performance in different MS phenotypes and its correlation to 
different lesion parameters as well as with corrected neocortical volume. The 
NP battery of tests was interpreted by the same assessor without prior 
knowledge of the MRI findings. Similar to previous reports,138 I found a 
significant association between lower cognitive scores and higher cortical 
lesion volume. Also a significant association was detected between different 
cognitive scores and cortical lesions, WM lesions mean MTR values. This 
could be explained by the disruption in the cortical subcortical tract 
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connections that is responsible for intact cognition. The noted contribution of 
lesions’ mean MTR values over their volume is consistent with the previously 
suggested correlation of the degree of damage in MS plaques to clinical 
parameters over their volume. As conventional MRI sequences do not have 
pathological specificity to differentiate between MS plaques of various 
pathological entities from mild inflammation to demyelination and axonal loss, 
hence correlation between simple lesion load and cognitive decline does not 
reflect a full representation of the effect of these lesions, and correlation of 
lesions microstructure may provide a more accurate representation of the effect 
of such lesion pathology. Like others,141 I found that cortical lesions and WM 
lesions have more influence on cognitive decline than GM atrophy.  
SPMS patients had the smallest cortical GMF in comparison with the other MS 
phenotypes on the other hand; difference was not significant on controlling for 
age and correcting for multiple comparisons. In a previous study138, a 
correlation between the GMF in MS patients and the cortical lesion volume 
was found. In this study we could not detect such a correlation, which could be 
due to the small sample included in comparison with the previous study which 
detected such a correlation. The higher magnetic field with increased 
resolution providing an advantage in increased accuracy in lesions detection 
and segmentation out of the cortex providing cleaner GM could be another 
reason for the lack of correlation unlike previous report.  
In this study the variation in GMF was associated with the degree of 
demyelination and axonal loss in the cortical and WM lesions, with cortical 
lesions showing higher association than WM lesions. 
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GM atrophy was shown to correlate with worsening in cognition not EDSS222, 
similarly in this study GMFc correlated with performance in BVMT but no 
correlation was found with physical disability. Various previous reports 
showed similar results to this study, with lack of correlation between physical 
disability and grey matter atrophy. 245,225 The discrepancy between my findings 
and some reports, which found such a correlation, is probably difference in 
sample size, as well as the use of disease modifying treatment through the 
disease course which could affect degree of atrophy amongst other parameters. 
The correlation between GMFc and cortical lesions mean MTR values is 
supported by early findings of reduced MTR values in the grey matter where 
atrophy is observed 216, which could be explained by the impact of the high 
degree of damage, as expressed by low mean MTR values, in cortical lesions 
on causing retrograde probably irreversible neuroaxonal loss.  
Early studies showed the correlation between neocortical grey matter mean 
MTR values and cognitive performance. 246 My finding that cognitive 
performance is significantly associated with cortical lesion mean MTR values 
not NAGM MTR values, when put in the same model, could be explained that 
the main effect in previous studies was of the unsegmented cortical lesions, 
hence in our study on segmenting those lesions out the effect of the NAGM 
has become negligible.  
I observed that the contribution of NAWM MTR to cognitive performance was 
significant in comparison with white matter lesions mean MTR values. This 
supports previous report that microstructural NAWM damage contributes to 
cognitive decline regardless WML volume.247 This could be explained by the 
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disruption of the widespread connections in the WM due to microstructural 
changes, as the integrity of WM connections is important for high brain 
functions.248 
The consistent finding in this study is the contribution of the degree of damage 
in lesions and NAWM to the cognitive function. This prompts to the 
significance of looking beyond lesion load and tissue atrophy to determine 
patient’s treatment or monitor response and treatment escalation. 
In this study I did not assess correlations between cognitive performance and 
regional neocortical atrophy, but it was suggested in previous studies that 
cortical atrophy was found predominantly in the superior temporal gyrus and 
the superior and middle frontal gyri in early stages of the disease.249 In MS 
patients with cognitive decline, mainly low scores on PASAT, neocortical 
atrophy was more pronounced in the frontal and temporal and parietal 
regions.250 
In this study, I did not investigate deep grey matter and their contribution to 
cognitive decline. I did not correlate various cognitive tests scores with the 
topographical distribution of lesions. The correlation between individual 
cognitive tests scores with white matter lesions depending on their regional 
distribution has been previously explored; however potential association with 
cortical lesions has not yet been examined.  
We illustrated the significant role the degree of damage in cortical lesions 
plays in patients’ physical and cognitive disability in different MS phenotypes. 
The degree of demyelination and remyelination in patients determine their 
level of disability to a large extent. We wanted to examine if the degree of 
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demyelination and remyelination over time, reflected by lesions mean MTR 
values, vary between patients’ phenotypes.  
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Chapter 6 
The change in focal lesion MTR across time in patients with 
MS of different disease phenotypes 
6.1 Abstract 
 
Introduction: 
Remyelination in MS appears to be significant, for protecting axonal integrity, 
restoring nerve conduction, and preventing long term physical disability. The 
degree of myelin loss in MS lesions (reflecting demyelination and 
remyelination) varies across disease subtypes, and probably this variation 
contributes to the level of disability different MS phenotypes manifest.  
Objectives:                       
This is an exploratory study that aimed to follow a small group of patients of 
different disease phenotypes (5 CIS, 4 RRMS, 6 PPMS, and 5 SPMS) over a 
period of 1 year. We aim to examine the variation of myelin status and axonal 
loss in MS patients of different subtypes longitudinally, and the ability of MTR 
at 7 T to detect GM remyelination.  
Methods:   
A baseline 7T PSIR and 7T MTR were acquired (time point 0), and the same 
protocol was acquired 12 months later (time point 1). Cortical lesions were 
segmented, and lesion mean MTR values were computed for each visit. I 
compared the changes in mean MTR values in cortical lesions among patients 
of different disease phonotypes, and its association with clinical parameters. 
Results: 
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In this exploratory study, most lesions either cortical or WM lesions in 
different MS subtypes remained unchanged across two time points irrespective 
of the chosen cut off. A significant percentage of lesions showed an increase in 
the average change in mean MTR values across the two time points while the 
rest of the lesions showed decrease in mean MTR values. The average change 
in the mean MTR values of individual CL over 12 months period was 0.053 ± 
0.089 in CIS patients, 0.001 ± 0.074 in RRMS patients, 0.018 ± 0.127 in PPMS 
patients, while in SPMS patients was 0.061 ± 0.105. There was significant 
difference among the groups in the average change in mean MTR values 
across two time point using one way ANOVA (p < 0.001, F= 12.47).  
Discussion: 
In this exploratory study most CL showed unchanged mean MTR values over 
the 12 months’ period, which may reflect the non-changing nature of mostly 
chronic cortical lesions over one year. Surprisingly, the frequency of cortical 
lesions showing increase and reduction in their mean MTR values was quite 
similar between CIS and SPMS patients; this was unexpected however as 
considering the progressive degree of disability in SPMS patients for which 
CL have substantial contribution, we would have expected possibly a more 
demyelinating picture in SPMS.  
What is more difficult to explain is the lack of significant remyelination in 
RRMS patients which could be due to the small number of patients included. 
Large longitudinal studies needed to confirm or refute those findings. 
Conclusion: 
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The frequency of lesions showing an increase of CL mean MTR values was 
similar in CIS and SPMS patients, which is counter intuitive. This conflicts 
with most pathology studies on SPMS patients. The average change in CL 
mean MTR values was higher in males than females. No correlation detected 
between the change in individual CL mean MTR values and disease duration 
or patients age.  
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6.2 Introduction 
Remyelination was first described in 1961 by Bunge et al using CSF barbotage 
model, by repeated withdrawal and reinjection of CSF into cat’s spinal cords. 
This has led to myelin loss which was followed by formation of new myelin 
with a slightly different staining quality.251 Not long after this, remyelination 
was described in MS lesions.252 
Early neuropathology examination of cortical lesions in MS brains proved to 
be challenging mainly as the cortex in general is much more cellular than the 
WM, which makes it more difficult to examine accurately. This in turn 
contributed to the difficulty to examine neuronal and axonal loss within the 
intracortical part of the lesion. 94 This has improved since the development of 
immunohistochemical preparations.   
In MS, apoptotic neurons were found to be significantly higher in 
demyelinated cortex compared to myelinated cortex.108 Axonal damage is also 
a well-known phenomenon in MS plaques, and it normally occurs at the peak 
of demyelination and inflammation.92  
In terms of correlations and regional variations of GM and WM demyelination, 
Gilmore et al reported that the proportion of GM demyelination correlated 
significantly with the proportion of WM demyelination. The proportions of 
GM demyelination was found to be significantly reduced in the motor cortex, 
especially in comparison with the cingulate cortex.253  
Merkler et al reported the transient nature of inflammatory infiltration and 
demyelination in the GM. EAE models targeted to the subcortical white matter 
(corpus callosum) were similar to targeted WM spinal cord EAE lesions in 
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terms of persisting anti-inflammatory cells infiltration, demyelination and 
axonal damage. 92  
Pathology studies indicated that remyelination by oligodendrocytes can occur 
in the CNS in MS patients.252 Remyelination in the CNS is very significant, to 
protect axonal integrity, and restore nerve conduction. Hence, in theory 
inducing remyelination is important to prevent long term physical disability in 
MS patients. Encouraging therapies promoting remyelination requires a well-
established imaging tool that could assess the degree of demyelination and 
remyelination in MS patients. 
6.2.1 Pathogenesis of demyelination and remyelination: 
MS is thought reflect oligodendrocyte pathology. So it could be that the 
regenerating oligodendrocytes have very short processes, hence the inability to 
wrap as efficiently as those with longer processes, however the problem could 
equally be due to defect with the regulatory signals causing restriction to the 
sheath thickness and the lengths of internodes and nodes in MS lesions.254 
Although demyelination mainly targets oligodendrocytes,255 during 
remyelination oligodendrocytes remain very quiescent, while progenitor cells 
are mainly responsible for remyelination.256  
Remyelination involves the formation of new oligodendrocytes. New mature 
oligodendrocytes normally originate from oligodendrocyte progenitor cells. 
Progenitor cells are widespread throughout the CNS.  Macrophages, 
oligodendrocytes, OPCs all play important role in remyelination. Macrophages 
play an important role in the removal of the myelin debris that is generated 
from demyelination which is important as CNS myelin contains proteins that 
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could inhibit the differentiation of oligodendrocyte progenitors during 
remyelination.257 Remyelination is generally dependant on timely interaction 
between astrocytes, macrophages, demyelinated axons and OPCs, so any delay 
in interaction between OPCs and demyelinated axons would be associated with 
temporal mismatch in the sequence of events for successful remyelination.258 
6.2.2 Pathology of demyelinated and remyelinated Lesions 
Pathological analysis of lesions showed the patterns of demyelination vary in 
subgroups of MS patients and at different stages of the disease.16 Lesions were 
classified into 4 different patterns. With pattern 2 the most frequent. Pattern I 
and II were found in patients who presented with all different clinical subtypes 
of the disease before biopsy or death, while pattern III lesions were found 
mainly in patients with a disease of less than 2 months duration before biopsy 
or autopsy.16 Pattern I and II show more perivenous distribution and tend to 
confluence resulting in large demyelinated plaques. 
The characteristic feature of remyelination that makes it very distinguished 
from normally myelinated tissue is that the sheath is always thinner and shorter 
than expected for the diameter of the axon, on the other hand the composition 
of the myelin and the manner in which it is formed are similar to those in the 
originally myelinated intact axons.259 On examining remyelination in 
demyelinated cortical lesions, it was noted that some cortical demyelinated 
lesions have very sharp lesions borders and those noted as demyelinated, 
whereas remyelinated cortical lesions have irregular, punctuate, less densely 
and less orderly arranged myelin under light microscopy.90 Cortical lesions 
shows more extensive remyelination than white matter lesions even on case 
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per case basis, with no difference detected in the extent of cortical and WM 
remyelination noted between SPMS and PPMS patients.90  
Remyelination in human and experimental tissue could be assessed using 
electron microscopy via measuring the quotient axon/fiber diameter which is 
known as g-ratio. Remyelinated fibers are characterised by thinner myelin 
sheaths, hence increased g-ratio indicating remyelination.  In a pathology study 
on MS brains of chronic progressive patients using electron microscopy, 
myelin sheaths appeared thin in areas of normal appearing cortex, and g-ratios 
were significantly higher in comparison with controls, which suggests that part 
of the normal appearing cortex in MS brains may indeed be remyelinated.90 
Albert et al examined myelin expression in oligodendroglial cells using  
immunohistochemistry.90 Oligodendroglia numbers were low in the centre of 
demyelinated cortical lesions regardless if they have remyelinated borders or 
not. As expected cortical lesions without evidence for remyelination showed 
low numbers of myelin basic protein (MBP) positive oligodendrocytes at the 
lesion border but had 2, 3- cyclinc nucleotide 3-phosphodiesterase (CNP) 
positive cells were detectable (indicating the presence of cells of the 
oligodendrocyte lineage).90 Interestingly they also found that the borders of 
remyelinated cortical lesions showed an increased number of both MBP and 
CNP positive cells even in comparison with normal appearing cortex.90  The 
presentence of lipid-laden macrophages or microglia in contact with thinly 
remyelinated fivers suggests ongoing active remyelination and 
demyelination.260  
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6.2.3 Variation of demyelination and remyelination in different stages of 
the disease 
The cycle of demyelination and remyelination is so important in determining 
the disease course in MS patients. Demyelination is necessary but not enough 
to cause permanent disability in MS patients. The lack of protective myelin 
causes axonal loss. Normally when demyelination is well established and 
remyelination is exhausted, this is when disability is progressive.261 
The pattern of demyelination is different in different stages of the disease. In 
acute MS, myelin is usually lost and there is usually associated axonal loss as 
well. In early stages of chronic MS more than 50% of the demyelinated lesions 
have thin myelin sheath giving them shadow appearance hence called shadow 
plaques and these plaques are suggestive to remyelination throughout the entire 
lesion. In late stage of the chronic MS, remyelination is mainly restricted to the 
margins of the lesions, with still a degree of preservation of axons, although 
the density of axons in the middle of lesions is fairly reduced.262 The degree of 
cortical demyelination was recognised to be much higher with disease duration 
longer than 10 years, although that was in a subset of patients.90 Studies 
showed that younger patients have greater GM demyelination with no 
influence of  disease duration.253 On the other hand both younger age and long 
disease duration were associated with more extensive WM demyelination.253 
The outcome of an MS relapse depends on the balance between the degree of 
demyelination and remyelination in active lesions, which is significant if a 
patient is going to develop SPMS. Even the pattern of remyelination in MS 
lesions varies depending on the stage of the disease. In chronic stage of the 
disease, remyelination is generally sparse and mostly involving the edges of 
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the lesions.262 Another pathology study149 described that PPMS patients show 
higher percentage of shadow plaques than SPMS patients and suggested that 
remyelination is more complete in PPMS patients than in SPMS patients which 
leads to larger WM and deep GM lesions in patients with SPMS phenotype. 
On the other hand the spinal cord did not show any variation in the rate of 
demyelination (as assessed by the volume of the slowly expanding and active 
lesions) and remyelination (as assessed by the volume of shadow plaques), 
although the size of each lesion has appeared to be bigger in the PPMS  
patients than in SPMS patients.149 
6.2.4 Factors influencing demyelination and remyelination: 
Bramow et al. 149 found demyelination to be more prominent in remyelinated 
tissue than in normal appearing tissue which they described as the 2nd hit 
theory. This was mainly explained by the effect of slowly expanding 
demyelination (which are more prevalent in SPMS than in PPMS patients) 
rather than active demyelination. 
Early pathology studies suggest that recurrence of demyelination in the shadow 
plaques contributes to future failure of remyelination in this region.263 . It was 
also shown that age influences the rate of lesions remyelination, not the extent 
of remyelination. 264 remyelination in the optic nerve following optic neuritis 
can continue for up to 2 years. 265 It is also noted that patients who die older 
show more shadow plaques in comparison with those who die at younger 
age.266 On the other hand, remyelination is more efficient when it is closer (72 
hours) to the demyelination which is thought to be due to the easier 
recruitment of remyelination progenitors at the time of demyelination,267 as 
well as the role inflammation plays in efficient remyelination. 
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Individual variation across patients in the degree of remyelination and the 
frequency of shadow plaques is also described. 266 It is also noted that the 
degree of remyelination is influenced by the location of the lesion as the 
lesions located subcortically or in the deep white matter showed more 
complete remyelination than the periventricular plaques.266  
Mixed cortical lesions, as they extend into both the cortex and the WM hence 
the assumption they are lesions of the same age, showed signs of more 
extensive remyelination (6.8 folds) in the cortical than in the WM portion of 
the same lesion.268 Moreover, the oligodendrocytes observed in the WM 
portion of the lesion had a dystrophic appearance, characterized by fragmented 
processes and no myelin internodes.268 It was suggested that white matter 
lesions expressed higher amounts of molecular inhibitors, such as GFAP, 
CD44, hyaluronan, and versican, which potentially inhibits brain repair and 
remyelination.268 
Whether targeting demyelination and enhancing remyelination in early stages 
of the disease is beneficial in terms of preventing long term disability is 
controversial. In  C57BL/6 mice that were fed cuprizone, complete 
remyelination after demyelination was found to restore the loco motor function 
is short term, on the other hand, it did not prevent late onset functional 
deficits.269 It also showed that a low degree of axonal degeneration has 
continued even after complete remyelination which probably causes the long 
term disability in MS patients with increase disease duration. On the other 
hand they could not exclude the long term effect of the cuprizone on axonal 
loss.269 
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Remyelination varies across MS patients, partially because of the previously 
discussed lesion heterogeneity. The degree of remyelination varies between 0 
and 96%.266  Another explanation to the variation in the degree of 
remyelination is the chronicity of the disease course.  It is documented that 
remyelination is very prominent in very early stages of the disease and it can 
start within a few weeks from the acute MS lesion evolution.270 Repeated 
demyelination can contribute to persistent demyelination and failure of 
remyelination.263 
6.2.5 Monitoring remyelination using MTR: 
Deloire- Grassin et al in 2000 reported in a comparative study analysing MTR 
in vivo and histological data in a toxic demyelination model, and MTR 
changes in correlation with the histopathological modifications of myelin. 
Reduction of MTR values was correlated with tissue destruction mainly 
demyelination and axonal loss, on the other hand the differentiation between 
the two is difficult.271 Several longitudinal MRI studies on WM lesions showed 
that MTR values drop initially with the enhancement of the lesion and then 
most lesions MTR values recover over subsequent months with most of the 
recovery within the first two months, while a very small subset of patients do 
not show MTR recovery.272 This reflects the degree of repair in these lesions 
which could vary between lesions which reflects again the heterogeneity of the 
MS plaques. It was reported that there is an association between the WM 
lesion MTR signal inhomogeneity on baseline MTR sequences and the change 
in lesion MTR 2 months later which is likely to reflect the stages of 
demyelination and remyelination.273 
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5 year longitudinal study274 (with a 6 monthly scans) of 30 MS patients showed 
focal MTR decline significantly in the WM tissue in prelesional phase up to 2  
years prior to the appearance of lesions on T2 sequence. .167 This could be 
explained by either increase susceptibility of these regions to lesion formation 
or the early abnormality of lesion formation and break down of blood brain 
barrier, another explanation is that these regions were influenced by nearby 
lesions causing disruption of the axons going through these apparently normal 
regions.  
Due to the heterogeneous evolution of various MS plaques, Chen et al used 
voxel based analysis to quantify the change in MTR of individual voxels of 
MS lesions over a period of 6.5 months.275 They found that after initial lesion 
enhancement, MTR values were low and stable in the lesion centre, while 
increased at the lesion border..275 voxel based analysis of individual lesions 276 
showed that over a period of 39 months some of the initially enhancing voxels 
showed ongoing decrease in MTR , some showed ongoing increase in the 
MTR and some showed low values that remained stable which is suggestive 
that heterogeneous demyelination and remyelination in individual lesions can 
carry on for years which has implications on the disease progress and the 
patients prognosis.  
To our knowledge the variation in focal cortical lesions myelination status over 
time has not been studied so far among different MS phenotypes. We aimed to 
follow a group of patients of different disease subtypes over 12 month’s 
period, to investigate the difference among different phenotypes in the degree 
of change in mean MTR values in focal cortical and WM lesions. 
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6.3 Patients and Methods: 
The initial protocol applied in chapter 3 at baseline (time point 0), was 
repeated on a subgroup of patients cohort that was used in chapter 3 (4 CIS, 6 
RRMS, 8 PPMS and 5 SPMS) 12 months later (time point 1). Figure 6.3 
Mean patients age 41 ± 16 years for CIS group, 41 ± 7 years for RRMS, 50 ± 6 
years for PPMS and 52 ± 6 years for SPMS. Mean disease duration for CIS 
patients was 0.93 ± 0.34, RRMS was 4.04 ± 2.45, and PPMS was 10.16 ± 3, 
while SPMS was 12.12 ± 7.86 years.  None of those patients was on disease 
modifying treatment. There was no change in any of the patients EDSS 
between time point 0 and time point 1. 
For each participant (patient and control), the GM maps extracted from the 
PSIR images at time point 1 were linearly and non-linearly registered onto the 
GM maps of the PSIR image at time point 0 image. The symmetric 
diffeomorphic (SyN) registration approach,
277
 which is part of the Advanced 
Normalization Tools (ANTs) package, was used due to its excellent 
performance and its ability to handle large deformations (such as those 
required to register control scans with ordinarily sized ventricles to patient 
scans with enlarged ventricles). All registrations were manually quality 
controlled. The GM maps were registered instead of the PSIR or MTR images 
as that made for improved registration quality, both qualitatively (upon visual 
inspection) and quantitatively (in terms of similarity metric, when comparing 
the mutual information of the PSIR images directly registered with SyN 
against that of the PSIR images registered by applying the deformation field 
estimated from the registration of GM maps). The estimated non-linear 
deformation fields were then applied to the MTR scans.  
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Manual comparison of individual lesions histograms in a pilot sample: 
Before exploring the mean change of lesion MTR, I attempted to demonstrate 
if histogram analysis can detect shifts of MTR values in lesions. In this first 
step a random sample of 23 segmented cortical and 10 WM lesions, of 
different subtypes, was selected in patients of different disease courses. I 
compared the histograms of those lesions over two time points of acquisitions. 
Lesion segmentation and histogram comparison was done manually as a sort of 
initial assessment. Due to the time consuming nature of the analysis, this 
methodology could not be applied on all cortical and WM lesions examined in 
all patients, hence an automated methodology was adopted as following.  
Examples of the histograms are demonstrated in figure 6.4. 
 
Automated analysis of all cortical and WM lesions in all patients: 
All cortical and WM lesions were segmented on the MTR images. Each lesion 
ROI was replaced by a small ball of radius 3 positioned at the lesion's centre 
and removed from it all voxels which might be CSF (i.e. all those voxels 
whose MTR is less than CSF mean + 1 CSF std). This provided a more 
consistent way of examining the core of each lesion, reducing partial volume 
effects and avoids assessing the lesions borders that might exhibit some degree 
of remyelination. Then the average MTR values in each GM and WM lesions 
(mean MTR time point 0 and time point 1) were computed and normalised 
them using a variety of techniques: 
1- By the overall MTR GM average, with the percentage difference between 
time point 0 and time point 1   
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2- By the overall MTR GM & WM average  
3- By the overall modulated MTR GM value. The modulation takes into 
account the amount of MTR variability calculated across all patients for 
each region in the Harvard/Oxford GM atlas, with the more variable 
regions counting less towards the modulated average. 
Each of these normalisation techniques has their advantages and 
disadvantages. For instance, the modulated GM normalisation should 
be more precise for cortical lesions but perhaps too strict for mixed 
lesions whilst the GM & WM normalisation should be more suitable to 
mixed lesions subtype but less good for pure GM lesions. Hence, it 
seemed that the second method which involves normalising the cortical 
lesions mean MTR values by the overall MTR GM& WM average is 
the most appropriate method. 
In order to set a threshold to classify the change in mean MTR values 
of each lesion into increasing, decreasing or no change, we tried 3 
different methods: 
1) We used 1 standard deviation of the average change in individual 
lesions mean MTR values as a cut off with lesions showing changes 
in their mean MTR values higher than that figure considered as 
having increase in their mean MTR values, while similar values 
meant no change, and lesions showing change in their mean MTR 
values less than that number considered with reduced mean MTR 
values across two time points. (Results reported in Table 6.1)  
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2) Trying in this pilot study to detect any signal of change of MTR 
over a period of a year  we also used a low threshold of change ( r 
0.05) The results are reported  in Table 6.3 
3) The third threshold was also used in between the above 1and 2 And 
results reported in Table 6.2  
The first and third thresholding techniques have not detected many 
lesions showing change and probably reflect the non-changing 
nature of mostly chronic cortical lesions over one year. As this is an 
exploratory study, mainly trying to understand the changes in 
individual lesions mean MTR values in different MS subtypes, we 
also used the least conservative threshold allowing us more lesions 
to examine. I fully appreciate that the results using this threshold 
might not reflect real change of myelin tissue but wanted to explore 
if I can identify directions for future research. 
 
6.4 Results: 
 
Comparing cortical lesions histograms across two time points: 
In a random sample of 23 cortical lesions (18 subpial, and 5 mixed lesions), 
histograms for those lesions were compared between two time points. 
(Illustrated in figure 6.4) Seven of those lesions showed stable MTR values 
histograms across the two time points, while 6 lesions showed shift of MTR 
histograms to the left, and 10 lesions showed MTR histograms shift to the right 
across the two time points.  
Comparing white matter lesions histograms across two time points: 
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On comparing histograms of a subgroup of 10 white matter lesions, 2 out of 
the 10 lesions showed stable MTR histograms, 5 lesions histograms showed a 
shift to the right, while 3 showed shift to the left across time point 0 and time 
point 1. 
Comparison between individual CL mean MTR values across time points: 
(automated analysis) 
Cortical lesions 
The collective number of cortical lesions in different MS subtypes and the 
percentage of lesions showing stable, increase or reduction in their mean MTR 
values across two time points is illustrated in Table 6.5. 
A significant difference was found in the frequency of cortical lesions showing 
increase or decrease in their mean MTR values among MS subtypes across 
time points using Pearson Chi-Square. Patients with RRMS showed the highest 
frequency of cortical lesions with decrease in mean MTR values across two 
time points, while CIS patients showed the lowest frequency. SPMS and CIS 
patients had the highest percentage of cortical lesions showing increase in 
mean MTR values across two time points in comparison with other MS 
patients’ subtypes. (Figure 6.1) 
The average change in the mean MTR values of individual cortical lesions 
over 12 months in CIS patients was .053 ± 0.089, RRMS 0.001 ± 0.074, PPMS 
0.018 ± 0.127, while SPMS was 0.061 ± 0.105. 
As the average changes of mean MTR values of individual cortical lesions 
across different MS phenotypes are normally distributed, one way ANOVA 
was applied to test any significant difference among the groups. Significant 
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difference was observed among different MS phenotypes in the average 
change of mean MTR values of individual cortical lesions (p < 0.001, F= 
12.47). On running a post hoc and correction for multiple comparisons, 
significant difference was detected between SPMS and RRMS (p < 0.05; 95% 
confidence interval 0.32 – 0.09), as well as between SPMS and PPMS (p 
<0.05; confidence interval 0.017 – 0.068). There was no significant difference 
between SPMS and CIS patients (p = 0.9; 95% confidence interval 0.05 - 
0.07).  
There was no significant difference among lesions subtypes in the degree of 
change in mean MTR values across two time points on using Pearson Chi 
Square (p = 0.07). Table 6.6 
The average change of individual cortical lesions mean MTR values over 12 
months’ time was the highest for mixed lesions (mean 0.04 ± 0.109), followed 
by subpial lesions ( mean 0.034 ± 0.104) while intracortical lesions (mean 
0.025 ± 0.112) showed the smallest degree of changes over the 12 months 
period.  
I could not detect any significant difference between cortical lesions subtypes 
in terms of the degree of change of mean MTR values over 12 months period 
on using one way ANOVA. (p=0.413, F= 0.886) 
On comparing the degree of change in individual cortical lesions mean MTR 
values between male and female subjects, it was observed that males show 
significantly (p= 0.001) higher average change in their cortical lesions mean 
MTR values (mean 0.056 ± 0.124) in comparison with female subjects (mean 
0.022 ± 0.097) on using Mann – Whitney U test. 
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There was no significant correlation between the changes in individual cortical 
lesions mean MTR values across time points and the disease duration, or age 
(rho = - 0.1, p = 0.08 and rho = -0.03, p =0.52 respectively) on using spearman 
correlation coefficient.  
White matter lesions 
There was a significant difference among the groups in the frequency of 
lesions showing increase or decrease in their mean MTR values using Pearson 
Chi – Square test (p < 0.01). Table 6.7 
The average changes in the mean MTR values in individual WM lesions was 
the highest in RRMS patients (mean 0.134 ± 0.143), followed by CIS (mean 
0.050 ± 0.131), and SPMS (mean 0.032 ± 0.193),  while PPMS patients 
showed the lowest variation in mean MTR values of individual WML across 
time points (mean 0.001 ± 0.242).  
As the changes in mean MTR values in individual WM lesions across the two 
time points was normally distributed, one way ANOVA was used to compare 
the distributions of these values among patients of different MS phenotypes. 
There was a significant difference in individual WML mean MTR values 
average change across time points. (p < 0.001, F = 10.4). On post hoc 
comparison among different phenotypes, significant difference in individual 
WML average change in mean MTR values between RRMS and PPMS 
patients. (p < 0.05, 95% confidence interval 0.069 and 0.202), as well as 
between RRMS and SPMS (p < 0.05, 95% confidence interval 0.039 and 
0.164). 
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The average change in mean MTR values of individual WML across the two 
time points was significantly higher in female (mean 0.098 ± 0.171) than male 
subjects (mean 0.012 ± 0.218) using Mann Whitney U test (p < 0.05).  
Using spearman’s correlation coefficient to assess the association between the 
changes of mean MTR values of individual WML across two time points with 
the patients age and disease duration, a significant negative correlation was 
found with patients age (rho = -0.2, p < 0.01), while no significant association 
was detected with disease duration (rho = - 0.1, p = 0.08).  
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(Figure 6.1) The average variation in mean MTR values in all cortical 
lesions across time points in different disease phenotypes  
(Figure 6.2) The average variation in mean MTR values in Mixed, 
Leukocortical, and Subpial lesions across time points  
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(Table 6.1) The change in cortical lesions mean MTR 
values in MS groups (Threshold 1 SDV of mean changes) 
 
 
MTR change 
Total decrease No change Increase 
MStype CIS 0 22 2 24 
RRMS 0 151 1 152 
PPMS 4 178 11 193 
SPMS 0 257 20 277 
Total 4 608 34 646 
The change in cortical lesions mean MTR values in MS groups across two 
time points using 1SDV of the mean changes in lesions MTR values between 
visits as a threshold to classify lesions. 
 
 
 
 
 
(Table 6.2) The change in cortical lesions mean MTR 
values in MS groups (Threshold 0.07) 
 
 
MTR change 
Total Decrease No change Increase 
MStype CIS 1 20 3 24 
RRMS 6 140 6 152 
PPMS 18 147 28 193 
SPMS 7 213 57 277 
Total 32 520 94 646 
The change in cortical lesions mean MTR values in MS groups across two 
time points using 0.07 as a threshold to classify the mean changes in individual 
lesions MTR values between visits. 
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(Table 6.3) The change in cortical lesions mean MTR values in MS groups 
(Threshold 0.05)  
 
 
 
MTR change 
Total Decrease 
No 
change Increase 
MStype CIS 1 15 8 24 
RRMS 15 129 8 152 
PPMS 32 116 45 193 
SPMS 18 166 93 277 
Total 
66 426 154 646 
The change in cortical lesions mean MTR values in MS groups across two 
time points using 0.05 as a threshold  to classify the mean changes in 
individual lesions MTR values between visits. 
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(Table) 6.4 The number of lesions and the change in mean MTR across the 
two time points in different patients 
Patient ID Disease subtype No of cortical 
lesions with 
mean MTR 
increase 
No of cortical 
lesions with no 
change in mean 
MTR  
No of cortical 
lesions with 
mean MTR 
decrease 
3 CIS 0 4 0 
4 CIS 2 1 0 
20 CIS 4 4 0 
26 CIS 2 6 1 
5 RRMS 1 11 1 
8 RRMS 1 10 1 
10 RRMS 1 8 6 
37 RRMS 4 30 1 
41 RRMS 0 35 1 
42 RRMS 2 35 3 
6 PPMS 2 10 5 
11 PPMS 2 19 6 
15 PPMS 3 16 0 
18 PPMS 13 14 12  
23 PPMS 2 0 0 
24 PPMS 0 5 4 
28 PPMS 0 4 0 
40 PPMS 23 19 5 
9 SPMS 38 32 1 
14 SPMS 21 35 4 
25 SPMS 23 48 3 
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Patient ID Disease subtype No of cortical 
lesions with 
mean MTR 
increase 
No of cortical 
lesions with no 
change in mean 
MTR  
No of cortical 
lesions with 
mean MTR 
decrease 
 
 
31 SPMS 7 31 6 
45 SPMS 4 19 4 
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(Table 6.5) Cortical lesions change in different MS phenotypes:  
Disease Phenotype 
(collective number 
of lesions in all 
patients) 
% of CL showing 
increase in mean 
MTR values 
% of CL showing 
reduction in mean 
MTR values 
% of CL showing no 
change in mean 
MTR values  
CIS (24) 33 4  63  
RRMS (152) 5  10  85 
PPMS (193) 23  16  61  
SPMS (277) 33 6  61  
The table illustrates the number of cortical lesions in different MS phenotypes 
and the percentage of lesions changing or showing stable mean MTR values 
over 12 months’ time. 
 
 
(Table 6.6) Cortical lesions subtypes change in different lesion subtypes 
Cortical lesion 
subtype 
% of lesions 
showing increase in 
mean MTR values 
% of lesions 
showing reduction 
in mean MTR values 
% of lesions 
showing stable 
mean MTR values 
Mixed lesion 25.4  10.2 64.4 
Subpial lesion 27.2  11.8  61  
Intracortical lesion 18  8.2  73.8 
The table illustrates the percentage of different cortical lesion subtypes 
showing stable, increase, or reduction in their mean MTR values over 12 
months’ time 
 
  
 
 
192 
 
 
(Table 6.7) The percentage of white matter lesions changing over time 
Different MS 
phenotypes 
(collective number 
of WML) 
% of WML showing 
increase in their 
mean MTR values 
% of WML showing 
reduction in their 
mean MTR values 
% of WML showing 
no change in their 
mean MTR values 
CIS (31) 32  13 55 
RRMS (110) 53  3  44 
PPMS (137) 33  27 40  
SPMS (189) 34 25 41 
WML = White matter lesion. 
The table illustrates the collective number of white matter lesions in different 
disease subtypes and the percentage of lesions showing stable, increase, or 
reduction of their mean MTR values over 12 months’ time.  
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(Figure 6.3) Subpial lesions on saturated MT images (MT sat) at time 
point 0 (left) and time point 1 (right)  
 
 
 
The figure illustrates two cortical lesions in two consecutive scans on MTsat 
sequence. At the baseline visit (left) the lesion has a lower mean MTR (more 
demyelination), while at the follow up scan 12 months later (right), both 
lesions seem less bright, reflecting an increase in their mean MTR 
(remyelination with an element of resolved oedema).   
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(Figure 6.4) Three cortical lesions with one having stable MTR voxels 
(Top), one increasing MTR (middle) and one decreasing MTR (bottom) 
across time point 0 (Blue) and time point 1 (Orange) 
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(Figure 6.5) Evolution of MTR values overtime 
 
The figure illustrates the lesion at time point 0 (left panel) and at time point 
1(right panel), showing a reduction in mean MTR value. 
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(Figure 6.6) 
Evolution of MTR values overtime  
 
The figure illustrates the change in a lesion’s mean MTR value over time. A 
cortical lesion is shown at baseline (left panel) and at a follow up scan 12 
months later (right panel), with increased mean MTR value, reflecting partial 
recovery of the lesion.  
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6.5 Discussion: 
Studies in animal models showed that primary demyelination of axons 
following traumatic injury usually undergo complete remyelination, and long 
lasting demyelination of axons is unusual.278 However, demyelination induced 
by immune mediated mechanism such as MS is associated with an 
unfavourable environment for oligodendrocytes which makes it difficult for 
remyelination in some cases to be complete.  
Various imaging sequences have been used to examine the degree of 
demyelination.279 In this exploratory study, we examined the variation in 
individual CL and WML mean MTR values over a period of a year among 
different MS subtypes, the frequency of those changes, their correlation with 
age, gender, and disease duration. Despite overlap of whole brain histograms 
of both time points as well as normalisation of lesions MTR values, a higher 
frequency of lesions in all patients’ subtypes seemed to show increase in their 
mean MTR values over the study period irrespective of the threshold used.  
Changes of lesions mean MTR values across MS subtypes 
The heterogeneity of oligodendrocyte destruction and preservation pattern 
influences the degree of remyelination in different MS disease subtypes.280 
Remyelination is frequent in all stages of the disease, although it is usually 
very limited in chronic lesions. Surprisingly, in this study the frequency of 
cortical lesions showing increase or reduction in their mean MTR values was 
quite similar between CIS and SPMS patients. The high degree of disability 
known in SPMS patients for which CL are found to have substantial 
contribution, could be explained by remyelinated lesions, with associated 
depletion of OPCs around the demyelinated plaques, becoming more and more 
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of a target to demyelination
263
 attacks rendering not only the degree, but the 
quality of remyelination in chronic MS lesions less and less conceivable. This 
could partially explain the smaller number of CL detectable in CIS patients 
with more efficient remyelination early on in the disease course in comparison 
with SPMS patients.  
In this study most CL and WML mean MTR values over the 12 months’ period 
remained unchanged. CIS and SPMS patients showed the highest frequency of 
CL exhibiting increase in their mean MTR values over the study period in 
comparison with the other groups, While RRMS patients had the highest 
frequency of WML showing increase in their mean MTR values across the 
study period in comparison with other disease subtypes. A histopathological 
study mainly on progressive MS patients’ samples, showed cortical 
remyelination more extensive than WM remyelination.90  
The frequency of WML showing reduction in their mean MTR values over the 
study period was higher than CL across all patients groups but was more 
pronounced in PPMS and SPMS patients. Despite the high impact of cortical 
lesions on patients disability, our findings emphasises the significant 
contribution of WML to disability progression in those disease 
subtypes.Disability progression in SPMS patients despite the high frequency of 
CL exhibiting increase in their mean MTR values, could be explained by the 
increase frequency ofWML experiencing reduction in their mean MTR values 
and probably disrupting long tract axons. 
In this study, the average change in cortical lesions mean MTR values was 
higher in CL in comparison with WML in SPMS patients, which is consistent 
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with pathology data suggesting that remyelination in cortical MS lesions is 
more extensive than in the WM lesions in chronic progressive MS brains.90  
Reduced degrees of remyelination seemed to have different mechanisms 
depending on the stage of the disease. In late stages of the disease it is mainly 
due to poor recruitment of oligodendrocytes, while in earlier stages of the 
disease where more oligodendrocytes are available, impaired maturation seem 
to be the main problem causing inefficient remyelination.254 Failure in 
recruitment phase could be due to the presence of antibodies against OPCs 281 
or repeated demyelination contributing to cells exhaustion in the affected 
region.270 Also the genetic and environmental variation between patients such 
as epigenetic changes in oligodendrocytes, growth factors, expression of 
myelin inhibitors or abnormal composition of the chronically demyelinated 
axons remain to be significant factors influencing the degree of remyelination 
is a possibility needs further examination.282,283  
Remyelination capacity in MS patients is variable not only between groups, 
but also within individual patients’ brain depending on several parameters. The 
localization of lesions influences the degree of remyelination. Pathology 
studies suggested that higher degree of remyelination was observed as lesions 
localize closer to the cortex.
140
 In this study, excluding RRMS patients, the 
average change in mean MTR values was higher in CL of MS subtypes in 
comparisons with WML. The frequency of lesions showing increase or 
reduction in mean MTR values was similar across mixed, intracortical, and 
subpial lesion subtypes.   
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In our SPMS patients, the average change in CL mean MTR values was higher 
than that of WML. Previous studies suggest that environment of chronically 
demyelinated cerebral cortex is more conductive to oligodendrogenesis and 
remyelination than the environment of chronically demyelinated white 
matter.268 Pathology data suggests that the number of oligodendrocyte 
progenitor cells in CL is not less than that in nonlesion cortex, hence their 
ability to produce myelinating oligodendrocyte might contribute to the greater 
repair capacity of CL when compared with chronic WML.268 
Previous pathology studies detected higher degree of WML remyelination and 
smaller degree of active demyelination in PPMS than in SPMS patients, 
although the remyelination was the significant effect even after correction for 
the effect of the active demyelination.149 In this exploratory study, PPMS and 
SPMS patients had similar frequency of WML showing increase, or reduction 
in their mean MTR values across two time points. This could be due to the 
short interval between scans (12 months apart) with most lesions remaining 
unchanged, hence the difficulty of comparing our results with gold standard 
pathology. 
Association of lesions mean MTR changes with disease duration 
In this study, no association was found between the degree of change in 
individual lesions mean MTR values and disease duration, which could be 
partially explained by the short disease duration of our patients especially of 
progressive MS patients in comparison with samples included in pathology 
studies.
90
 Histological analysis do not allow for longitudinal studies, and the 
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lack of robust imaging techniques measuring remyelination makes it difficult 
to determine the exact frequency and stages of remyelination in vivo. 
Demyelination is known to be more abundant in progressive stages of the 
disease; however the correlation with disease duration is rather variable across 
different studies. Surprisingly in our study, the frequency of CL exhibiting 
reduction in their mean MTR values across time point was similar in CIS and 
SPMS groups. However, SPMS patients showed high frequency of WML with 
mean MTR reduction in comparison with CIS and RRMS patients. No 
association was detected between disease duration and either CL or WML 
mean MTR values changes. This is similar to a previous pathology study 
suggesting variation in the degree of remyelination between early and 
progressive MS subtypes with no obvious correlation with disease duration.
140
 
The lack of correlation with disease duration in our study could be due to the 
short disease duration of our subjects in comparison with other studies. 
Another possibility is the different techniques used assessing remyelination 
with pathology being the gold standard, in comparison with our study using 
MTR at 7T with the disadvantage of inhomogeneity probably affecting some 
of our measures.  
We found that CL exhibiting increase in their mean MTR values across time 
points was prominent in all patients groups, with the lowest degree in PPMS 
patients. Patients with SPMS particularly had shorter disease duration, in 
comparison with other studies. In pathology studies, shadow plaques were 
more frequent in RRMS patients than in SPMS patients.266 Remyelination in 
cortical lesions was evident in more than 95% of patients with long standing 
MS.90 Another pathology study reported that remyelination is extensive in a 
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subset of SPMS patients with longer disease duration but it was clear that this 
was in a subset of patients while the rest showed low remyelinating capacity.266 
My results should be interpreted with caution due to the small sample number 
included. 
Association of lesions mean MTR changes with age  
Remyelination is regulated by multiple factors which constitute a very 
complex signalling network that has to be very tightly regulated in order to 
create an optimum environment for a successful remyelination. Views 
regarding age as a factor that could influence remyelination are conflicting. In 
this study, there was no association between age and the degree of change of 
mean MTR values in either cortical or white matter lesions. Age associated 
reduction in remyelination was reported with impairment of OPCs recruitment 
and differentiation into remyelinating oligodendrocytes in older animal.284 The 
rate of colonisation of OPCs in depleted areas in animal models was found to 
show steady decline in their rate of depleted tissue colonisation by OPCs with 
age.258 It was suggested that not only the age related changes in biological 
characters of these OPCs but also the age related variation in the environment 
of the demyelinated plaques influencing the rate of the OPCs migration, 
proliferation or differentiation into myelin sheath forming oligodendrocytes. 258 
Macrophages are a significant source of growth factors 285 and important for 
clearance of myelin in the lesion, hence are very important for remyelination 
and it is noted that they are deficient in aged tissue due to observed delayed 
inflammatory response.286 Pathology studies, showed active remyelination to 
be present in patients of all ages with no correlation between the extent of 
remyelinated lesions and age at death.268 Shields et al suggested that age 
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influences the rate of remyelination rather than the degree of remyelination.264 
This was found on following the animals at 4 and 9 weeks. At 4 weeks young 
rats showed higher degree of remyelination than young rats while at 9 weeks, 
there was no difference in the total extent of remyelination between young and 
old animals. 
Association of lesions mean MTR changes with gender  
In this study, the average change in WML mean MTR values was significantly 
higher in females than males; a similar finding was suggested by pathology 
study on animal models. Similarly Goldscmidt et al 140 examined biopsies from 
MS brains of different disease duration. They found that WML in women brains 
showed more extensive yet not significant remyelination capacity than WML 
in male brains. However this was not replicated in CL, as the average change 
was found to be higher in males than in females. Studies support the view of 
sex dependent variation in the degree of remyelination. More oligodendrocyte 
progenitors were observed in cultures of female neonatal rodents’ brains than 
males. Treatment with 17β- estradiol delayed the exit of oligodendrocyte 
progenitor cells from the cell cycle, while progesterone was found to enhance 
cellular branching, which suggests that sex hormones probably contribute to 
gender specific difference in repair.287 Another study288 suggested that the 
variation in remyelination capacity between male and female animal models is 
only apparent in old rats, although, they could not demonstrate a role for sex 
steroid hormones in influencing remyelination in either young or old animals.  
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Conclusion: 
The percentage of CL exhibiting increase in their mean MTR values over 12 
months period was similar in CIS and SPMS patients possibly suggesting the 
high frequency of remyelination at least in a subset of SPMS patient. The 
average increase in CL mean MTR values was the lowest in PPMS patients. 
The frequency of WML showing reduction in their mean MTR values over the 
study period was higher than CL across all patients groups but was more 
pronounced in PPMS and SPMS patients suggesting the significant 
contribution of WML on patient’s disability. 
It is significant to note that we cannot imply causality from this study. 
Although causality could be interpreted on occasion from human longitudinal 
studies, it is very difficult to control for various parameters. Animal studies 
would be required to help provide insights into the causal relationship of the 
mechanisms of damage in brain tissue in MS. 
Limitations of this work: 
There are a number of caveats to MT imaging. First, the effect of B1 
inhomogeneities present at high field can reduce sensitivity (increase variance) 
in MT measures, although these are reduced to some extent in MTR maps due 
to the way MTR is calculated and corrected for B1 effects
137,178 Second, the 
MTR maps are sensitive to movement artefacts, which will be exacerbated by 
acquiring two MTR images separately. Despite registration of those images, 
intra-scan movement during the 3D acquisition could degrade the quality of 
the final MTR maps. Due to the reduced myelin content in the outermost layers 
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of the cortex, it could be difficult to use MTR alone to classify CL especially 
for the subpial lesions, but the raw MT images especially the MTsat provide 
clearer contrast between the cortex and the CSF, and hence easier 
classification. This is an exploratory study and we are currently following our 
patients longitudinally, which will help to address some of the concerns raised.    
In this study we used the variance in mean MTR values across two time points 
as a cut off to classify the degree of change in lesions mean MTR values, 94% 
of lesions did not show any change in their mean MTR values across the two 
time points. This is probably due to the short interval between scans, and we 
expect that with following those patients for longer period of time, more 
detectable changes would be observed. This is an exploratory study hence the 
reason we used a smaller cut off point rather than the standard deviation of the 
mean difference over time to explore the different degrees of change in 
individual lesions mean MTR values among MS groups. 
There is great degree of variation in the MTR values due to multiple factors. 
The variation in relationship between different tissue types and MTR, and the 
difficulty in predicting the behaviour of individual tissues in different MR 
system provides another challenge. As previously mentioned the low MTR can 
be a result of reduction of the capacity of the macromolecules to exchange 
magnetization with the surrounding water molecules or due to the amount of 
these macromolecules.  Also the use of off-resonance saturation pulse, can 
cause unwanted direct saturation effects on the liquid pool.289   
Studying the degree of remyelination in MS lesions in vivo is challenging, 
mainly due to the lack of robust imaging techniques. Another aspect is that 
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remyelination has proven to be heterogeneous even in lesions within the same 
patients brain.
140
   
Exact interpretation of these results is quite difficult, as the change in focal 
lesions mean MTR values is multifactorial. It reflects partially demyelination 
involving some of lesions voxels while other voxels may show remyelination 
or even failure of remyelination with static MTR values.   Longitudinal voxel 
based studies for that number of lesions in such a number of patients does not 
seem practically plausible in terms of resources availability due to the lack of 
availability of automated method as yet. Also the changes in the MTR values 
are specific but not restricted to myelin pathology, as the reduction in MTR 
could be not only correlated to the myelin loss in brain tissue but to a degree 
with associated axonal loss as well, and the discrimination between both is 
often unachievable by imaging techniques. However when Schmierer et al 62 
regressed MTR on axon count and myelin transmittance at the same time, the 
association between MTR and axonal count disappeared. 
The calculation of MTR for individual voxels or for a region of interest 
depends on the accuracy of the registration of the saturated and the unsaturated 
images. A shift of 1mm or less due to patient motion could affect the 
calculated values. Also the partial volume effect between white and grey 
matter tissue or cortical tissue and CSF can affect the MTR values. 
 I did not assess exactly the mean MTR values in lesions but instead for 
practicality lesions were replaced with radius 3 small ball expanding from the 
centre of the lesions, hence the possibility that some of these voxels could have 
been contaminated by normal appearing brain tissue. 
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Finally, we examined a small sample of patients, 10-11 subjects of each 
phenotype. Future larger studies in attempt to replicate this project’s findings 
will be necessary. 
I did not assess the influence of topographical distribution of focal lesions on 
the variation in mean MTR values across time points. I measured mainly 
cortical volume although cortical thickness is a more robust measure of 
atrophy but its applicability could be difficult as it mainly requires the use of 
FreeSurfer, which is not adapted for use on 7T scans. Similarly. I did not 
obtain any fMRI data, which would have been very helpful to verify the 
association between various cognitive functions and cortical pathology. I did 
not take into consideration white matter volume or thalamic volume either. 
There were no spinal cord measures included into this study.  
For cognitive assessment I used BICAMs, which does not take into 
consideration executive function or working memory tests.  
Assessing the degree of demyelination and remyelination, and finding a 
feasible way to enable its application into clinical practice could assist 
determining patient treatment options and monitor response. 
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Chapter 7 
General Discussion& Conclusion 
Grey matter pathology in general and cortical lesions in particular have proven 
to be a very significant part of MS pathology. Cortical lesions have always 
been difficult to examine in vivo, but over the past few years various imaging 
sequences have emerged improving cortical lesions detection, hence expanding 
the horizon to explore the contribution of cortical lesions to physical and 
cognitive disability in MS patients. Various imaging studies take into account 
the cortical lesion load and its association with disability without taking into 
account the degree of damage in these lesions and its correlation with the 
different clinical parameters in those patients. 
In this project we had several objectives: 
We initially aimed to find a sequence with pathological specificity that is 
sensitive to depicting cortical lesions within a clinically acceptable acquisition 
time.  
Magnetization transfer imaging has a good potential, through its semi 
quantitative properties which gives it superiority over conventional MR 
sequences, which lack pathological specificity in distinguishing different 
disease characteristics. Pathology studies showed the reduction of MTR values 
to correlate with tissue destruction mainly demyelination and axonal loss. We 
wanted to use one sequence type that would enable us to detect cortical lesions 
and provide us with information regarding lesional microscopical 
characteristics. 
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We initially explored the ability of MTR scans at 7T to detect cortical lesions. 
This sequence has the advantage of being a quantitative method, hence the 
capability to detect the degree of damage in tissue reflected in mean MTR 
values.  
We examined 18 MS patients and 9 healthy controls using 7T MTR, 7T 
MPRAGE, and 7T T2*. On a subset (8 subjects) of the same patient cohort, 3T 
3D DIR was acquired on the same session. We compared the ability of each of 
those sequences to detect cortical lesions.  
7T MTR appeared to improve cortical lesion detection in comparison with 
other 7T sequences (MPRAGE and T2*) and 3T 3D DIR. The abnormalities 
that were found on MTR corresponded to cortical lesions on the other 
sequences. Ultra-high field MRI increases the signal to noise ratio, hence 
enhance the detection of GM lesions. In our study, the 7T T2* rate of cortical 
lesion detection was particularly low in comparison with previous studies, but 
this partly because we used lower in-plane resolution as a trade-off for larger 
coverage of the brain in shorter acquisition time.  
Retrospective analysis in our study showed more lesions that were not detected 
in prospective study. In the retrospective study, we examined all sequences 
simultaneously which provided complementary information about cortical 
lesions using different sequences. We know from pathology and imaging 
studies that different lesions are sensitive to different imaging modalities.  
We found that MTR was a useful sequence in depicting cortical lesions and 
can be acquired within clinically acceptable time. MTR is a semiquantitative 
myelin sequence that is sensitive to depicting cortical lesions of all subtypes in 
 
 
210 
 
comparison with the other examined sequences. MTR was superior to 
conventional imaging sequences due to its pathological specificity. MTR 
values correlate mainly to myelin content in brain tissue and to a lesser degree 
with axonal loss. 
As MTR is a considered primarily a myelin sequence but with an element of 
axonal loss detection, we wanted to compare the degree of demyelination, and 
potentially axonal loss
290
 in cortical lesions in different disease phenotypes, 
and assess the correlation between the degree of damage and physical 
disability. 
I used a larger sample of patient representatives of all MS phenotypes (11 CIS, 
11 RRMS, 10 PPMS, and 10 SPMS). We acquired 7T MTR, and 7T PSIR on 
each patient. I compared cortical lesions counts, volume, and lesions mean 
MTR values amongst the groups. Cortical lesion count and volume were 
higher in SPMS patients than in other MS phenotypes. This was mainly due to 
the high number of mixed lesion subtypes. Subpial lesion volume was larger in 
the progressive forms of the disease, although the difference was to a smaller 
extent in comparison with mixed lesions. The lower number of lesions in early 
stages of the disease is probably due to the higher capacity to repair in early 
MS brains, with reduced efficiency of repair later on in the disease. 
Moreover the mean MTR values of individual cortical lesions were lower in 
SPMS patients in comparison with CIS and RRMS patients. On the other hand, 
the difference was not significant between PPMS and RRMS patients.  
Individual lesion damage in our study appeared to be clinically significant as 
individual cortical lesions mean MTR values was independently associated 
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with the degree of disability in patients. We could not replicate the same 
finding for white matter lesions mean MTR values. This suggests the important 
contribution of cortical lesions over white matter lesions in the degree of 
patients physical disability. Out of all cortical lesions subtypes, mixed lesions 
mean MTR values were associated with the degree of physical disability, 
probably because they are the most abundant lesion subtype. Another 
explanation is the location of mixed lesions that could be disrupting long tracts 
before they end in the cortex. 
Subpial lesions had the lowest mean MTR values in comparison with 
intracortical and mixed lesion subtypes. This could be due to the lower myelin 
content in the outermost layers of the cortex, or less likely due to 
contamination of cortical lesions segmentation with nearby CSF voxels. 
The presence of cortical lesions is specific to MS, significant in the diagnosis 
of the disease, and very helpful to differentiate it from MS mimics. The 
variation in the mean MTR values of individual cortical lesions among 
different MS phenotypes potentially provides additional tool to help 
differentiate these subgroups, which could potentially help management plans.   
Physical disability correlated with cortical lesion load as well as with mean 
MTR values of individual cortical lesions, but not white matter lesions. The 
main significant correlation was with mixed lesions volume and mean MTR 
values. The location of mixed lesions to the cortex, hence the cell soma of long 
projecting axons, such as the corticospinal neurons, may be a contributing 
factor to patients degree of disability over white matter lesions. Such a finding 
is very significant in developing future treatment options for MS. Monitoring 
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the response to these therapeutic options is very significant especially in 
clinical trials. In our correlations we did not take into consideration the spatial 
distribution of cortical lesions, hence we cannot account for the functional 
localization of these lesions.  
It was clear in our study that the influence of cortical lesions load and mean 
MTR values is more prominent than the influence of white matter lesions. The 
difference of mean MTR values in individual cortical and white matter lesions 
among different MS phenotypes suggests the heterogeneity in the pathogenesis 
of different types of the disease. 
After examining the contribution of individual cortical lesion mean MTR 
values to the degree of physical disability, we similarly wanted to explore the 
association between the degree of damage in cortical lesions as reflected by 
their mean MTR values and the degree of cognitive impairment. 
I used the same patient cohort that was used for physical disability cortical 
lesion mean MTR values correlations. That group included 11 CIS, 11 RRMS, 
10 PPMS, and 10 SPMS patients. I used BICAMS to assess patient’s cognitive 
performance. It is mainly composed of 3 neuropsychometric subtests SDMT, 
CVLL, and BVMT tests. Those tests have been modified to be practically 
appealing for clinical use with no impact on the sensitivity or specificity to 
detect cognitive impairment. 
As others reported
206
, we found that SDMT and BVMT-R were the most 
sensitive tests for cognitive performance in different MS phenotypes. 
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In this study, we found a significant correlation between lower cognitive scores 
and higher cortical lesion volume. I also found a significant association 
between different cognitive scores and cortical lesions and white matter lesions 
mean MTR values. This could be explained by cortical-subcortical tracts being 
very significant for good cognitive performance.  
The correlation between cognitive scores and cortical lesions mean MTR 
values rather than their volume is an emphasis of the significance of the degree 
of damage in individual lesions over the mere lesion size. This also supports 
the notion that the state of tissue microscopic structure is more significant 
representation to the patient’s clinical state than the macroscopic changes. 
I found that cortical grey matter fraction was the lowest in SPMS patients in 
comparison with the other phenotypes, although the difference did not reach 
statistical significance. In this study cortical grey matter fraction did not 
correlate with physical disability represented by EDSS but it correlated with 
cognitive decline mainly BVMT scores. Previous reports
291
 showed that 
regional cortical thinning in primary motor cortex correlated significantly with 
pyramidal FSS scores. However, in our study we did not attempt to correlate 
topographical distribution of cortical volume loss to the degree of disability 
due to technical reasons. Cortical thickness is probably a more accurate 
measure than cortical volume but far more challenging technique to implement 
especially on high field scanning.  
I found that SPMS patients had the smallest cortical grey matter fraction. 
Unlike other reports 
83
 there was no correlation between the cortical grey 
matter fraction and cortical lesion load. This could be partially due to better 
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quality of cortical lesion segmentation with the use of high resolution scans in 
comparison with lower resolutions used by other studies. Reassuringly, cortical 
grey matter fraction correlated with cortical lesions mean MTR values which 
supports our previous suggestion of the significance of the degree of damage in 
lesions over the volume and its contribution to various clinical and radiological 
parameters. This correlation could be explained by damage in lesions causing 
retrograde axonal loss hence causing higher degree of atrophy.  
With the consistent finding of the contribution of the degree of damage in 
lesions over lesions volume to various clinical parameters, it seemed crucial to 
examine normally appearing tissue and explore the variation in the degree of 
damage in normal appearing tissue among different MS groups and its 
correlation to different clinical parameters. 
The degree of damage in NAWM and NAGM indicated by their mean MTR 
values was the severest in SPMS patients. The differences in NAWM mean 
MTR values not NAGM mean MTR values was statistically significant. The 
less significant difference between patients phenotypes in their NAGM is 
probably due to the high resolution scans allowing cortical lesions 
segmentation in probably more accurate way than other studies using lower 
resolution scans with less chance of NAGM contamination by undetected 
cortical lesions.  
Cognitive performance correlated more with NAWM mean MTR values than 
with white matter lesions mean MTR values. This suggests the importance of 
white matter tracts integrity for higher cognitive functions. This illustrates the 
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significance of looking beyond lesion load and tissue atrophy to determine 
patient’s treatment or monitor response and treatment escalation. 
The pathogenesis of diffuse injury in the NAWM is controversial. Diffuse 
axonopathy independently form the focal demyelinating lesions, which could 
explain diffuse spread changes in NAWM of PPMS patients. Alternatively it 
could be secondary to retrograde Wallerian degeneration of the axons 
transecting demyelinated lesions which is supported by pathology studies 
showing correlation of WML load with the axonal density and number of 
axons crossing the corpus callosum in the corresponding lesions. 
To further understand the pathology of normal appearing tissue and the role 
cortical and white matter lesions play, we examined in the same cohort of 
patients the influence of cortical and white matter lesions on nearby normal 
appearing tissue. We found mean MTR values to be lower in the normal 
appearing tissue voxels for up to 10 mm around nearby white matter lesions 
while cortical lesions influence on nearby tissue was limited to a shorter 
distance of 3 mm. This suggests that lesions especially white matter lesions are 
significant in the pathogenesis of diffuse tissue injury, although the role of 
diffuse axonopathy which independent from the focal demyelinating changes 
could be equally significant. 
Both mechanisms probably coexist in each MS phenotype with variable degree 
depending on the MS type, with the latter probably more prominent in PPMS 
patients while in other MS phenotypes retrograde wallerian degeneration of the 
axons transecting demyelinated lesions could be the main contributing factor to 
the diffuse normal appearing tissue injury. The degree of axonal loss in the 
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corpus callosum was previously found to correlate with the lesion load of the 
corresponding projection areas which suggested mutual local and collateral 
effects on the changes in NAWM. 
Several other factors could influence mean MTR values in the NAWM, such 
as the voxel location in relation to the ventricular CSF interface.  
Unlike other studies, we could not find significant difference between the 
degree of damage in NAGM as indicated by their mean MTR values among 
different MS phenotypes, which could be due to the high resolution of our 
scans; and the ability to segment cortical lesions which probably went 
undetected in previous studies using lower resolution conventional MRI scans. 
Understanding normal appearing tissue integrity, its clinical correlations, the 
pathogenesis of microscopic abnormalities and its relation to white matter and 
cortical lesions is crucial for future better understanding of MS pathology. 
Remyelination in MS is very significant for protecting axonal integrity, restore 
nerve conduction, and prevent long term physical disability.  
We found a variation in the degree of damage in focal lesions among different 
MS phenotypes, which could reflect the variation in the rate of demyelination 
and remyelination in lesions in various MS phenotypes. Pathological analysis 
of MS lesions showed variation in the patterns of demyelination in MS patients 
subtypes and at different stages of the disease. Moreover, studies showed that 
cortical lesions generally showed more extensive remyelination in comparison 
with white matter lesions even on case by case basis. 
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We examined the variation in myelin status in MS patients of different MS 
subtypes longitudinally over a 12-month period. We found that the pattern of 
demyelination and remyelination is different in different MS phenotypes, 
which could be due to the heterogeneity of oligodendrocyte destruction and 
preservation pattern.  
Studies 
262
 showed that remyelination is usually limited in chronic stages of the 
disease, in contrast with our study we found that frequency of cortical lesions 
showing increase or reduction in their mean MTR values was quite similar 
between CIS and SPMS patients. It is well reported 
280
 that the high degree of 
remyelination in early stages of the disease, which we found in this cohort, but 
in terms of the findings in SPMS patients, only a few pathology studies 
292
 
showed a high degree of remyelination in cortical lesions in a subset of SPMS 
patients.  
The high degree of disability in our SPMS patients who had similar degree of 
remyelination as our CIS patients could be explained by the remyelinated 
lesions in SPMS patients becoming increasingly the target of demyelination 
attacks rendering not only the degree, but also the quality of remyelination in 
chronic MS lesions gradually poorer. Pathology studies
262
suggest that in 
chronic stages of the disease, remyelination is generally sparse and mostly 
involving the edges of the lesions. Moreover, early pathology studies
263
 
suggest that recurrence of demyelination in shadow plaques contributes to 
future failure of remyelination in that region. 
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Most lesions in the longitudinal study did not show any change in their mean 
MTR values, which is expected with the short time frame of the study and the 
lack of change in any of the patients EDSS.  
The average change in cortical lesions mean MTR values was higher than in 
WML mean MTR values in SPMS patients, which is consistent with pathology 
data suggesting that remyelination in cortical MS lesions is more extensive 
than in the WM lesions in SPMS patients. Other studies suggested that 
environment of chronically demyelinated cerebral cortex is more conducive to 
oligodendrogenesis and remyelination than the environment of chronically 
demyelinated white matter. Moreover, the number of oligodendrocyte 
progenitor cells in cortical lesions is not less than that in nonlesion cortex; 
hence their ability to produce myelinating oligodendrocyte might contribute to 
the greater repair capacity of cortical lesions when compared to chronic white 
matter lesions. 
Remyelination capacity is variable not only among MS groups but even within 
individual patients depending on several factors. Lesion location could 
influence the degree of remyelination to a degree as higher degree of 
remyelination was reported in lesions closer to the cortex.
266
 In our study we 
found that the degree of remyelination in cortical lesions was higher than the 
degree of remyelination in white matter lesions.  
We found that generally cortical lesions showing increase in their mean MTR 
values across time was prominent in all patients groups, with the lowest degree 
in PPMS patients. This could be due to a technical issue with the scanner, 
images registration or analysis. 
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I could not detect a correlation between disease duration and the degree of 
remyelination in early or progressive MS subtypes. This could be due to the 
short disease duration in our subjects in comparison with other studies. 
The balance between demyelination and remyelination is so important in 
determining the disease course in MS patients. When demyelination is well 
established and remyelination is exhausted, this is when disability occurs. 
Frequently the balance between the degree of demyelination and the degree of 
remyelination in active lesions determines the outcome of an MS relapse. 
Heterogeneous demyelination and remyelination in individual lesions has 
implications on disease progression and the degree of disability. Being able to 
monitor the degree of damage in lesions over time in a practical way could 
prove to be crucial for future patient management and monitoring treatment 
response especially remyelinating agents.  
Overall, we found that MTR at 7 T is a sensitive sequence to depicting cortical 
lesions in comparison with other conventional MRI sequences that are 
currently being used for cortical lesions detection. MTR at 7 T has the 
advantage over currently used MRI sequences of being pathologically specific 
to microscopic changes in brain tissue especially myelin content.  
The degree of damage in SPMS cortical lesions were the highest in comparison 
with cortical lesions in other disease phenotypes. The degree of damage in 
cortical lesions as reflected in their mean MTR values correlated with the 
degree of physical disability as well as cognitive impairment in those patients. 
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The degree of demyelination and remyelination is variable in cortical lesions in 
different disease phenotypes. Developing MTR sequence at 7T could provide a 
crucial step in further understanding MS pathology, and help future 
management.  
Future Work: 
MTR at 7 Tesla has proven to be beneficial in understanding cortical lesions 
pathology, the variation between different MS phenotypes and the association 
with physical and cognitive disability. With this in mind we hope in our future 
studies to build on this work further: 
1- Perform the baseline study in a bigger cohort using a powered study, 
with recruiting an extra arm, involving patients on disease modifying 
treatment. 
2- Extend the longitudinal study to follow patients yearly for the next 4 
years and then every 3 years for the next 20 years to explore short term 
variations and longer term variations in cortical lesions pathology, its 
association with physical and cognitive pathology in different MS 
groups. 
3- Examine the sensitivity of MTR at 3Tesla to depict cortical lesions 
especially as a comparison between 7Tesla MTR and 3Tesla MTR. If 
MTR at 3 Tesla has proven to be capable of depicting cortical lesions, 
it will be crucial for practical applications as 7Tesla scanners so far are 
only available for research. 
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